finasteride and Cancer of Prostate

finasteride has been researched along with Cancer of Prostate in 478 studies

Research

Studies (478)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	83 (17.36)	18.2507
2000's	231 (48.33)	29.6817
2010's	156 (32.64)	24.3611
2020's	8 (1.67)	2.80

Authors

Authors	Studies
Belle, C; Cassiani, C; Comerci, A; Danza, G; De Bellis, A; Dini, S; Guarna, A; Machetti, F; Marrucci, A; Occhiato, EG; Payne, AH; Serio, M	1
Brodie, AM; Grigoryev, DN; Kato, K; Long, BJ; Njar, VC; Nnane, IP	1
Choi, EW; Fan, G; Kim, K; Kim, S; Mar, W; Park, MK	1
Brodie, AM; Chopra, P; Farquhar, R; Gediya, LK; Guo, Z; Handratta, VD; Kataria, R; Newman, D; Njar, VC; Qiu, Y; Vasaitis, TS	1
Bondesson, U; Hedeland, M; Lennernäs, H; Lundahl, A	1
Bratoeff, E; Cabeza, M; Garrido, M; Heuze, Y; Ramírez-Apan, T; Sánchez, A; Soriano, J	1
Alvarez-Manrique, B; Bratoeff, E; Cabeza, M; Cortés-Benítez, F; Ramírez-Apan, MT	1
Chen, H; Deng, ZA; Lv, DJ; Qian, YN; Shen, JL; Tian, XM; Wang, CL; Yu, YZ; Yuan, M; Zhang, HB; Zhang, JX; Zhao, SC	1
Chen, H; Hu, P; Li, J; Qian, Y; Shen, J; Zhang, J	1
Chau, CH; Figg, WD; Goodman, PJ; Neuhouser, ML; Pollak, MN; Price, DK; Thompson, IM; Till, C	1
Chan, CH; Chan, YS; Chiu, PK; Lau, SY; Leung, CH; Liu, AQ; Ng, CF; Poon, WT; Tang, WL; Teoh, JY; Yee, CH; Yuen, SK	1
Medina, CA; Plata, M; Zuluaga, L	1
Kramer, B; Tangen, CM; Thompson, IM	1
Rose, BS; Sarkar, RR	1
Ahmed, M; Cieza-Borrella, C; Eeles, R; Goh, C; Kote-Jarai, Z; Saunders, E; Schumacher, FR	1
Chen, Y; Cui, D; Gao, Y; Lei, Y; Li, R; Tang, Q; Wang, D; Wang, H; Wang, L; Zhang, B	1
Ahmed, HU; Arya, M; Day, E; Dobbs, C; Dudderidge, T; Emberton, M; Fiorentino, F; McCracken, S; Prevost, AT; Reddy, D; Shah, TT; Staffurth, J; Sydes, M; Winkler, M	1
Boukovala, M; Brössner, C; Efstathiou, E; Gustafsson, JA; Spetsieris, N; Wang, L; Warner, M; Wu, WF	1
Hu, H; Liang, G; Liu, Z; Yang, J; Yang, Y; Zhang, H; Zhao, F	1
Loughlin, KR	1
De Marzo, AM; Drake, CG; Goodman, PJ; Isaacs, WB; Johnson-Pais, TL; Leach, RJ; Lippman, SM; Lucia, MS; Parnes, HL; Platz, EA; Santella, RM; Tangen, CM; Thompson, IM; Till, C; Winchester, DA; Xu, J; Zheng, SL	1
Gelfond, J; Kabra, A; Liss, MA	1
Abate-Shen, C; Barbieri, CE; Cremers, S; Dutta, A; Golombos, DM; Kim, JY; Liu, D; Mitrofanova, A; Mosquera, JM; Mostaghel, EA; Panja, S; Virk, RK; Zott, R	1
Álvarez-Véliz, S; Berroeta-Mauriziano, D; Carrasco-Zuber, JE; Carreño-Orellana, N; Moll-Manzur, C; Porras-Kusmanic, N	1
Ben-Zvi, T; Bergeron, A; Caron, A; Dujardin, T; Fradet, V; Fradet, Y; Lacombe, L; Léger, C; Lévesque, J; Lodde, M; Nguile-Makao, M; Pouliot, F; Tiguert, R; Toren, P	1
Liss, MA; Thompson, IM	1
Ambrosone, CB; Figg, WD; Goodman, PJ; Hsing, A; Lippman, SM; Neuhouser, ML; Platek, ME; Platz, EA; Reichardt, JKV; Santella, RM; Stanczyk, FZ; Tang, L; Tangen, CM; Thompson, IM; Till, C; Wu, Y; Yao, S	1
Kaplan, SA	3
Ambrosone, C; Chu, LW; Goodman, PJ; Han, S; Hoque, AM; Hsing, AW; Leach, R; Tangen, CM; Thompson, I; Till, C; Yang, B; Yu, K; Zhu, Y	1
Shah, SQ; Uddin, G	1
Barlow, WE; Goodman, PJ; Hershman, DL; Ramsey, SD; Tangen, CM; Thompson, IM; Till, C; Unger, JM	1
Fan, Y; Jarosek, SL; Konety, BR; Lawrentschuk, NL; Sathianathen, NJ	1
Konety, BR; Sathianathen, NJ	1
Resnick, MJ	1
Ankerst, D; Gelfond, J; Goros, M; Hernandez, J; Leach, RJ; Liang, Y; Liss, MA; Thompson, IM	1
Dai, JY; Goodman, PJ; LeBlanc, M; Lucia, MS; Tangen, CM; Thompson, IM	1
Darke, AK; Ford, LG; Goodman, PJ; LeBlanc, ML; Lucia, MS; Minasian, LM; Parnes, HL; Tangen, CM; Thompson, IM	1
Palm, S; Stapff, MP	1
Garnick, MB	1
Goodman, PJ; Tangen, CM; Thompson, IM	2
Azen, CG; Pike, MC; Stanczyk, FZ	1
Al Edwan, G; Fleshner, N	1
Gomella, LG	1
Eisermann, K; Ma, HM; Masoodi, KZ; Nelson, JB; Nguyen, HM; O'Malley, K; Parikh, RA; Pascal, LE; Ramos Garcia, R; Shevrin, DH; Vessella, RL; Wang, Y; Wang, Z	1
Nambiar, D; Singh, RP	1
Lu, X; Mehrotra, DV; Shepherd, BE	1
Azzouni, F; Godoy, A; Ip, C; Mohler, JL; Wilton, JH; Wu, Y	1
Cheng, J; Chhipa, RR; Halim, D; Ip, C; Mohler, JL; Wu, Y; Zhang, HY	1
Morgentaler, A; Traish, AM	1
Stanczyk, FZ	1
Ford, LG; Godley, PA; Goodman, PJ; Lucia, MS; Minasian, LM; Parnes, HL; Tangen, CM; Thompson, IM	1
LeFevre, M	1
McCarthy, M	1
Marchesi, V	1
Payton, S	1
Andriole, GL; Vemana, G	1
Ankerst, DP; Boeck, A; Goodman, PJ; Tangen, CM; Thompson, IM; Till, C	1
Andriole, GL; Freedland, SJ; Hamilton, RJ; Vemana, G	1
Beck, AP; Henningson, JN; Lindshield, BL; Opoku-Acheampong, AB; Unis, D	1
Walsh, PC	5
Revannasiddaiah, S; Susheela, SP	1
Rees, J	1
Almeida, R; Deffune, E; Delella, FK; Fávaro, WJ; Felisbino, SL; Lacorte, LM; Moroz, A	1
Taneja, SS	1
Seftel, AD	1
Bhargava, S	1
Printz, C	1
Babayan, RK	1
Kristal, A; Platz, EA; Thompson, I	1
Michel, MS; Nitschmann, S; von Hardenberg, J	1
Arnold, KB; Burton-Chase, AM; Caggiano, V; Carlin, S; Goodman, PJ; Gritz, ER; Hill, S; Lieber, MM; Meyskens, FL; Minasian, LM; Moinpour, CM; Moody-Thomas, S; Padberg, RM; Probstfield, JF; Ryan, A; See, WA; Szczepanek, C; Tangen, CM; Thompson, IM	1
Goodman, PJ; Kristal, AR; Neuhouser, ML; Peters, U; Schenk, JM; Song, X; Tangen, CM; Till, CA; Torkko, KC	1
Andrew, R; Faqehi, AM; Homer, NZ; Hughes, KA; Naredo, G; Stewart, LH; Upreti, R; Walker, BR	1
Cagnon, VH; Hetzl, AC; Kido, LA; Montico, F	1
Ambrosone, CB; Figg, WD; Goodman, PJ; Hoque, A; Hsing, AW; Kristal, AR; Lippman, SM; Neuhouser, ML; Parnes, HL; Platz, EA; Price, DK; Reichardt, JK; Santella, RM; Stanczyk, FZ; Tangen, CM; Thompson, IM; Till, C; vanBokhoven, A; Yao, S	1
Casabé, A; Glina, S; Henneges, C; Roehrborn, CG; Sorsaburu, S; Viktrup, L	1
De Marzo, AM; Gaonkar, G; Goodman, PJ; Heaphy, CM; Joshu, CE; Lippman, SM; Lucia, MS; Meeker, AK; Peskoe, SB; Platz, EA; Thompson, IM	1
Chau, CH; Chen, X; Chu, L; Figg, WD; Goodman, PJ; Hoque, A; Hsing, AW; Johnson-Pais, TL; Leach, RJ; Parnes, HL; Price, DK; Reichardt, JK; Schenk, JM; Tangen, CM; Thompson, IM; Till, C	1
Azoulay, L; Benayoun, S; Eberg, M; Pollak, M	1
Figg, WD; Thompson, IM	1
Cagnon, VH; Kido, LA; Montico, F; Rowley, DR; San Martin, R	1
Lippman, SM; Lucia, MS; Nash, SH; Parnes, HL; Platz, EA; Schenk, J; Song, X; Thompson, IM; Till, C	1
Bortolato, M; Garcia-Segura, LM; Melcangi, RC; Traish, AM; Zitzmann, M	1
Brant, WO; Darke, A; Hotaling, JM; Myers, JB; Patel, DP; Schenk, JM	1
La Vecchia, C	1
Cai, W; Guo, Y; Jiang, Y; Li, W; Wang, X; Yang, S	1
Barber, JR; De Marzo, AM; Drake, CG; Goodman, PJ; Gurel, B; Kristal, AR; Lippman, SM; Lucia, MS; Murtola, TJ; Nelson, WG; Parnes, HL; Peskoe, SB; Platz, EA; Sutcliffe, S; Thompson, IM; Umbehr, M	1
Ding, J; Duan, L; Qi, J; Qian, X; Xu, D; Zhu, Y	1
Block, NL; Rick, FG	1
Basler, JW; Brown, PH; Davis, JW; Do, KA; Efstathiou, E; Gorlov, IP; Hoque, AM; Kim, J; Klein, EA; Lee, JJ; Li Ning Tapia, EM; Lippman, SM; Logothetis, CJ; Lotan, Y; Magi-Galluzzi, C; Parnes, HL; Pettaway, CA; Pisters, LL; Prokhorova, IN; Stephenson, A; Thompson, IM; Troncoso, P; Vornik, LA; Wang, X; Ward, JF	1
Arias-Santiago, S; Camacho-Martínez, FM	1
Barlow, WE; Goodman, PJ; Hershman, DL; Minasian, LM; Ramsey, SD; Tangen, CM; Thompson, IM; Till, C; Unger, JM; Wright, JD	1
Fan, D; Jin, S; Niu, Y; Wang, K; Wang, M; Xing, N	1
Cohen, SI	1
Chadha, VD; Dhawan, DK; Jan, G; Passi, ND	1
Acevedo, C; Cabezas, J; Castellón, EA; Contreras, HR; Huidobro, C; Mendoza, P; Noé, G; Sánchez, C; Vergara, J	1
Vastag, B	1
Soloway, M	1
Roobol, MJ; Schröder, FH; van den Bergh, RC; van Leeuwen, PJ; Wolters, T	1
McBride, D	1
Sarvis, JA; Thompson, IM	2
Arnold, KB; Goodman, PJ; Kristal, AR; Lin, DW; Neuhouser, ML; Schenk, JM; Song, Y; Stanczyk, FZ; Thompson, IM	1
Stattin, P; Wirén, S	1
Altwein, J; Dörsam, J	1
Bass, R; Dennis, KL; Holzbeierlein, J; Langenstroer, P; Perry, B; Tawfik, O; Thrasher, JB	1
Logothetis, CJ; Schellhammer, PF	1
Coltman, CA; Darke, AK; Ford, LG; Goodman, PJ; La Rosa, FG; Lucia, MS; Parnes, HL; Thompson, IM	1
Coltman, CA; Goodman, PJ; Lucia, MS; Redman, MW; Tangen, CM; Thompson, IM	1
Ford, L; Parnes, H; Pinsky, P	1
Edwards, JL	1
Adolfsson, J	1
Eggener, S; Orvieto, M	1
Fleshner, NE; Rittmaster, RS; Thompson, IM	1
Bañez, LL; Blake, GW; Crawford, ED; McLeod, DG; Moul, JW	1
Alcaraz, A; Castro, R; Desgrandchamps, F; Hammerer, P; Montorsi, F; Schröder, F	1
Fitzpatrick, JM; Schröder, FH; Schulman, C; Zlotta, AR	1
Parekh, DJ; Reed, AB	1
Binkowitz, BS; Carides, AD; Heyden, NL; Kaplan, SA; Liu, KS; Meehan, AG; Roehrborn, CG; Vaughan, ED	1
Andriole, GL	1
Montie, JE	1
Mitka, M	1
Adomat, HH; Gleave, ME; Guns, ES; Hendy, SC; Locke, JA; Nelson, CC	1
Kraljic, I; Kusic, Z; Spajic, B; Tarle, M	1
Acquaro, C; Carvalho, RF; Felisbino, SL; Justulin, LA; Silva, MD	1
Kim, J; Li, J	1
Delella, FK; Felisbino, SL; Justulin, LA	1
Elliott, CS; Presti, JC; Shinghal, R	1
Gong, Z; Goodman, PJ; Kristal, AR; Schenk, JM; Tangen, CM; Thompson, IM	1
Schröder, FH; Vis, AN	1
Wyllie, MG	1
Ala-Opas, M; Auvinen, A; Määttänen, L; Murtola, TJ; Stenman, UH; Tammela, TL	1
Frankel, PH; Twardowski, P	1
Gupta, S; Hua, V; Jovanovic, BD; Nelson, JB; Ramos-Garcia, R; Shevrin, D; Wang, Y; Wang, Z	1
Keller, DL	1
Dorff, TB; Leibowitz, RL; Symanowski, J; Tucker, S; Vogelzang, NJ	1
Azzouzi, AR; Bigot, P; Lebdai, S	1
Lilja, H; Savage, CJ; Vickers, AJ	1
Abouassaly, R; Klein, EA; Stephenson, AJ	1
Baker, SG; Darke, AK; Kramer, BS; Parnes, HL; Pinsky, P	1
Albanes, D; Goodman, P; Hoque, A; Hsing, AW; Kristal, A; Neuhouser, ML; Parnes, HL; Platz, EA; Pollak, M; Till, C	1
Bühler, P; Elsässer-Beile, U; Fischer, T; Gierschner, D; Schultze-Seemann, W; Wetterauer, U; Wolf, P	1
Andriole, GL; Strope, SA	1
Ambrosone, CB; Goodman, PJ; Hoque, A; Hsing, AW; Kappil, M; Kristal, A; Lucia, S; Parnes, H; Santella, RM; Tangen, C; Thompson, I; Till, C; Wang, Q	1
Leahy, Y	1
Hori, S; Ohtani, H; Satoh, H; Sawada, Y; Suzuki, R	1
Blackwell, RH; Helfand, BT; McVary, KT	1
Das, K; Lim, D; Lorena, PD; Ng, LK; Reichardt, JK; Salto-Tellez, M; Shen, L; Siow, WY; Teh, M	1
Chaudhary, UB; Turner, JS	1
Gupta, S; Nelson, JB; Ramos-Garcia, R; Shevrin, D; Wang, Y; Wang, Z	1
Bruchovsky, N; Locke, JA	1
Türkeri, L	1
Diamandis, EP	1
Pais, P	1
Cui, L; Gao, JP; Hong, BF; Lü, XY; Xu, AX; Zhang, X; Zhu, J	1
Mulders, PF; Pfeiffer, MJ; Schalken, JA	1
Hamilton, RJ; Kahwati, LC; Kinsinger, LS	1
Kim, ED; White, WM	1
Bertele', V; Garattini, S	1
Schmidt, LJ; Tindall, DJ	1
Figg, WD; Hsing, AW; Hulin-Curtis, SL; Petit, D; Reichardt, JK	1
Barry, MJ; Hoffman, RM; Roberts, RG	1
Moul, JW; Reed, SD; Scales, CD; Schulman, KA; Stewart, SB; Sun, J; Xu, J	1
Parekh, DJ	1
Ambrosone, CB; King, IB; Kristal, AR; Neuhouser, ML; Platz, EA; Song, X; Thompson, IM; Till, C	1
Gontero, P; Oderda, M; Richiardi, L; Tizzani, A; Zitella, A	1
Albanes, D; Brasky, TM; Goodman, P; King, IB; Kristal, AR; Neuhouser, ML; Song, X; Thompson, IM; Till, C; White, E	1
Arnold, KB; Kristal, AR; Lin, DW; Neuhouser, ML; Schenk, JM; Tangen, CM; Thompson, IM; White, E	1
Ambrosone, CB; Figg, WD; Goodman, PJ; Hoque, A; Hsing, AW; Kristal, AR; Lippman, SM; Neuhouser, ML; Parnes, HL; Platz, EA; Price, DK; Reichardt, JK; Santella, RM; Stanczyk, FZ; Tang, L; Tangen, CM; Thompson, IM; Till, C; Yao, S	1
Justice, R; Keegan, P; Ning, YM; Pazdur, R; Theoret, MR; Zhang, JJ	1
Alberts, DS; Bartels, HG; Bartels, PH; Carmignani, G; DeCensi, A; Decobelli, O; Hurle, R; Maffezzini, M; Mazzucchelli, R; Montironi, R; Puntoni, M	1
Bhardwaj, TR; Dhingra, N; Kumar, A; Kumar, M; Mehta, N; Mukhopadhyay, T	1
Wirth, M; Zastrow, S	1
Freedland, SJ; Hamilton, RJ	1
Bismarck, E; Fischer, C; Lümmen, G; Schmitz-Dräger, BJ	1
Justman, S	1
Ahles, T; Gu, L; Halabi, S; Hussain, A; Kaplan, E; Kelly, WK; Monk, JP; Philips, G; Picus, J; Small, EJ; Vogelzang, N	1
Lindshield, BL; Nelsen, MK; Opoku-Acheampong, AB; Unis, D	1
Byrns, MC; Duan, L; Mindnich, R; Penning, TM	1
Carter, HB; Feng, Z; Landis, P; Pierorazio, PM; Ross, AE; Schaeffer, EM; Trock, BJ; Walsh, PC	1
Bubley, G; Dumas, C; Slater, S	1
Cvijetić, S; Dodig, S; Jurasović, J; Milković-Kraus, S; Mück-Šeler, D; Mustapić, M; Pašalić, D; Pauković, P; Pavlović, M; Pivac, N; Pizent, A	1
Azzouni, F; Mohler, J	1
Camarena-Reynoso, HR; Jimenez-Rios, MA; Ketchum, NS; Liang, Y; Louden, C; Thompson, IM	1
Chiba, Y	1
Bismarck, E; Fischer, C; Schmitz-Dräger, BJ; Schöffski, O	1
Chang, SN; Kao, CH; Liang, JA; Lin, MC; Muo, CH; Sun, LM; Sung, FC	1
Paller, CJ; Smith, TJ	1
Moul, JW; Reed, SD; Scales, CD; Stewart, SB	1
De Marzo, AM; Gaydos, CA; Goodman, PJ; Hoque, AM; Hsing, AW; Jenkins, FJ; Nelson, WG; Platz, EA; Sutcliffe, S; Thompson, IM; Till, C; Zenilman, JM	1
Chung, DE; Kaplan, SA; Lee, RK; Scherr, DS; Te, AE; Tewari, A; Vaughan, ED	1
Ehdaie, B	1
Chu, LW; Figg, WD; Goodman, PJ; Hoque, A; Hsing, AW; Kristal, AR; Lippman, SM; Neuhouser, ML; Patel, SK; Platz, EA; Reichardt, JK; Stanczyk, FZ; Tangen, CM; Thompson, IM; Till, C; Van Bokhoven, A	1
Cespedes, D; Darke, AK; Donaldson, GW; Ganz, PA; Johnson, CR; Meyskens, FL; Moinpour, CM; Patrick, DL; Shumaker, SA; Thompson, IM; Ware, JE	1
Damjanoski, I; Küfer, R; Müller, J; Rinnab, L; Schnöller, TJ	1
Akre, O; Friis, S; Granath, F; Gustafsson, O; Kjellman, A; Sørensen, HT	1
Dunn, BK; Greenwald, P; Umar, A	1
Andriole, GL; Nepple, KG	1
Autorino, R; Berardinelli, F; Cindolo, L; Fanizza, C; Pirozzi, L; Romero, M; Schips, L	1
Figg, WD; Goodman, PJ; Hoque, A; Hsing, AW; Kristal, A; Lucia, MS; Neuhouser, ML; Parnes, HL; Platz, EA; Pollak, M; Tangen, CM; Tao, Y; Thompson, IM; Till, C	1
Kujala, PM; Murtola, TJ; Tammela, TL	1
Fromer, D; Ghafar, MA; Kaplan, SA; Lam, JS; Te, AE; Volpe, MA	1
Tisman, G	1
Bladou, F; Chartier-Kastler, E; Chautard, D; Coloby, P; Desgrandchamps, F; Fontaine, E; Haillot, O; Irani, J; Lechevallier, E; Pariente, JL; Ravery, V; Soulie, M	1
Anderson, WR; Harris, NM; Holmes, SA	1
Crowley, JJ; Goodman, PJ; Gower, KB; Pauler, DK; Thompson, IM	1
Bahnson, R; Bissonette, EA; Miller, NL; Theodorescu, D; Wilson, J	1
Grönberg, H	1
Klein, EA	2
Jacobsen, SJ; Roberts, RO	1
Fitzpatrick, JM	2
Bissonette, EA; Krupski, T; Petroni, GR; Theodorescu, D	1
Derksen, JE; Gaston, K; Pruthi, RS	1
Scardino, PT	1
Atkins, JN; Carlin, SM; Cespedes, RD; Coltman, CA; Crowley, JJ; Ford, LG; Goodman, PJ; Lieber, MM; Lippman, SM; Lucia, MS; Miller, GJ; Ryan, A; Szczepanek, CM; Tangen, CM; Thompson, IM	1
Bittmann, L; Brufsky, A; Kantoff, PW; Kaplan, ID; Kaufman, DS; Manola, J; Oh, WK; Smith, MR	1
Reynolds, T	3
Zuger, A	1
O'Reilly, P	1
Levenson, D	1
Dunn, TA; Ewing, CM; Isaacs, WB; Luo, J; Walsh, PC	1
Thompson, CA	1
Beer, TM	1
Kantoff, PW; Rubin, MA	2
Barzell, WE	1
Roehrborn, CG	1
Ellis, RJ; Lee, SC	2
Burke, HB	1
Cote, RJ; Ross, RK; Skinner, E	1
Schwartz, DT	1
Adolfsson, J; Borkowski, A; Fitzpatrick, J; Kirk, D; Marberger, M; Prezioso, D; Rabaça, C; Solsona, E; Teillac, P	1
Barqawi, AB; Crawford, ED; Handel, L; Moul, JW; Ziada, A	1
Coltman, CA; Djavan, B; Klein, EA; Lippman, SM; Thompson, IM	1
Bartsch, G; Boccon Gibod, L; Djavan, B; Iversen, P; Marberger, M; Schulman, C; Teillac, P; Zlotta, A	1
Higgins, B; Thompson, IM	1
Douglas, RC; Lazier, CB; Rittmaster, RS; Thomas, LN; Vessey, JP	1
Hellerstedt, B	1
Barqawi, A; Crawford, ED; Gamito, E; O'Donnell, C	1
Carlin, SM; Coltman, CA; Crowley, JJ; Ford, LG; Goodman, PJ; Ryan, A; Tangen, CM; Thompson, IM	1
Lee, D	1
Djavan, B; Michel, MS; Seitz, C; Thompson, I; Waldert, M	1
Rannikko, A; Ruutu, M	1
Klein, EA; Thompson, IM	1
Reddy, GK	1
Bostwick, DG; Civantos, F; Montironi, R; Qian, J; Roehrborn, CG	1
Ferrari, AC; McCarron, JP; Mencher, SK; Wang, LG	1
Pitts, WR	6
Bott, SR; Foley, CL; Kirby, RS; Shergill, IS	1
Febbo, PG; George, DJ; Kantoff, PW; Kaplan, ID; Kaufman, DS; Leibowitz, SB; Manola, J; Oh, WK; Regan, MM; Smith, MR; Tay, MH	1
Coltman, CA; Crawford, ED; Crowley, JJ; Ford, LG; Goodman, PJ; Lippman, SM; Lucia, MS; Minasian, LM; Parnes, HL; Pauler, DK; Tangen, CM; Thompson, IM	1
Cahlon, O; Cesaretti, JA; Kollmeier, MA; Stock, RG; Stone, NN	1
Hausmann, R; Reich, O; Steif, CG; Thalmann, G	1
Zielinski, SL	1
Chapman, K; Habib, FK; Ho, CK; Lyons, V; Ross, M	1
Brodie, AM; Handratta, VD; Jelovac, D; Kataria, R; Long, BJ; Njar, VC; Nnane, IP	1
Barud, W; Palusinski, R	1
Gustafsson, JA; Imamov, O; Lopatkin, NA	1
Ford, LG; Parnes, HL; Thompson, IM	1
Barassin, C; Dossou, U; Hartmann, RW; Kang, MJ; Mathur, S; Picard, F; Seidel, SB	1
Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Muzi, P; Vicentini, C	1
Fourcade, RO	1
Schulman, C	1
Levinson, A; Lowe, FC; Nagler, EA	1
Carver, BS; Eastham, JA; Kattan, MW; Scardino, PT	1
Kakizoe, T	1
Iwasaki, M; Tsugane, S	1
Coltman, CA; Crowley, JJ; Ford, LG; Goodman, PJ; LeBlanc, M; Thompson, IM; Unger, JM	1
Cadeddu, JA; Lee, JJ; Lippman, SM; Lotan, Y; Roehrborn, CG	1
Bissonette, E; Miller, N; Smolkin, ME; Theodorescu, D	1
Hutson, T; Mariani, S; Price, N; Sartor, O	1
Hampton, T	1
Benli, K; Bulut, S; Gökkaya, S; Memiş, A; Ozdal, OL; Ozden, C	1
Etzioni, R; Kristal, AR; Zeliadt, SB	1
Chen, G; Geng, J; Zhang, YF	1
Mellon, JK	1
Etzioni, RD; Penson, DF; Ramsey, SD; Thompson, IM; Zeliadt, SB	1
Ankerst, DP; Etzioni, RD; Goodman, PJ; Howlader, N; Penson, DF; Shaw, PA; Thompson, IM	1
Allory, Y; Cochand Priollet, B; de la Taille, A; Leroy, X; Molinié, V; Paraf, F; Ruffion, A	1
Hakenberg, OW; Wirth, MP	1
Goodman, PJ; Klein, EA; Lippman, SM; Tangen, CM; Thompson, IM	1
Talcott, JA	1
Canby-Hagino, ED; Thompson, IM	1
Andriole, G; Bostwick, D; Civantos, F; Epstein, J; Lucia, MS; McConnell, J; Roehrborn, CG	1
Abbou, C; Allory, Y; Cussenot, O; de la Taille, A; Faucon, H; Huang, W; Kuten, A; Leroy, X; Molinié, V; Rebillard, X; Rubin, MA; Salomon, L; Vacherot, F	1
Ai, J; Cai, X; Eggener, SE; Jain, PM; Oram, S; Roehl, KA; Stern, JA; Wang, Z	1
Leisinger, HJ; Wisard, M	1
Coupal, L; Grover, S; Hajek, D; Lowensteyn, I; Marchand, S; Trachtenberg, J	1
Federman, DG	1
Frazee, LA; Lowe, JF	1
Herman, ZS; Krysiak, R; Okopień, B; Szkróbka, W	1
Carroll, PR; Cowan, JE; DuChane, J; Elkin, EP; Kawakami, J; Latini, DM	1
Guess, BW; Jennrich, RI; Johnson, HJ; Lam, RY; Scholz, MC; Strum, SB	1
Brand, TC; Canby-Hagino, ED; Hernandez, J; Thompson, IM	1
Atiemo, H; Borkowski, A; Jacobs, SC; Kyprianou, N; Sutton, MT; Vyas, A; Yingling, M	1
Becker, RE; Dalrymple, SL; Denmeade, SR; Isaacs, JT; Xu, Y	1
Lee, JJ; Lippman, SM; Lotan, Y; Roehrborn, CG; Svatek, RS	2
Goetzl, MA; Holzbeierlein, JM	1
Fleshner, N; Kulkarni, G	1
Bankhead, C	1
Ankerst, DP; Chi, C; Coltman, CA; Goodman, PJ; Lippman, SM; Lucia, MS; Parnes, HL; Tangen, CM; Thompson, IM	1
Ammar, H; Gupta, C; Malani, AK	1
Figg, WD; Parnes, HL	1
Brand, TC; Canby-Hagino, E; Hernandez, J; Thompson, I	1
Hamdy, FC	1
Albanes, D; Chi, C; Gong, Z; Goodman, PJ; Hsing, AW; Kristal, AR; Lippman, SM; Neuhouser, ML; Platz, EA; Pollak, MN; Thompson, IM	1
Bratoeff, E; Cabeza, M; Gracia, I; Heuze, I; Ochoa, M; Pérez, V; Ramírez, E; Ramírez-Apan, T; Rojas, A; Terán, N	1
Barry, MJ; D'Amico, AV	1
Hoque, A	1
Agarwal, S; Cohen, SI; Handel, LN; Kelty, PJ; Schiff, SF	1
Auvinen, A; Hakama, M; Määttänen, L; Murtola, TJ; Tammela, TL	1
Ankerst, DP; Thompson, IM	2
Grogg, AL; Issa, MM; Runken, MC; Shah, MB	1
Hara, N; Labrie, F; Nishiyama, T; Suzuki, K; Takahashi, K; Yamana, K	1
Gescher, AJ; Jain, S; Marczylo, TH; Mellon, JK; Steward, WP; Thorpe, JF	1
Dunn, BK; Ford, LG	1
Coltman, CA; Goodman, PJ; Lippman, SM; Lucia, MS; Parnes, HL; Tangen, CM; Thompson, IM	1
Asamoto, M; Cho, YM; Shirai, T; Suzuki, S; Takahashi, S; Tang, M	1
Matthews, PA	1
Lümmen, G; Schäfer, RM; Schmitz-Dräger, BJ	1
Coltman, CA; Darke, A; La Rosa, FG; Lippman, SM; Lucia, MS; Parnes, HL; Redman, MW; Thompson, IM	1
Vale, S	1
Benaim, E; Rittmaster, R; Roehrborn, CG; Serfling, R; Shulman, M; Thompson, GL; Xiao, Z	1
Jewett, MA; Klotz, LH	1
Thompson, IM	1
Ankerst, DP; Coltman, CA; Darke, AK; Donaldson, GW; Ganz, PA; Langley, C; Lippman, SM; Moinpour, CM; Patrick, DL; Shumaker, SA; Thompson, IM; Ware, JE	1
de Vere White, RW	1
Chi, C; Coltman, CA; Goodman, PJ; Lippman, SM; Lucia, MS; Parnes, HL; Pauler Ankerst, D; Tangen, CM; Thompson, IM	1
Andriole, GL; Grubb, RL; Humphrey, PA; Serfling, RJ	1
Anderson, KM; Carides, AD; Cohen, YC; Daifotis, AG; Gann, PH; Heyden, NL; Liu, KS	1
Civantos, F; Coltman, CA; Crawford, ED; Darke, AK; Epstein, JI; Ford, LG; Goodman, PJ; Kattan, MW; La Rosa, FG; Lippman, SM; Lucia, MS; Parnes, HL; Reuter, VE; Tangen, CM; Thompson, IM	1
Bismarck, E; Dörsam, HJ; Fischer, C; Lümmen, G; Schmitz-Dräger, BJ	1
Douglas, RC; Lazier, CB; Rittmaster, RS; Thomas, LN; Tindall, DJ; Too, CK	1
Hernandez, J; Hudak, SJ; Thompson, IM	1
Goodman, P; Kristal, AR; Lucia, MS; Parnes, HL; Song, Y; Tangen, C; Thompson, IM	1
Arnold, KB; Goodman, P; Kristal, AR; Neuhouser, ML; Penson, DF; Schenk, JM; Thompson, IM	1
Rittmaster, RS; Tindall, DJ	1
Helling, TJ	1
Clarke, N; Koltz, L	1
Lucia, MS; Tangen, CM; Thompson, IM	1
Golbano, JM; Lóppez-Aparicio, P; Pérez-Albarsanz, MA; Recio, MN	1
Chen, X; Figg, WD; Gardner, ER; Price, DK	1
Hagerty, K; Kramer, BS; MacDonald, R; Schellhammer, P; Wilt, TJ	1
Hamdy, FC; Rouprêt, M	1
Irani, J	2
Allory, Y; Molinié, V	1
de la Taille, A	1
Villers, A	1
Coltman, CA; Lippman, SM; Parnes, HL; Tangen, CM; Thompson, IM	1
Barry, MJ; Kaufman, DS; Wu, CL	1
Angelucci, A; Bologna, M; Festuccia, C; Gravina, GL; Muzi, P; Pomante, R; Vicentini, C	1
Gormley, GJ; Guess, HA; Oesterling, JE; Stoner, E	1
Droz, JP	1
Rittmaster, RS	1
Fleshner, NE; Trachtenberg, J	2
Klee, GG; Oesterling, JE; Ruckle, HC	1
Cook, T; Gormley, GJ; Guess, H; Ng, J; Stoner, E; Walsh, P	1
Konen, JC	1
Stoner, E	1
Ferguson, D; Gormley, GJ; Round, E; Stoner, E	1
Schröder, FH	1
Appell, RA	1
Andriole, G; Boake, R; Crawford, D; DeKernion, J; Kadmon, D; Lieber, M; Rajfer, J; Schroeder, F; Smith, J; Soloway, M	1
Schlegel, PN	1
Blumenstein, B; Brawley, OW; Coltman, CA; Crowley, J; Feigl, P; Ford, LG; Kramer, BS; Thompson, I; Wolf, M	1
Alberts, DS; Boone, CW; Covey, JM; Crowell, JA; Doody, LA; Greenwald, P; Kelloff, GJ; Knapp, GG; Lubet, RA; Steele, VE	1
Brawley, OW; Coltman, CA; Ryan, A; Thompson, IM	1
Coltman, C; Feigl, P; Thompson, I	1
Alberti, C	1
Akaza, H; Ideyama, Y; Imada, S; Koiso, K; Kudo, M; Shirai, T; Tsukamoto, S	1
Greco, KE; Kulawiak, L	1
Biordi, L; Bologna, M; Festuccia, C; Muzi, P; Vicentini, C	1
Geller, J	1
Brawley, OW; Ford, LG; Johnson, KA; Kramer, BS; Nayfield, SG; Perlman, JA	1
Délos, S; Iehlé, C; Martin, PM; Raynaud, JP	1
Brawley, OW; Thompson, IM	2
Henderson, BE; Pike, MC; Ross, RK	1
Brawley, O; Gormley, GJ; Thompson, I	1
Carsol, JL; Délos, S; Ghazarossian, E; Martin, PM; Raynaud, JP	1
Gormley, GJ	4
Trachtenberg, J	1
Coltman, CA; Thompson, IM	1
Audia, JE; Bruchovsky, N; Goode, RL; Hsiao, KC; Kaefer, M; Krushinski, JH; Lee, C; Leibovitch, IY; Neubauer, BL; Steidle, CP; Sutkowski, DM	1
Hiipakka, RA; Kokontis, JM; Liao, S; Umekita, Y	1
Brawley, OW; Cheson, BD; Phillips, PH	1
Andriole, GL; Charlton, ET; Johnson, B; Ornstein, DK; Rao, GS	1
Bartels, PH; Diamanti, L; Hamilton, PW; Montironi, R; Pomante, R; Thompson, D	1
Fair, WR; Fleshner, NE	1
di Salle, E; Giudici, D; Zaccheo, T	2
Nukui, F	1
Berlane, K; Brufsky, A; Fontaine-Rothe, P; Jiroutek, M; Kantoff, P; Kaplan, I; Kaufman, D; Rieker, P	1
Johnson, H; McDermed, JE; Scholz, MC; Strum, SB; Tisman, G	1
Agha, A; Bach, M; Gormley, G; Johansen, T; Krarup, T; Lagerkvist, M; Oesterling, JE; Roy, J; Shown, T; Waldstreicher, J	2
Kaisary, AV; Matveev, VB; Sandhu, SS	1
Coltman, CA; Crowley, J; Thompson, IM	1
Lowe, FC; Staiman, VR	1
Akaza, H; Ideyama, Y; Onozawa, M; Shirai, T; Tsukamoto, S	1
Allerton, J; Coltman, CA; Higgins, B; Lovato, L; Optenberg, S; Seay, T; Thompson, I	1
Schulman, CC; Zlotta, AR	1
Andriole, GL; Cook, TJ; Crawford, ED; Epstein, JI; Guess, HA; Hudson, P; Jackson, CL; Kadmon, D; Patterson, L; Romas, NA; Waldstreicher, J; Wise, H	1
Cote, RJ; Henderson, BE; Mertes, SJ; Pike, MC; Ross, RK; Salem, CE; Skinner, EC; Stanczyk, FZ	1
Brodie, A; Kato, K; Ling, YZ; Liu, Y; Lu, Q; Nnane, IP; Wang, X	1
Andriole, GL; Ornstein, DK; Smith, DS	1
Baumann, LS; Kelso, EB	1
Litwin, MS	1
Chapman, B	1
Bannow, J; Epstein, JI; Fitch, WP; Gottesman, J; Hodge, GB; Lecksell, K; Parra, R; Peterson, L; Rouse, S; Schellhammer, PF; Short, K; Waldstreicher, J; Yang, XJ	1
Andriole, GL; Beiser, JA; Ornstein, DK	1
Coltman, CA; Feigl, P; Thompson, IM	1
Altwein, J; Boyle, P; Denis, LJ; Griffiths, K; Kirby, R; Robertson, C; Schröder, F; Turkes, A	1
Bostwick, DG	1
Andriole, GL; Bhayani, SB	1
Bostwick, DG; Cheng, L; Ramnani, D	1
Bergner, D; Boyle, P; Bracken, RB; deVere White, R; Gittelman, M; Gray, T; Melman, A; Roehrborn, CG; Shown, T; Taylor, A; Waldstreicher, J; Wang, D	1
Bartels, PH; Duval da Silva, V; Mazzucchelli, R; Montironi, R; Pomante, R; Thompson, D; Vaught, L	1
Ehren-van Eekelen, C; Helin, H; Kallioniemi, OP; Koivisto, PA; Schleutker, J; Trapman, J	1
Brawley, OW; Parnes, H	1
Denis, LJ; Griffiths, K	1
Bruchovsky, N; Crook, JM; Gleave, ME; Godwin, L; Goldenberg, SL; Hoffart, D; Klotz, LH; Sadar, M; Warkentin, M	1
Calvert, RC; Mikhailidis, DP; Morgan, RJ; Thompson, CS	1
Brodie, AM; Grigoryev, DN; Ling, YZ; Liu, Y; Long, BJ; Nnane, IP	1
Atkinson, JO; Coltman, CA; Deantoni, E; Gritz, ER; Harvey, C; Hill, MS; Lovato, LC; Moinpour, CM; Parzuchowski, J; Ryan, AM; Thomas, SM; Thompson, IM; Underwood, SM	1
Margiotti, K; Novelli, G; Reichardt, JK; Sangiuolo, F	1
Nelson, WG; Wilding, G	1
Kolvenbag, G; Neubauer, BL; Trump, DL; Waldstreicher, JA; Wissel, PS	1
Coltman, CA; Goodman, P; Klein, EA; Kouril, M; Ryan, A; Thompson, IM	1
Leibowitz, RL; Tucker, SJ	1
Stephenson, J	1
Broering, JM; Carroll, PR; Grossfeld, GD; Latini, D; Lubeck, DP; Small, EJ	1
Lieberman, R	1
Brooks, JD; DePrimo, SE; Shinghal, R; Vidanes, G	1
Goodman, PJ; Kristal, AR; Neuhouser, ML; Patterson, RE; Thompson, IM	1
Amin, P; Chen, T; Dawson, N; Engstrom, C; Hussain, A; Naslund, M	1
Steers, WD	1
Campbell, PE; Charles, GM; Cooke, DB; D'Agustino, JL; Deleon, M; Guillory, BO; Jackson, BA; Johnson, DE; Johnson, KP; Matthews, QL; McKay, J; Rowe, GC; Verret, CR; Williams, MV	1
Barnes, S; Brawley, OW; Parnes, H	1
Reid-Pitts, W	1
Geller, J; Sionit, L	1
Crawford, ED; DeAntoni, EP; Fair, WR; Kelloff, GJ; Lieber, MM; Miller, GJ; Scardíno, PT	1
Andriole, G; Fair, WR; Ferguson, D; Gormley, GJ; Ng, J; Presti, JC; Seidmon, EJ; Sogani, PC	1
Fiorelli, G; Serio, M	1
Jenks, S	1
Berman, C; Brooks, JR; Nguyen, H; Prahalada, S; Primka, RL; Rasmusson, GH; Slater, EE	1

Reviews

104 review(s) available for finasteride and Cancer of Prostate

Article	Year
Association of finasteride with prostate cancer: A systematic review and meta-analysis. Medicine, 2020, Volume: 99, Issue:15 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2020
5α-Reductase Inhibitors Could Prevent the Clinical and Pathological Progression of Prostate Cancer: A Meta-analysis. Urology journal, 2021, Apr-11, Volume: 18, Issue:3 Topics: 5-alpha Reductase Inhibitors; Disease Progression; Dutasteride; Finasteride; Humans; Male; Prostatic Neoplasms	2021
The clinical applications of five-alpha reductase inhibitors. The Canadian journal of urology, 2021, Volume: 28, Issue:2 Topics: 5-alpha Reductase Inhibitors; Alopecia; Dutasteride; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms	2021
[Finasteride adverse effects: An update]. Revista medica de Chile, 2016, Volume: 144, Issue:12 Topics: 5-alpha Reductase Inhibitors; Alopecia; Blood Glucose; Erectile Dysfunction; Finasteride; Humans; Lipid Metabolism; Male; Prostatic Hyperplasia; Prostatic Neoplasms; Spermatogenesis	2016
Prostate cancer prevention with 5-alpha reductase inhibitors: concepts and controversies. Current opinion in urology, 2018, Volume: 28, Issue:1 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Dihydrotestosterone; Dutasteride; Early Detection of Cancer; Finasteride; Humans; Male; Organ Size; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Receptors, Androgen; Risk Factors	2018
Advances in prostate cancer chemoprevention: a translational perspective. Nutrition and cancer, 2013, Volume: 65 Suppl 1 Topics: Androgen Antagonists; Animals; Anticarcinogenic Agents; Antioxidants; Azasteroids; Carotenoids; Chemoprevention; Clinical Trials as Topic; Curcumin; Disease Models, Animal; Dutasteride; Finasteride; Flavonoids; Genistein; Humans; Lycopene; Male; Phytochemicals; Polyphenols; Prostate; Prostatic Neoplasms; Risk Factors; Selenium; Silybin; Silymarin; Tea; Vitamin E	2013
Chemoprevention of prostate cancer. Annual review of medicine, 2014, Volume: 65 Topics: 5-alpha Reductase Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Azasteroids; Carotenoids; Dietary Supplements; Dutasteride; Finasteride; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Life Style; Lycopene; Male; Plant Extracts; Primary Prevention; Prostatic Neoplasms; Selective Estrogen Receptor Modulators; Selenium; Serenoa; Vitamin E	2014
Prevention of prostate cancer: outcomes of clinical trials and future opportunities. American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting, 2014 Topics: Clinical Trials as Topic; Clinical Trials, Phase III as Topic; Finasteride; Humans; Inflammation; Male; Middle Aged; Prostatic Neoplasms; Selenium; Treatment Outcome; Vitamin E	2014
Adverse effects of 5α-reductase inhibitors: What do we know, don't know, and need to know? Reviews in endocrine & metabolic disorders, 2015, Volume: 16, Issue:3 Topics: 5-alpha Reductase Inhibitors; Alopecia; Animals; Central Nervous System; Cholestenone 5 alpha-Reductase; Cognition Disorders; Depression; Diabetes Mellitus; Dutasteride; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms; Psychoses, Substance-Induced; Sexual Dysfunction, Physiological; Steroids	2015
Prostate cancer chemoprevention: update of the prostate cancer prevention trial findings and implications for clinical practice. Current oncology reports, 2008, Volume: 10, Issue:6 Topics: Aged; Chemoprevention; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Placebos; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Risk; Sexual Dysfunction, Physiological	2008
Androgens and prostate cancer risk. Best practice & research. Clinical endocrinology & metabolism, 2008, Volume: 22, Issue:4 Topics: Androgens; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2008
5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications. Prostate cancer and prostatic diseases, 2009, Volume: 12, Issue:2 Topics: 5-alpha Reductase Inhibitors; Antineoplastic Agents; Azasteroids; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms	2009
Pharmacological approaches to reducing the risk of prostate cancer. European urology, 2009, Volume: 55, Issue:5 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Age Factors; Aged; Azasteroids; Chemoprevention; Diet; Dutasteride; Early Detection of Cancer; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Incidence; Life Style; Male; Middle Aged; Primary Prevention; Prostatic Neoplasms; Risk Assessment	2009
A broader role for 5ARIs in prostate disease? Existing evidence and emerging benefits. The Prostate, 2009, Jun-01, Volume: 69, Issue:8 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Aged; Aging; Azasteroids; Dihydrotestosterone; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Sulfonamides; Tamsulosin; Testosterone; Urinary Tract Infections	2009
Prostate cancer: a serious disease suitable for prevention. BJU international, 2009, Volume: 103, Issue:7 Topics: Aged; Azasteroids; Cholestenone 5 alpha-Reductase; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Selenium; Toremifene; Vitamin E	2009
The utility of 5-alpha reductase inhibitors in the prevention and diagnosis of prostate cancer. Current opinion in urology, 2009, Volume: 19, Issue:3 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Biopsy; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2009
Overview of pivotal studies for prostate cancer risk reduction, past and present. Urology, 2009, Volume: 73, Issue:5 Suppl Topics: 5-alpha Reductase Inhibitors; Azasteroids; Clinical Trials as Topic; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms	2009
Molecular profiles of finasteride effects on prostate carcinogenesis. Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:6 Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Androgens; Animals; Anticarcinogenic Agents; Apoptosis; Apoptosis Regulatory Proteins; Azasteroids; Dihydrotestosterone; Disease Progression; Dutasteride; Epithelial Cells; Finasteride; Humans; Isoenzymes; Male; Neoplasm Proteins; Neoplasms, Hormone-Dependent; Patient Selection; Prostate; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Stromal Cells	2009
Key targets of hormonal treatment of prostate cancer. Part 2: the androgen receptor and 5alpha-reductase. BJU international, 2009, Volume: 104, Issue:9 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Azasteroids; Clinical Trials as Topic; Dutasteride; Finasteride; Humans; Male; Neoplasms, Hormone-Dependent; Prostatic Neoplasms	2009
High-grade prostate cancer and finasteride. BJU international, 2010, Volume: 105, Issue:4 Topics: 5-alpha Reductase Inhibitors; Aged; Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prevalence; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome	2010
Chemoprevention of prostate cancer. The Urologic clinics of North America, 2010, Volume: 37, Issue:1 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Chemoprevention; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Primary Prevention; Prostatic Neoplasms; Risk Factors	2010
Update on chemoprevention for prostate cancer. Current opinion in urology, 2010, Volume: 20, Issue:3 Topics: Azasteroids; Chemoprevention; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms; Risk Factors; Vitamins	2010
Finasteride. Expert opinion on drug metabolism & toxicology, 2010, Volume: 6, Issue:7 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Animals; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2010
Steroid 5 α-reductase inhibitors targeting BPH and prostate cancer. The Journal of steroid biochemistry and molecular biology, 2011, Volume: 125, Issue:1-2 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Clinical Trials as Topic; Dutasteride; Finasteride; Humans; Male; Molecular Structure; Prostatic Hyperplasia; Prostatic Neoplasms	2011
Finasteride metabolism and pharmacogenetics: new approaches to personalized prevention of prostate cancer. Future oncology (London, England), 2010, Volume: 6, Issue:12 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Cytochrome P-450 CYP3A; Finasteride; Genetic Variation; Glucuronosyltransferase; Humans; Male; Precision Medicine; Prostatic Neoplasms; Testosterone	2010
Prostate cancer prevention with 5 alpha-reductase inhibitors. Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer, 2011, Volume: 188 Topics: 5-alpha Reductase Inhibitors; Clinical Trials as Topic; Digital Rectal Examination; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms	2011
[Prostate cancer. Current and practice-relevant news from urology in 2011]. Der Urologe. Ausg. A, 2011, Volume: 50 Suppl 1 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Azasteroids; Biopsy; Combined Modality Therapy; Dutasteride; Finasteride; Guideline Adherence; Humans; Male; Middle Aged; Neoplasm Grading; Prognosis; Prostate; Prostatectomy; Prostatic Neoplasms; Survival Rate	2011
[Primary prevention of urologic tumors: prostate cancer]. Der Urologe. Ausg. A, 2011, Volume: 50, Issue:10 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Dutasteride; Feeding Behavior; Finasteride; Humans; Male; Micronutrients; Nutritional Requirements; Primary Prevention; Prostatic Neoplasms; Risk Factors; Treatment Outcome; Vitamins	2011
Dutasteride for the treatment of prostate-related conditions. Expert opinion on drug safety, 2012, Volume: 11, Issue:2 Topics: 5-alpha Reductase Inhibitors; Animals; Antineoplastic Agents, Hormonal; Azasteroids; Dutasteride; Evidence-Based Medicine; Finasteride; Humans; Male; Patient Selection; Prostatic Hyperplasia; Prostatic Neoplasms; Risk Assessment; Risk Factors; Treatment Outcome	2012
Role of 5α-reductase inhibitors in prostate cancer prevention and treatment. Urology, 2012, Volume: 79, Issue:6 Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Azasteroids; Combined Modality Therapy; Drug Therapy, Combination; Dutasteride; Finasteride; Humans; Male; Primary Prevention; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic	2012
[Chemoprevention of prostate cancer - a plea]. Aktuelle Urologie, 2012, Volume: 43, Issue:3 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Anti-Inflammatory Agents, Non-Steroidal; Azasteroids; Cost Savings; Dutasteride; Finasteride; Germany; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; National Health Programs; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators	2012
Future directions in cancer prevention. Nature reviews. Cancer, 2012, Volume: 12, Issue:12 Topics: Aromatase Inhibitors; Azasteroids; Breast Neoplasms; Cancer Vaccines; Diet; Dutasteride; Female; Finasteride; Humans; Immunotherapy; Life Style; Male; Motor Activity; Neoplasms; Nicotiana; Obesity; Prostatic Neoplasms; Selective Estrogen Receptor Modulators; Vaccines	2012
Hormonal treatment for male-pattern hair loss: implications for cancer of the prostate? BJU international, 2002, Volume: 90, Issue:7 Topics: Alopecia; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone	2002
Prostate cancer epidemiology. Lancet (London, England), 2003, Mar-08, Volume: 361, Issue:9360 Topics: Adult; Aged; Diet; Enzyme Inhibitors; Finasteride; Humans; Incidence; Male; Middle Aged; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Selenium	2003
The clinical implications of the prostate cancer prevention trial. BJU international, 2003, Volume: 92, Issue:7 Topics: Aged; Diagnostic Errors; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Incidence; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome	2003
Prevention of prostate cancer with finasteride: US/European perspective. European urology, 2003, Volume: 44, Issue:6 Topics: Aged; Attitude of Health Personnel; Biopsy, Needle; Controlled Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Europe; Finasteride; Humans; Immunohistochemistry; Male; Middle Aged; Practice Patterns, Physicians'; Primary Prevention; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Sensitivity and Specificity; Treatment Outcome; United States	2003
Chemotherapeutic prevention studies of prostate cancer. The Journal of urology, 2004, Volume: 171, Issue:2 Pt 2 Topics: Anticarcinogenic Agents; Antioxidants; Azasteroids; Carotenoids; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Lycopene; Male; Prostatic Neoplasms; Vitamin E	2004
The Prostate Cancer Prevention Trial: current status. The Journal of urology, 2004, Volume: 171, Issue:2 Pt 2 Topics: Anticarcinogenic Agents; Endpoint Determination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Research Design	2004
Hormonal therapy options for patients with a rising prostate-specific antigen level after primary treatment for prostate cancer. Urology, 2003, Dec-29, Volume: 62 Suppl 1 Topics: Adenocarcinoma; Androgen Antagonists; Androgens; Anilides; Antineoplastic Agents, Hormonal; Chemotherapy, Adjuvant; Combined Modality Therapy; Diethylstilbestrol; Disease-Free Survival; Drug Administration Schedule; Enzyme Inhibitors; Finasteride; Gonadotropin-Releasing Hormone; Humans; Male; Neoplasm Proteins; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Orchiectomy; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Salvage Therapy; Tosyl Compounds; Treatment Outcome	2003
Effect of finasteride on risk of prostate cancer: how little we really know. Journal of cellular biochemistry, 2004, Feb-15, Volume: 91, Issue:3 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Clinical Trials as Topic; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate; Prostatic Neoplasms; Testosterone	2004
[Chemoprevention of prostate cancer]. Der Urologe. Ausg. A, 2004, Volume: 43, Issue:5 Topics: Anticarcinogenic Agents; Azasteroids; Chemoprevention; Dutasteride; Europe; Finasteride; Humans; Male; Patient Care Management; Prostatic Neoplasms; Treatment Outcome	2004
Update on chemoprevention of prostate cancer. Current opinion in urology, 2004, Volume: 14, Issue:3 Topics: Aged; Carotenoids; Cyclooxygenase Inhibitors; Enzyme Inhibitors; Finasteride; Humans; Lycopene; Male; Middle Aged; Prevalence; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Selenium; Tea; United States; Vitamin D; Vitamin E	2004
Finasteride, a selective 5-alpha-reductase inhibitor, in the prevention and treatment of human prostate cancer. Clinical prostate cancer, 2004, Volume: 2, Issue:4 Topics: 5-alpha Reductase Inhibitors; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2004
Does finasteride alter the pathology of the prostate and cancer grading? Clinical prostate cancer, 2004, Volume: 2, Issue:4 Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Animals; Disease Models, Animal; Enzyme Inhibitors; Finasteride; Humans; Male; Neoplasm Staging; Prostate; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms	2004
An update on the use of 5alpha-reductase inhibitors. Drugs of today (Barcelona, Spain : 1998), 2004, Volume: 40, Issue:3 Topics: Adrenergic alpha-Antagonists; Azasteroids; Cholestenone 5 alpha-Reductase; Drug Therapy, Combination; Dutasteride; Finasteride; Humans; Isoenzymes; Male; Prostatic Hyperplasia; Prostatic Neoplasms; Randomized Controlled Trials as Topic	2004
Prevention of hormone-related cancers: prostate cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Jan-10, Volume: 23, Issue:2 Topics: Androgens; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Genetic Predisposition to Disease; Humans; Male; Models, Genetic; Polymorphism, Genetic; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors	2005
Approach to management of clinically localized prostate cancer in patients with human immunodeficiency virus. Urology, 2005, Volume: 65, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Anilides; Antineoplastic Agents, Hormonal; Antiretroviral Therapy, Highly Active; Biomarkers, Tumor; Brachytherapy; Case Management; Combined Modality Therapy; Cryosurgery; Finasteride; Follow-Up Studies; HIV Infections; Humans; Leuprolide; Life Expectancy; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Proteins; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Radiotherapy, High-Energy; Retrospective Studies; Tosyl Compounds	2005
[Prostate cancer. Introduction]. Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63, Issue:2 Topics: 5-alpha Reductase Inhibitors; alpha-Tocopherol; Antineoplastic Agents, Hormonal; Diet, Fat-Restricted; Diet, Vegetarian; Enzyme Inhibitors; Finasteride; Genetic Therapy; Humans; Male; Neoadjuvant Therapy; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Selenium	2005
[Risk factors and current chemoprevention studies in prostate cancer]. Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63, Issue:2 Topics: 5-alpha Reductase Inhibitors; beta Carotene; Dairy Products; Diet, Fat-Restricted; Diet, Vegetarian; Enzyme Inhibitors; Exercise; Finasteride; Fish Oils; Humans; Life Style; Male; Meat; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; Selenium; Vitamin E	2005
Implications of the prostate cancer prevention trial: a decision analysis model of survival outcomes. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Mar-20, Volume: 23, Issue:9 Topics: Aged; Decision Trees; Enzyme Inhibitors; Finasteride; Humans; Incidence; Male; Middle Aged; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Survival Analysis; Treatment Outcome	2005
The finasteride prostate cancer prevention trial (PCPT)--what have we learned? European journal of cancer (Oxford, England : 1990), 2005, Volume: 41, Issue:13 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors	2005
[Is tumour grade applicable to finasteride-treated prostate cancer?]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2005, Volume: 15, Issue:3 Topics: 5-alpha Reductase Inhibitors; Animals; Atrophy; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Neoplasm Staging; Prostate; Prostatic Hyperplasia; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms	2005
[Prevention of prostate cancer]. Deutsche medizinische Wochenschrift (1946), 2005, Sep-09, Volume: 130, Issue:36 Topics: 5-alpha Reductase Inhibitors; Animals; Anticarcinogenic Agents; Azasteroids; Carotenoids; Dutasteride; Enzyme Inhibitors; Finasteride; Fishes; Flavonoids; Fruit; Humans; Isoflavones; Lycopene; Male; Neoplasms, Hormone-Dependent; Phenols; Polyphenols; Prostatic Neoplasms; Selenium; Soy Milk; Tea; Vegetables; Vitamin D; Vitamin E	2005
Mechanisms of disease: Prostate cancer--a model for cancer chemoprevention in clinical practice. Nature clinical practice. Oncology, 2005, Volume: 2, Issue:5 Topics: Androgens; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Chemoprevention; Diet; Enzyme Inhibitors; Epidemiologic Studies; Finasteride; Humans; Inflammation; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic	2005
The effects of 5alpha-reductase inhibitors on the natural history, detection and grading of prostate cancer: current state of knowledge. The Journal of urology, 2005, Volume: 174, Issue:6 Topics: Antineoplastic Agents; Cholestenone 5 alpha-Reductase; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Neoplasm Staging; Prostatic Neoplasms	2005
[Prostate cancer prevention]. Revue medicale suisse, 2006, Jan-11, Volume: 2, Issue:48 Topics: Chemoprevention; Diet; Enzyme Inhibitors; Finasteride; Humans; Life Style; Male; Prostatic Neoplasms	2006
Can prostate cancer be prevented? Nature clinical practice. Urology, 2005, Volume: 2, Issue:1 Topics: Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms; Selenium; Vitamin E	2005
Update on prostate cancer chemoprevention. Pharmacotherapy, 2006, Volume: 26, Issue:3 Topics: 5-alpha Reductase Inhibitors; Anti-Inflammatory Agents, Non-Steroidal; Azasteroids; Carotenoids; Chemoprevention; Clinical Trials as Topic; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms; Selenium; Vitamin E; Vitamins	2006
[Prostate cancer chemoprevention]. Przeglad lekarski, 2005, Volume: 62, Issue:9 Topics: Carotenoids; Drug Therapy; Enzyme Inhibitors; Finasteride; Humans; Isoflavones; Lycopene; Male; Prostatic Neoplasms; Selenium; Soy Foods; Vitamin A; Vitamin D; Vitamin E	2005
Chemoprevention of prostate cancer with finasteride. Expert opinion on pharmacotherapy, 2006, Volume: 7, Issue:7 Topics: Animals; Antineoplastic Agents, Hormonal; Finasteride; Humans; Male; Prostatic Neoplasms	2006
Finasteride as a chemopreventive agent in prostate cancer: impact of the PCPT on urologic practice. Nature clinical practice. Urology, 2006, Volume: 3, Issue:8 Topics: Clinical Trials, Phase III as Topic; Enzyme Inhibitors; Finasteride; Humans; Incidence; Male; Precancerous Conditions; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors; United States	2006
Should finasteride be used to prevent prostate cancer? Current treatment options in oncology, 2006, Volume: 7, Issue:5 Topics: Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms	2006
Looking back at PCPT: looking forward to new paradigms in prostate cancer screening and prevention. European urology, 2007, Volume: 51, Issue:1 Topics: 5-alpha Reductase Inhibitors; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors	2007
Prostate cancer prevention and finasteride. The Journal of urology, 2006, Volume: 176, Issue:5 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms	2006
A review of phase III clinical trials of prostate cancer chemoprevention. Annals of the Royal College of Surgeons of England, 2007, Volume: 89, Issue:3 Topics: Antineoplastic Agents; Azasteroids; Clinical Trials, Phase III as Topic; Dutasteride; Enzyme Inhibitors; Finasteride; Forecasting; Humans; Male; Prostatic Neoplasms; Selenium Compounds; Vitamin E	2007
Hormonal interventions to prevent hormonal cancers: breast and prostate cancers. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2007, Volume: 16, Issue:3 Topics: Androgen Receptor Antagonists; Antineoplastic Agents, Hormonal; Breast Neoplasms; Female; Finasteride; Humans; Male; Primary Prevention; Prostatic Neoplasms; Raloxifene Hydrochloride; Selective Estrogen Receptor Modulators; Tamoxifen	2007
Hormone ablation therapy: lightening the load for today's prostate cancer patient. Urologic nursing, 2007, Volume: 27 Suppl Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Antineoplastic Agents, Hormonal; Combined Modality Therapy; Drug Monitoring; Finasteride; Flutamide; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Mass Screening; Neoplasm Staging; Nurse's Role; Nursing Assessment; Oligopeptides; Patient Education as Topic; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quality of Life; Treatment Outcome	2007
Chemoprevention of prostate cancer: lessons learned. BJU international, 2007, Volume: 100 Suppl 2 Topics: Antineoplastic Agents; Enzyme Inhibitors; Family Practice; Finasteride; Humans; Male; Prostatic Neoplasms; Risk Factors; Risk Reduction Behavior	2007
Type 1 and type 2 5alpha-reductase expression in the development and progression of prostate cancer. European urology, 2008, Volume: 53, Issue:2 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Azasteroids; Clinical Trials as Topic; Disease Progression; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Isoenzymes; Male; Prostatic Neoplasms	2008
Role of 5 alpha-reductase inhibitors in the management of prostate cancer. Clinical interventions in aging, 2006, Volume: 1, Issue:4 Topics: 5-alpha Reductase Inhibitors; Aged; Azasteroids; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2006
The rationale for inhibiting 5alpha-reductase isoenzymes in the prevention and treatment of prostate cancer. The Journal of urology, 2008, Volume: 179, Issue:4 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androgen Receptor Antagonists; Azasteroids; Dihydrotestosterone; Disease Progression; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Isoenzymes; Male; Prostate; Prostatic Neoplasms; Receptors, Androgen	2008
Five-alpha-reductase Inhibitors for prostate cancer prevention. The Cochrane database of systematic reviews, 2008, Apr-16, Issue:2 Topics: 5-alpha Reductase Inhibitors; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Randomized Controlled Trials as Topic	2008
Androgens and prevention of prostate cancer. Current opinion in endocrinology, diabetes, and obesity, 2008, Volume: 15, Issue:3 Topics: Androgens; Anticarcinogenic Agents; Azasteroids; Dutasteride; Finasteride; Humans; Male; Prostate; Prostatic Neoplasms; Selenium; Signal Transduction; Vitamin E	2008
The effect of finasteride on prostate specific antigen: review of available data. The Journal of urology, 1996, Volume: 155, Issue:1 Topics: 5-alpha Reductase Inhibitors; Adult; Age Factors; Aged; Aged, 80 and over; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Reference Values; Sensitivity and Specificity; Time Factors	1996
Finasteride. The New England journal of medicine, 1994, Jan-13, Volume: 330, Issue:2 Topics: Acne Vulgaris; Alopecia; Androgens; Finasteride; Hirsutism; Humans; Male; Oxidoreductases; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms	1994
Prostate-specific antigen: critical issues for the practicing physician. Mayo Clinic proceedings, 1994, Volume: 69, Issue:1 Topics: Adult; Age Distribution; Aged; Finasteride; Humans; Male; Middle Aged; Palpation; Prostate-Specific Antigen; Prostatic Neoplasms; Rectum; Reference Values	1994
5 alpha-reductase inhibitors and prostatic disease. Clinical endocrinology, 1994, Volume: 41, Issue:2 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androgens; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Finasteride; Humans; Male; Prostate; Prostatic Diseases; Prostatic Hyperplasia; Prostatic Neoplasms; Testosterone	1994
Pathogenesis and medical management of benign prostatic hyperplasia. Seminars in nephrology, 1994, Volume: 14, Issue:6 Topics: Adrenergic alpha-Antagonists; Adult; Aged; Androgen Antagonists; Finasteride; Humans; Male; Mass Screening; Middle Aged; Prostate-Specific Antigen; Prostatectomy; Prostatic Hyperplasia; Prostatic Neoplasms	1994
Chemoprevention of prostate cancer. Seminars in urology, 1995, Volume: 13, Issue:2 Topics: Androgen Antagonists; Cholesterol; Depression, Chemical; Diet; Eflornithine; Finasteride; Humans; Male; Prostatic Neoplasms; Retinoids; Vitamin E	1995
Chemoprevention of prostate cancer with finasteride. Important advances in oncology, 1995 Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prostatic Neoplasms; Randomized Controlled Trials as Topic	1995
Prostate cancer prevention: risk reduction through life-style, diet, and chemoprevention. Oncology nursing forum, 1994, Volume: 21, Issue:9 Topics: Diet; Finasteride; Humans; Life Style; Male; Prostatic Neoplasms; Risk Factors	1994
The potential for hormonal prevention trials. Cancer, 1994, Nov-01, Volume: 74, Issue:9 Suppl Topics: 5-alpha Reductase Inhibitors; Adult; Breast Neoplasms; Female; Finasteride; Humans; Male; Middle Aged; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Receptors, Estrogen; Tamoxifen	1994
Chemoprevention of prostate cancer. Urology, 1994, Volume: 43, Issue:5 Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Animals; Dietary Fats; Eflornithine; Fenretinide; Finasteride; Humans; Male; Prevalence; Primary Prevention; Prostatic Neoplasms; Risk Factors	1994
The potential application of finasteride for chemoprevention of prostate cancer. Annals of the New York Academy of Sciences, 1995, Sep-30, Volume: 768 Topics: 5-alpha Reductase Inhibitors; Animals; Anticarcinogenic Agents; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms	1995
Finasteride: a clinical review. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 1995, Volume: 49, Issue:7-8 Topics: Alopecia; Enzyme Inhibitors; Finasteride; Hirsutism; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms	1995
Healthcare resources should be targeted to chemoprevention: the argument against. European urology, 1996, Volume: 29 Suppl 2 Topics: Anticarcinogenic Agents; Clinical Trials as Topic; Cost-Benefit Analysis; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Health Care Rationing; Health Resources; Humans; Male; Primary Prevention; Prostatic Neoplasms; Public Opinion	1996
Screening for prostate cancer: opportunities for prevention. Seminars in urologic oncology, 1996, Volume: 14, Issue:2 Suppl 2 Topics: Bias; Combined Modality Therapy; Enzyme Inhibitors; Finasteride; Humans; Male; Mass Screening; Primary Prevention; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Time Factors; Treatment Outcome	1996
Evaluation of men on finasteride. Seminars in urologic oncology, 1996, Volume: 14, Issue:3 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Mass Screening; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms	1996
Selections from current literature: androgenetic alopecia: the science behind a new oral treatment. Family practice, 1998, Volume: 15, Issue:5 Topics: 5-alpha Reductase Inhibitors; Alopecia; Biomarkers, Tumor; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone	1998
Prostatic adenocarcinoma following androgen deprivation therapy: the new difficulty in histologic interpretation. Anatomic pathology (Chicago, Ill. : annual), 1998, Volume: 3 Topics: Adenocarcinoma; Androgen Antagonists; Cholestenone 5 alpha-Reductase; Diagnosis, Differential; Enzyme Inhibitors; Finasteride; Humans; Immunohistochemistry; Male; Oxidoreductases; Prostatic Neoplasms	1998
Hormonal manipulation for rising PSA after radical prostatectomy. Seminars in urologic oncology, 1999, Volume: 17, Issue:3 Topics: Androgen Antagonists; Anilides; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Flutamide; Humans; Male; Neoplasm Recurrence, Local; Nitriles; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Tosyl Compounds	1999
Treatment changes in prostatic hyperplasia and cancer, including androgen deprivation therapy and radiotherapy. The Urologic clinics of North America, 1999, Volume: 26, Issue:3 Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Enzyme Inhibitors; Finasteride; Humans; Immunohistochemistry; Male; Prostatic Hyperplasia; Prostatic Neoplasms	1999
Prostate cancer prevention trials in the USA. European journal of cancer (Oxford, England : 1990), 2000, Volume: 36, Issue:10 Topics: 5-alpha Reductase Inhibitors; Aged; Animals; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Neoplasms; Rabbits; Risk Factors; Selenium; Vitamin E	2000
Exploitable mechanisms for the blockade of androgenic action. The Prostate. Supplement, 2000, Volume: 10 Topics: Androgen Antagonists; Drug Therapy, Combination; Enzyme Inhibitors; Estrogens; Finasteride; Forecasting; Humans; Intracellular Membranes; Male; Prostatic Neoplasms; Protein-Tyrosine Kinases; Signal Transduction	2000
Pharmacogenetics of human androgens and prostatic diseases. Pharmacogenomics, 2001, Volume: 2, Issue:1 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Finasteride; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Male; Pharmacogenetics; Polymorphism, Single Nucleotide; Prostatic Hyperplasia; Prostatic Neoplasms; Receptors, Androgen	2001
Androgen deprivation therapy for patients with clinically localized (stages T1 to T3) prostate cancer and for patients with biochemical recurrence after radical prostatectomy. Urology, 2001, Volume: 58, Issue:2 Suppl 1 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Disease Progression; Drug Administration Schedule; Finasteride; Humans; Male; Neoplasm Recurrence, Local; Neoplasm Staging; Orchiectomy; Postoperative Complications; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quality of Life; Treatment Outcome	2001
Androgen deprivation therapy for prostate cancer chemoprevention: current status and future directions for agent development. Urology, 2001, Volume: 58, Issue:2 Suppl 1 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Chemoprevention; Drug Design; Finasteride; Gene Expression Profiling; Humans; Male; Oligonucleotide Array Sequence Analysis; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms	2001
Prevention of prostate cancer. Hematology/oncology clinics of North America, 2001, Volume: 15, Issue:3 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adenocarcinoma; Androgen Antagonists; Androgens; Animals; Anticarcinogenic Agents; Antioxidants; Carotenoids; Case-Control Studies; Cohort Studies; Dietary Fats; Double-Blind Method; Enzyme Inhibitors; Finasteride; Genetic Predisposition to Disease; Humans; Incidence; Insulin-Like Growth Factor I; Life Style; Lycopene; Male; Mice; Mice, Transgenic; Micronutrients; Neoplasms, Hormone-Dependent; Prospective Studies; Prostatic Hyperplasia; Prostatic Neoplasms; Racial Groups; Randomized Controlled Trials as Topic; Risk Factors; Selenium; Soybean Proteins; Vitamin D; Vitamin E	2001
5alpha-reductase activity in the prostate. Urology, 2001, Volume: 58, Issue:6 Suppl 1 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Animals; Cryptorchidism; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Forecasting; Humans; Infertility, Male; Isoenzymes; Male; Mice; Mice, Knockout; Mutation; Penile Erection; Penis; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Receptors, Androgen; Testis; Tumor Cells, Cultured	2001
The future of prostate cancer prevention. Annals of the New York Academy of Sciences, 2001, Volume: 952 Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Adult; Aged; Androgen Antagonists; Androgens; Anticarcinogenic Agents; Antioxidants; Clinical Trials as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Diet; Double-Blind Method; Enzyme Inhibitors; Finasteride; Forecasting; Humans; Male; Middle Aged; Multicenter Studies as Topic; Neoplasms, Hormone-Dependent; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk; Selenium; Soybean Proteins; Treatment Outcome; Vitamin A; Vitamin D; Vitamin E	2001
Chemoprevention strategies for prostate cancer: the role of 5 alpha-reductase inhibitors. Journal of cellular biochemistry. Supplement, 1992, Volume: 16H Topics: 5-alpha Reductase Inhibitors; Aged; Androgens; Androstenes; Animals; Azasteroids; Finasteride; Humans; Male; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms	1992
Chemoprevention of prostate cancer: guidelines for possible intervention strategies. Journal of cellular biochemistry. Supplement, 1992, Volume: 16H Topics: Androstenes; Anticarcinogenic Agents; Azasteroids; Finasteride; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic	1992
Dual control by androgens and peptide growth factors of prostatic growth in human benign prostatic hyperplasia. Molecular and cellular endocrinology, 1991, Volume: 78, Issue:1-2 Topics: 5-alpha Reductase Inhibitors; Androgens; Androstenes; Azasteroids; Carcinoma; Cell Division; Cells, Cultured; Dihydrotestosterone; Epidermal Growth Factor; Finasteride; Gonadotropin-Releasing Hormone; Growth Substances; Humans; Insulin-Like Growth Factor I; Male; Peptides; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Tumor Cells, Cultured	1991
Role of 5 alpha-reductase inhibitors in the treatment of advanced prostatic carcinoma. The Urologic clinics of North America, 1991, Volume: 18, Issue:1 Topics: 5-alpha Reductase Inhibitors; Androgens; Androstenes; Animals; Azasteroids; Finasteride; Humans; Male; Prostate; Prostatic Neoplasms	1991

Trials

89 trial(s) available for finasteride and Cancer of Prostate

Article	Year
Serum markers, obesity and prostate cancer risk: results from the prostate cancer prevention trial. Endocrine-related cancer, 2022, 01-20, Volume: 29, Issue:2 Topics: Biomarkers; Case-Control Studies; Finasteride; Humans; Male; Obesity; Prostatic Neoplasms; Risk Factors	2022
Germline genetic variation in prostate susceptibility does not predict outcomes in the chemoprevention trials PCPT and SELECT. Prostate cancer and prostatic diseases, 2020, Volume: 23, Issue:2 Topics: 5-alpha Reductase Inhibitors; Aged; Biomarkers, Tumor; Case-Control Studies; Clinical Trials as Topic; DNA Mutational Analysis; Finasteride; Follow-Up Studies; Genetic Predisposition to Disease; Germ-Line Mutation; Humans; Male; Polymorphism, Single Nucleotide; Prognosis; Prostatic Neoplasms; Risk Factors; Survival Rate	2020
Comparative Healthcare Research Outcomes of Novel Surgery in prostate cancer (IP4-CHRONOS): A prospective, multi-centre therapeutic phase II parallel Randomised Control Trial. Contemporary clinical trials, 2020, Volume: 93 Topics: Ablation Techniques; Androgen Antagonists; Anilides; Brachytherapy; Costs and Cost Analysis; Equivalence Trials as Topic; Finasteride; Humans; Male; Neoadjuvant Therapy; Neoplasm Recurrence, Local; Nitriles; Progression-Free Survival; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Radiotherapy; Research Design; Tosyl Compounds; United Kingdom	2020
Association between variants in genes involved in the immune response and prostate cancer risk in men randomized to the finasteride arm in the Prostate Cancer Prevention Trial. The Prostate, 2017, Volume: 77, Issue:8 Topics: Aged; Biopsy; Finasteride; Genetic Association Studies; Humans; Inflammation; Interleukin-10; Interleukin-8; Male; Middle Aged; Neoplasm Grading; Polymorphism, Single Nucleotide; Prostate; Prostatic Neoplasms; Urological Agents	2017
Hormonal manipulation with finasteride or oral contraception does not influence incidence of renal cell carcinoma. European journal of cancer prevention : the official journal of the European Cancer Prevention Organisation (ECP), 2018, Volume: 27, Issue:5 Topics: 5-alpha Reductase Inhibitors; Aged; Carcinoma, Renal Cell; Colorectal Neoplasms; Contraception; Contraceptives, Oral; Dutasteride; Female; Finasteride; Follow-Up Studies; Humans; Incidence; Kidney Neoplasms; Longitudinal Studies; Lung Neoplasms; Male; Middle Aged; Ovarian Neoplasms; Prostatic Hyperplasia; Prostatic Neoplasms; Risk Factors; Self Report	2018
Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors. BJU international, 2018, Volume: 121, Issue:3 Topics: 5-alpha Reductase Inhibitors; Aged; Antigens, Neoplasm; Dutasteride; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Grading; Prospective Studies; Prostatic Neoplasms; Risk Factors; Single-Blind Method; Watchful Waiting	2018
Associations between polymorphisms in genes related to estrogen metabolism and function and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Carcinogenesis, 2018, 02-09, Volume: 39, Issue:2 Topics: 5-alpha Reductase Inhibitors; Aged; Aromatase; Case-Control Studies; Estrogens; Finasteride; Genetic Predisposition to Disease; Genotype; Humans; Male; Middle Aged; Polymorphism, Single Nucleotide; Prostatic Neoplasms	2018
Circadian genes and risk of prostate cancer in the prostate cancer prevention trial. Molecular carcinogenesis, 2018, Volume: 57, Issue:3 Topics: 5-alpha Reductase Inhibitors; Aged; Basic Helix-Loop-Helix Transcription Factors; Case-Control Studies; Circadian Clocks; Finasteride; Humans; Male; Middle Aged; Nerve Tissue Proteins; Polymorphism, Single Nucleotide; Prostate; Prostatic Neoplasms; Risk Factors	2018
Finasteride does not prevent bladder cancer: A secondary analysis of the Medical Therapy for Prostatic Symptoms Study. Urologic oncology, 2018, Volume: 36, Issue:7 Topics: 5-alpha Reductase Inhibitors; Androgens; Dihydrotestosterone; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prognosis; Prostatic Neoplasms; Urinary Bladder Neoplasms	2018
The effect of 3-month finasteride challenge on biomarkers for predicting cancer outcome on biopsy: Results of a randomized trial. PloS one, 2018, Volume: 13, Issue:10 Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Aged, 80 and over; Antigens, Neoplasm; Biomarkers, Tumor; Biopsy; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Oncogene Proteins, Fusion; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome	2018
Case-only Methods Identified Genetic Loci Predicting a Subgroup of Men with Reduced Risk of High-grade Prostate Cancer by Finasteride. Cancer prevention research (Philadelphia, Pa.), 2019, Volume: 12, Issue:2 Topics: 5-alpha Reductase Inhibitors; Biomarkers, Tumor; Finasteride; Genetic Loci; Humans; Male; Middle Aged; Neoplasm Grading; Polymorphism, Single Nucleotide; Prostatic Neoplasms; Risk Factors	2019
Effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer. The Journal of steroid biochemistry and molecular biology, 2013, Volume: 138 Topics: 5-alpha Reductase Inhibitors; Aged; Androstane-3,17-diol; Androstenedione; Dihydrotestosterone; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone	2013
Predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and American Urological Association symptom score. Urology, 2013, Volume: 82, Issue:5 Topics: Aged; Aged, 80 and over; Anticarcinogenic Agents; Biopsy; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Multivariate Analysis; Odds Ratio; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Regression Analysis; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome; Urological Agents	2013
Factors associated with adherence to an end-of-study biopsy: lessons from the prostate cancer prevention trial (SWOG-Coordinated Intergroup Study S9217). Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2014, Volume: 23, Issue:8 Topics: 5-alpha Reductase Inhibitors; Biopsy; Double-Blind Method; Finasteride; Humans; Male; Patient Compliance; Prostatic Neoplasms; Research Design; ROC Curve	2014
Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer: results from the Prostate Cancer Prevention Trial. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2014, Volume: 23, Issue:8 Topics: 5-alpha Reductase Inhibitors; Aged; Case-Control Studies; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Prostatic Neoplasms; Risk Factors; Vitamin D	2014
Effect of finasteride on serum androstenedione and risk of prostate cancer within the prostate cancer prevention trial: differential effect on high- and low-grade disease. Urology, 2015, Volume: 85, Issue:3 Topics: Androstenedione; Case-Control Studies; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Neoplasm Grading; Prostatic Neoplasms; Risk Assessment	2015
Treatment satisfaction and clinically meaningful symptom improvement in men with lower urinary tract symptoms and prostatic enlargement secondary to benign prostatic hyperplasia: Secondary results from a 6-month, randomized, double-blind study comparing f International journal of urology : official journal of the Japanese Urological Association, 2015, Volume: 22, Issue:6 Topics: 5-alpha Reductase Inhibitors; Aged; Double-Blind Method; Drug Therapy, Combination; Finasteride; Humans; Male; Middle Aged; Organ Size; Patient Satisfaction; Phosphodiesterase 5 Inhibitors; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatism; Severity of Illness Index; Tadalafil	2015
Prostate stromal cell telomere shortening is associated with risk of prostate cancer in the placebo arm of the Prostate Cancer Prevention Trial. The Prostate, 2015, Aug-01, Volume: 75, Issue:11 Topics: 5-alpha Reductase Inhibitors; Biopsy; Chromosomal Instability; Disease Progression; Finasteride; Humans; Male; Middle Aged; Prostate; Prostatic Neoplasms; Risk Factors; Stromal Cells; Telomere Homeostasis; Telomere Shortening	2015
Finasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention Trial. PloS one, 2015, Volume: 10, Issue:5 Topics: Aged; Case-Control Studies; Cytochrome P-450 CYP3A; Finasteride; Genetic Testing; Humans; Logistic Models; Male; Middle Aged; Polymorphism, Single Nucleotide; Prostatic Neoplasms	2015
Serum Retinol and Carotenoid Concentrations and Prostate Cancer Risk: Results from the Prostate Cancer Prevention Trial. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2015, Volume: 24, Issue:10 Topics: 5-alpha Reductase Inhibitors; Aged; Antioxidants; Biomarkers, Tumor; Carotenoids; Finasteride; Follow-Up Studies; Humans; Incidence; Male; Middle Aged; Pilot Projects; Prospective Studies; Prostatic Neoplasms; Risk Factors; Survival Rate; Time Factors; United States; Vitamin A; Vitamins	2015
Non-steroidal anti-inflammatory drug (NSAID) use is not associated with erectile dysfunction risk: results from the Prostate Cancer Prevention Trial. BJU international, 2016, Volume: 117, Issue:3 Topics: 5-alpha Reductase Inhibitors; Age Distribution; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Erectile Dysfunction; Finasteride; Humans; Male; Middle Aged; Prostatic Neoplasms; Risk Factors	2016
Tissue Effects in a Randomized Controlled Trial of Short-term Finasteride in Early Prostate Cancer. EBioMedicine, 2016, Volume: 7 Topics: Administration, Oral; Aged; Apoptosis; Biomarkers, Tumor; Cell Proliferation; Double-Blind Method; Finasteride; Humans; Logistic Models; Male; Middle Aged; Neoplasm Grading; Prostatic Neoplasms; Receptors, Androgen; Treatment Outcome	2016
The Prostate Cancer Prevention Trial and European Randomized Study of Screening for Prostate Cancer risk calculators indicating a positive prostate biopsy: a comparison. BJU international, 2008, Volume: 102, Issue:9 Topics: Aged; Biopsy, Needle; Finasteride; Humans; Male; Mass Screening; Middle Aged; Multivariate Analysis; Nomograms; Predictive Value of Tests; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors	2008
Serum steroid and sex hormone-binding globulin concentrations and the risk of incident benign prostatic hyperplasia: results from the prostate cancer prevention trial. American journal of epidemiology, 2008, Dec-15, Volume: 168, Issue:12 Topics: Aged; Finasteride; Follow-Up Studies; Gonadal Steroid Hormones; Humans; Incidence; Male; Middle Aged; Prevalence; Prognosis; Prostatic Hyperplasia; Prostatic Neoplasms; Retrospective Studies; Sex Hormone-Binding Globulin; Surveys and Questionnaires; Time Factors; United States	2008
Effects of short-term finasteride on apoptotic factors and androgen receptors in prostate cancer cells. The Journal of urology, 2009, Volume: 181, Issue:2 Topics: Aged; Apoptosis; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Finasteride; Humans; Immunohistochemistry; Male; Middle Aged; Neoadjuvant Therapy; Neoplasm Staging; Preoperative Care; Probability; Prognosis; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Receptors, Androgen; Reference Values; Sensitivity and Specificity; Tumor Cells, Cultured	2009
Pathologic characteristics of cancers detected in The Prostate Cancer Prevention Trial: implications for prostate cancer detection and chemoprevention. Cancer prevention research (Philadelphia, Pa.), 2008, Volume: 1, Issue:3 Topics: Aged; Antineoplastic Agents; Biopsy; Chemoprevention; Early Detection of Cancer; Finasteride; Follow-Up Studies; Humans; Lymphatic Metastasis; Male; Middle Aged; Neoplasm Invasiveness; Organ Size; Placebos; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Treatment Outcome; Tumor Burden	2008
Finasteride does not increase the risk of high-grade prostate cancer: a bias-adjusted modeling approach. Cancer prevention research (Philadelphia, Pa.), 2008, Volume: 1, Issue:3 Topics: Aged; Bias; Biomarkers; Biopsy; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Models, Statistical; Neoplasm Staging; Odds Ratio; Placebos; Prevalence; Prostatectomy; Prostatic Neoplasms; Risk	2008
Estimating rates of true high-grade disease in the prostate cancer prevention trial. Cancer prevention research (Philadelphia, Pa.), 2008, Volume: 1, Issue:3 Topics: Aged; Antineoplastic Agents; Biopsy; Disease Progression; False Positive Reactions; Finasteride; Humans; Male; Middle Aged; Neoplasm Staging; Placebos; Prostatic Neoplasms	2008
Combined low-dose flutamide plus finasteride vs low-dose flutamide monotherapy for recurrent prostate cancer: a comparative analysis of two phase II trials with a long-term follow-up. BJU international, 2009, Volume: 104, Issue:3 Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Epidemiologic Methods; Finasteride; Flutamide; Humans; Male; Middle Aged; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome	2009
PCPT: Evidence that finasteride reduces risk of most frequently detected intermediate- and high-grade (Gleason score 6 and 7) cancer. Urology, 2009, Volume: 73, Issue:5 Topics: 5-alpha Reductase Inhibitors; Administration, Oral; Age Factors; Aged; Biopsy, Needle; Dose-Response Relationship, Drug; Drug Administration Schedule; Early Detection of Cancer; Finasteride; Humans; Immunohistochemistry; Logistic Models; Male; Middle Aged; Neoplasm Staging; Primary Prevention; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Treatment Outcome; Tumor Burden	2009
Finasteride modifies the relation between serum C-peptide and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:3 Topics: C-Peptide; Case-Control Studies; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Finasteride; Humans; Insulin Resistance; Leptin; Male; Middle Aged; Prostatic Neoplasms; Risk Factors	2010
Serum oxidized protein and prostate cancer risk within the Prostate Cancer Prevention Trial. Cancer prevention research (Philadelphia, Pa.), 2010, Volume: 3, Issue:4 Topics: Case-Control Studies; Double-Blind Method; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Finasteride; Humans; Male; Middle Aged; Oxidative Stress; Prostatic Neoplasms; Protein Carbonylation; Risk Factors	2010
Serum lycopene concentration and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2011, Volume: 20, Issue:4 Topics: 5-alpha Reductase Inhibitors; Aged; Biomarkers, Tumor; Carotenoids; Case-Control Studies; Finasteride; Humans; Lycopene; Male; Middle Aged; Prostatic Neoplasms; Risk Factors	2011
Serum phospholipid fatty acids and prostate cancer risk: results from the prostate cancer prevention trial. American journal of epidemiology, 2011, Jun-15, Volume: 173, Issue:12 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Case-Control Studies; Fatty Acids, Omega-3; Fatty Acids, Omega-6; Finasteride; Humans; Male; Middle Aged; Prevalence; Prostatic Hyperplasia; Prostatic Neoplasms; Risk Factors	2011
Association of symptomatic benign prostatic hyperplasia and prostate cancer: results from the prostate cancer prevention trial. American journal of epidemiology, 2011, Jun-15, Volume: 173, Issue:12 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Case-Control Studies; Finasteride; Humans; Male; Middle Aged; Prevalence; Prostatic Hyperplasia; Prostatic Neoplasms; Risk Factors	2011
A randomized phase IIb presurgical study of finasteride vs. low-dose flutamide vs. placebo in men with prostate cancer. Efficacy monitored by karyometry. Urologic oncology, 2013, Volume: 31, Issue:5 Topics: 5-alpha Reductase Inhibitors; Aged; Androgen Antagonists; Cell Nucleus; Cost-Benefit Analysis; Disease Progression; Dose-Response Relationship, Drug; Double-Blind Method; Finasteride; Flutamide; Humans; Karyometry; Male; Middle Aged; Preoperative Period; Prospective Studies; Prostate; Prostatic Neoplasms; Treatment Outcome	2013
Efficacy of peripheral androgen blockade in prostate cancer patients with biochemical failure after definitive local therapy: results of Cancer and Leukemia Group B (CALGB) 9782. Cancer, 2012, Sep-01, Volume: 118, Issue:17 Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Finasteride; Flutamide; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Failure	2012
Prospective study of cytomegalovirus serostatus and prostate cancer risk in the Prostate Cancer Prevention Trial. Cancer causes & control : CCC, 2012, Volume: 23, Issue:9 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Case-Control Studies; Cytomegalovirus; Cytomegalovirus Infections; Finasteride; Humans; Male; Middle Aged; Prospective Studies; Prostatic Neoplasms; Risk Factors; Seroepidemiologic Studies	2012
Associations of serum sex steroid hormone and 5α-androstane-3α,17β-diol glucuronide concentrations with prostate cancer risk among men treated with finasteride. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2012, Volume: 21, Issue:10 Topics: 5-alpha Reductase Inhibitors; Aged; Androstane-3,17-diol; Case-Control Studies; Finasteride; Glucuronides; Gonadal Steroid Hormones; Humans; Male; Middle Aged; Prostatic Neoplasms; Risk; Sex Hormone-Binding Globulin	2012
Health-related quality-of-life findings for the prostate cancer prevention trial. Journal of the National Cancer Institute, 2012, Sep-19, Volume: 104, Issue:18 Topics: 5-alpha Reductase Inhibitors; Activities of Daily Living; Aged; Anticarcinogenic Agents; Finasteride; Health Status; Humans; Male; Mental Health; Middle Aged; Models, Statistical; Prospective Studies; Prostatic Neoplasms; Quality of Life; Surveys and Questionnaires	2012
Insulin-like growth factors and insulin-like growth factor-binding proteins and prostate cancer risk: results from the prostate cancer prevention trial. Cancer prevention research (Philadelphia, Pa.), 2013, Volume: 6, Issue:2 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Case-Control Studies; Finasteride; Humans; Insulin-Like Growth Factor Binding Proteins; Male; Middle Aged; Prostatic Neoplasms; Risk Factors; Somatomedins	2013
PSA response to finasteride challenge in men with a serum PSA greater than 4 ng/ml and previous negative prostate biopsy: preliminary study. Urology, 2002, Volume: 60, Issue:3 Topics: Biopsy, Needle; Depression, Chemical; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Palpation; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms	2002
Biomarker-based methods for determining noncompliance in a prevention trial. Controlled clinical trials, 2002, Volume: 23, Issue:6 Topics: Aged; Algorithms; Biomarkers; Dihydrotestosterone; Drug Monitoring; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Patient Compliance; Prostatic Neoplasms; Randomized Controlled Trials as Topic; ROC Curve; Sensitivity and Specificity	2002
The influence of finasteride on the development of prostate cancer. The New England journal of medicine, 2003, Jul-17, Volume: 349, Issue:3 Topics: 5-alpha Reductase Inhibitors; Aged; Antineoplastic Agents, Hormonal; Biopsy; Finasteride; Humans; Male; Middle Aged; Morbidity; Neoplasms, Hormone-Dependent; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms	2003
Finasteride and flutamide therapy in patients with advanced prostate cancer: response to subsequent castration and long-term follow-up. Urology, 2003, Volume: 62, Issue:1 Topics: Adenocarcinoma; Adult; Aged; Androgen Antagonists; Androgens; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Bone Neoplasms; Disease Progression; Drug Resistance, Neoplasm; Enzyme Inhibitors; Finasteride; Flutamide; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasms, Hormone-Dependent; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Survival Rate; Treatment Outcome	2003
Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy. Urology, 2003, Volume: 62, Issue:5 Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Enzyme Inhibitors; Finasteride; Flutamide; Follow-Up Studies; Humans; Life Tables; Male; Neoplasm Recurrence, Local; Prospective Studies; Prostatectomy; Prostatic Neoplasms; Radioisotope Teletherapy; Survival Analysis; Treatment Outcome	2003
Implementation of the Prostate Cancer Prevention Trial (PCPT). Controlled clinical trials, 2004, Volume: 25, Issue:2 Topics: Chemoprevention; Cholestenone 5 alpha-Reductase; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prevalence; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Research Design	2004
Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per milliliter. The New England journal of medicine, 2004, May-27, Volume: 350, Issue:22 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Biopsy; Finasteride; Humans; Male; Middle Aged; Prevalence; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Risk	2004
Combined modality treatment in the management of high-risk prostate cancer. International journal of radiation oncology, biology, physics, 2004, Aug-01, Volume: 59, Issue:5 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Brachytherapy; Combined Modality Therapy; Finasteride; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Palladium; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Radiotherapy, Conformal; Testosterone	2004
Effect of short-term finasteride therapy on peroperative bleeding in patients who were candidates for transurethral resection of the prostate (TUR-P): a randomized controlled study. Prostate cancer and prostatic diseases, 2005, Volume: 8, Issue:3 Topics: Age Factors; Aged; Anticoagulants; Aspirin; Finasteride; Hemoglobins; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Renal Insufficiency; Risk; Time Factors; Transurethral Resection of Prostate; Urethra; Warfarin	2005
Long-term effects of finasteride on prostate specific antigen levels: results from the prostate cancer prevention trial. The Journal of urology, 2005, Volume: 174, Issue:3 Topics: Aged; Aged, 80 and over; Biomarkers, Tumor; Biopsy; Double-Blind Method; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Long-Term Care; Male; Middle Aged; Prognosis; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Reference Values	2005
Effect of finasteride on the sensitivity of PSA for detecting prostate cancer. Journal of the National Cancer Institute, 2006, Aug-16, Volume: 98, Issue:16 Topics: Aged; Area Under Curve; Biopsy; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Prostatitis; Research Design; ROC Curve; Sensitivity and Specificity	2006
Obesity, diabetes, and risk of prostate cancer: results from the prostate cancer prevention trial. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2006, Volume: 15, Issue:10 Topics: Adenocarcinoma; Age Factors; Aged; Body Mass Index; Diabetes Mellitus; Enzyme Inhibitors; Finasteride; Humans; Logistic Models; Male; Middle Aged; Neoplasm Staging; Obesity; Prostatic Neoplasms; Research Design; Risk Factors; Waist-Hip Ratio	2006
Sensitivity and specificity of prostate-specific antigen for prostate cancer detection with high rates of biopsy verification. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 2006, Volume: 78, Issue:4 Topics: Biopsy; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Sensitivity and Specificity	2006
Finasteride improves the sensitivity of digital rectal examination for prostate cancer detection. The Journal of urology, 2007, Volume: 177, Issue:5 Topics: Biopsy; Diagnosis, Differential; Digital Rectal Examination; Dose-Response Relationship, Drug; Enzyme Inhibitors; Finasteride; Humans; Male; Prognosis; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Sensitivity and Specificity	2007
Finasteride decreases the risk of prostatic intraepithelial neoplasia. The Journal of urology, 2007, Volume: 178, Issue:1 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms	2007
Longitudinal analysis of sexual function reported by men in the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute, 2007, Jul-04, Volume: 99, Issue:13 Topics: Aged; Anticarcinogenic Agents; Cholestenone 5 alpha-Reductase; Double-Blind Method; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Humans; Longitudinal Studies; Male; Middle Aged; Placebos; Prostatic Neoplasms; Surveys and Questionnaires; Time Factors	2007
Prediction of prostate cancer for patients receiving finasteride: results from the Prostate Cancer Prevention Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jul-20, Volume: 25, Issue:21 Topics: Administration, Oral; Aged; Biopsy, Needle; Confidence Intervals; Digital Rectal Examination; Disease-Free Survival; Dose-Response Relationship, Drug; Drug Administration Schedule; Finasteride; Follow-Up Studies; Humans; Immunohistochemistry; Male; Middle Aged; Multivariate Analysis; Neoplasm Staging; Odds Ratio; Predictive Value of Tests; Preventive Medicine; Probability; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Survival Analysis; Treatment Outcome	2007
Detection bias due to the effect of finasteride on prostate volume: a modeling approach for analysis of the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute, 2007, Sep-19, Volume: 99, Issue:18 Topics: Aged; Anticarcinogenic Agents; Bias; Biopsy, Needle; Enzyme Inhibitors; Finasteride; Humans; Incidence; Logistic Models; Male; Middle Aged; Models, Statistical; Odds Ratio; Prostatic Neoplasms; Rectum; Research Design; Severity of Illness Index; Treatment Outcome; Ultrasonography; United States	2007
Finasteride and high-grade prostate cancer in the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute, 2007, Sep-19, Volume: 99, Issue:18 Topics: Aged; Anticarcinogenic Agents; Bias; Biopsy, Needle; Black or African American; Confounding Factors, Epidemiologic; Enzyme Inhibitors; Finasteride; Humans; Incidence; Logistic Models; Male; Middle Aged; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Severity of Illness Index; United States; White People	2007
Finasteride, prostate cancer, and weight gain: evidence for genetic or environmental factors that affect cancer outcomes during finasteride treatment. The Prostate, 2008, Feb-15, Volume: 68, Issue:3 Topics: Aged; Biopsy; Enzyme Inhibitors; Finasteride; Humans; Linear Models; Male; Middle Aged; Prostatic Neoplasms; Treatment Outcome; Weight Gain	2008
Effect of finasteride on prostate-specific antigen density. Urology, 1994, Volume: 43, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Finasteride; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Predictive Value of Tests; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Sensitivity and Specificity	1994
Three-year safety and efficacy data on the use of finasteride in the treatment of benign prostatic hyperplasia. Urology, 1994, Volume: 43, Issue:3 Topics: Adult; Aged; Aged, 80 and over; Dihydrotestosterone; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Severity of Illness Index; Urodynamics	1994
Clinical experience of the detection of prostate cancer in patients with benign prostate hyperplasia treated with finasteride. The Finasteride Study Group. The Journal of urology, 1994, Volume: 151, Issue:5 Topics: Aged; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Palpation; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms	1994
Treatment with finasteride following radical prostatectomy for prostate cancer. Urology, 1995, Volume: 45, Issue:3 Topics: Aged; Aged, 80 and over; Combined Modality Therapy; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms	1995
Design of the Prostate Cancer Prevention Trial (PCPT). Controlled clinical trials, 1995, Volume: 16, Issue:3 Topics: Aged; Bias; Confounding Factors, Epidemiologic; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Random Allocation; Randomized Controlled Trials as Topic; Reproducibility of Results; Research Design; Sample Size; Sexual Dysfunction, Physiological; United States	1995
Combination finasteride and flutamide in advanced carcinoma of the prostate: effective therapy with minimal side effects. The Journal of urology, 1995, Volume: 154, Issue:5 Topics: Aged; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibitors; Finasteride; Flutamide; Follow-Up Studies; Humans; Luteinizing Hormone; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Remission Induction; Testosterone	1995
Prostate Cancer Prevention Trial launched. Journal of the National Cancer Institute, 1993, Oct-20, Volume: 85, Issue:20 Topics: Finasteride; Humans; Male; Middle Aged; Prostatic Neoplasms	1993
Combined finasteride and flutamide therapy in men with advanced prostate cancer. Urology, 1996, Volume: 48, Issue:6 Topics: Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibitors; Finasteride; Flutamide; Humans; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms	1996
Finasteride and flutamide as potency-sparing androgen-ablative therapy for advanced adenocarcinoma of the prostate. Urology, 1997, Volume: 49, Issue:6 Topics: Adenocarcinoma; Aged; Androgen Antagonists; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Flutamide; Follow-Up Studies; Humans; Male; Middle Aged; Neoplasm Staging; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Sexuality; Treatment Failure	1997
Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. The Finasteride PSA Study Group. Urology, 1997, Volume: 50, Issue:1 Topics: Adult; Aged; Aged, 80 and over; Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms	1997
The chemoprevention of prostate cancer and the Prostate Cancer Prevention Trial. Cancer treatment and research, 1996, Volume: 88 Topics: 5-alpha Reductase Inhibitors; Androgens; Antineoplastic Agents; Chemoprevention; Combined Modality Therapy; Disease Progression; Eflornithine; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Neoplasms; Risk Factors; Vitamins	1996
Chemoprevention of prostate cancer: the Prostate Cancer Prevention Trial. The Prostate, 1997, Nov-01, Volume: 33, Issue:3 Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Antineoplastic Agents, Hormonal; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Neoplasms; Selenium; Vitamin D; Vitamin E	1997
Army and Air Force leadership in the Prostate Cancer Prevention Trial. Urology, 1998, Volume: 51, Issue:4A Suppl Topics: Enzyme Inhibitors; Finasteride; Humans; Leadership; Male; Middle Aged; Military Personnel; Prostatic Neoplasms; United States	1998
Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study. Urology, 1998, Volume: 52, Issue:2 Topics: Aged; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Sensitivity and Specificity	1998
The effect of finasteride on the prostate gland in men with elevated serum prostate-specific antigen levels. British journal of cancer, 1998, Volume: 78, Issue:3 Topics: Adenocarcinoma; Aged; Biopsy; Cell Division; Enzyme Inhibitors; Epithelial Cells; Evaluation Studies as Topic; Finasteride; Humans; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms	1998
Biochemical response to testicular androgen ablation among patients with prostate cancer for whom flutamide and/or finasteride therapy failed. Urology, 1998, Volume: 52, Issue:6 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Finasteride; Flutamide; Gonadotropin-Releasing Hormone; Humans; Male; Middle Aged; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Failure	1998
Does long-term finasteride therapy affect the histologic features of benign prostatic tissue and prostate cancer on needle biopsy? PLESS Study Group. Proscar Long-Term Efficacy and Safety Study. Urology, 1999, Volume: 53, Issue:4 Topics: Aged; Biopsy, Needle; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Prostatic Neoplasms; Time Factors	1999
Prostate Cancer Prevention Trial (PCPT) update. European urology, 1999, Volume: 35, Issue:5-6 Topics: Aged; Biopsy, Needle; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Libido; Male; Middle Aged; Prostatic Neoplasms; Survival Rate; Treatment Outcome; United States	1999
Finasteride in association with either flutamide or goserelin as combination hormonal therapy in patients with stage M1 carcinoma of the prostate gland. International Prostate Health Council (IPHC) Trial Study Group. The Prostate, 1999, Jul-01, Volume: 40, Issue:2 Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Aged, 80 and over; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Carcinoma; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Flutamide; Follicle Stimulating Hormone; Goserelin; Humans; Luteinizing Hormone; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms	1999
Serum prostate-specific antigen and prostate volume predict long-term changes in symptoms and flow rate: results of a four-year, randomized trial comparing finasteride versus placebo. PLESS Study Group. Urology, 1999, Volume: 54, Issue:4 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Predictive Value of Tests; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Urodynamics	1999
Intermittent androgen suppression for prostate cancer: Canadian Prospective Trial and related observations. Molecular urology, 2000,Fall, Volume: 4, Issue:3 Topics: Androgen Antagonists; Androgen Receptor Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Cyclic AMP-Dependent Protein Kinases; Disease Progression; Enzyme Inhibitors; Finasteride; Humans; Male; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Receptors, Androgen; Signal Transduction; Testosterone; Time Factors; Tosyl Compounds	2000
Minority recruitment in the prostate cancer prevention trial. Annals of epidemiology, 2000, Volume: 10, Issue:8 Suppl Topics: Aged; Demography; Finasteride; Humans; Life Style; Male; Middle Aged; Minority Groups; Patient Selection; Pilot Projects; Placebos; Prostatic Neoplasms; Racial Groups; Randomized Controlled Trials as Topic	2000
The Prostate Cancer Prevention Trial: Current status and lessons learned. Urology, 2001, Volume: 57, Issue:4 Suppl 1 Topics: 5-alpha Reductase Inhibitors; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Palpation; Patient Selection; Prostate-Specific Antigen; Prostatic Neoplasms	2001
Treatment of localized prostate cancer with intermittent triple androgen blockade: preliminary results in 110 consecutive patients. The oncologist, 2001, Volume: 6, Issue:2 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Finasteride; Flutamide; Follow-Up Studies; Gonadotropin-Releasing Hormone; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Staging; Nitriles; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds; Treatment Outcome	2001
Dietary supplement use in the Prostate Cancer Prevention Trial: implications for prevention trials. Nutrition and cancer, 2001, Volume: 39, Issue:1 Topics: Aged; Antioxidants; Body Mass Index; Dietary Supplements; Double-Blind Method; Educational Status; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Primary Prevention; Prostatic Neoplasms; Risk Factors; Surveys and Questionnaires; Time Factors	2001
Docetaxel followed by hormone therapy after failure of definitive treatments for clinically localized/locally advanced prostate cancer: preliminary results. Seminars in oncology, 2001, Volume: 28, Issue:4 Suppl 15 Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Agents, Phytogenic; Docetaxel; Finasteride; Goserelin; Humans; Leuprolide; Male; Middle Aged; Neoplasm Recurrence, Local; Nitriles; Paclitaxel; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Salvage Therapy; Taxoids; Tosyl Compounds	2001
Castration-like effects on the human prostate of a 5 alpha-reductase inhibitor, finasteride. Journal of cellular biochemistry. Supplement, 1992, Volume: 16H Topics: 5-alpha Reductase Inhibitors; Androstenes; Azasteroids; Dihydrotestosterone; Finasteride; Humans; Male; Orchiectomy; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Testosterone	1992
Multicenter, randomized, double-blind, placebo controlled study to investigate the effect of finasteride (MK-906) on stage D prostate cancer. The Journal of urology, 1992, Volume: 148, Issue:4 Topics: 5-alpha Reductase Inhibitors; Acid Phosphatase; Aged; Aged, 80 and over; Androstenes; Azasteroids; Biomarkers, Tumor; Double-Blind Method; Finasteride; Humans; Male; Middle Aged; Neoplasm Staging; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life	1992

Other Studies

285 other study(ies) available for finasteride and Cancer of Prostate

Article	Year
19-nor-10-azasteroids: a novel class of inhibitors for human steroid 5alpha-reductases 1 and 2. Journal of medicinal chemistry, 1997, Mar-28, Volume: 40, Issue:7 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Enzyme Inhibitors; Female; Humans; Magnetic Resonance Spectroscopy; Male; Mass Spectrometry; Prostatic Neoplasms; Tumor Cells, Cultured	1997
Novel 17-azolyl steroids, potent inhibitors of human cytochrome 17 alpha-hydroxylase-C17,20-lyase (P450(17) alpha): potential agents for the treatment of prostate cancer. Journal of medicinal chemistry, 1998, Mar-12, Volume: 41, Issue:6 Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androstadienes; Animals; Antineoplastic Agents; Enzyme Inhibitors; Humans; Imidazoles; Ketoconazole; Male; Microsomes; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Testis; Triazoles; Tumor Cells, Cultured	1998
A novel class of inhibitors for steroid 5alpha-reductase: synthesis and evaluation of umbelliferone derivatives. Bioorganic & medicinal chemistry letters, 2001, Sep-03, Volume: 11, Issue:17 Topics: 5-alpha Reductase Inhibitors; Coumarins; Drug Design; Drug Evaluation, Preclinical; Enzyme Inhibitors; Humans; Inhibitory Concentration 50; Male; Prostatic Neoplasms; Structure-Activity Relationship; Tumor Cells, Cultured; Umbelliferones	2001
Novel C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens: synthesis, in vitro biological activity, pharmacokinetics, and antitumor activity in the LAPC4 human prostate cancer xenograft model. Journal of medicinal chemistry, 2005, Apr-21, Volume: 48, Issue:8 Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androstadienes; Animals; Antineoplastic Agents; Azoles; Benzimidazoles; Cell Line, Tumor; Cell Proliferation; Humans; Isoenzymes; Male; Mice; Mice, SCID; Mutation; Prostatic Neoplasms; Pyrazines; Radioligand Assay; Receptors, Androgen; Steroid 17-alpha-Hydroxylase; Structure-Activity Relationship; Tissue Distribution; Transcription, Genetic; Transcriptional Activation; Xenograft Model Antitumor Assays	2005
In vivo investigation in pigs of intestinal absorption, hepatobiliary disposition, and metabolism of the 5α-reductase inhibitor finasteride and the effects of coadministered ketoconazole. Drug metabolism and disposition: the biological fate of chemicals, 2011, Volume: 39, Issue:5 Topics: 14-alpha Demethylase Inhibitors; 5-alpha Reductase Inhibitors; Animals; Bile; Drug Interactions; Finasteride; Half-Life; Injections, Intravenous; Intestinal Absorption; Ketoconazole; Liver; Male; Prostatic Neoplasms; Swine	2011
Effect of dehydroepiandrosterone derivatives on the activity of 5α-reductase isoenzymes and on cancer cell line PC-3. Bioorganic & medicinal chemistry, 2014, Nov-01, Volume: 22, Issue:21 Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cells, Cultured; Cholestenone 5 alpha-Reductase; Cricetinae; Dehydroepiandrosterone; Female; Humans; Isoenzymes; Male; Mice; Middle Aged; Prostate; Prostatic Neoplasms; Rats	2014
Synthesis of 17β-N-arylcarbamoylandrost-4-en-3-one derivatives and their anti-proliferative effect on human androgen-sensitive LNCaP cell line. European journal of medicinal chemistry, 2016, Oct-04, Volume: 121 Topics: Androgens; Androstenes; Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Chemistry Techniques, Synthetic; Humans; Leukocytes, Mononuclear; Male; Prostatic Neoplasms; Rats	2016
Synthesis and biological evaluation of arylpiperazine derivatives as potential anti-prostate cancer agents. Bioorganic & medicinal chemistry, 2019, 01-01, Volume: 27, Issue:1 Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Binding Sites; Cell Line, Tumor; Cell Proliferation; Drug Design; Drug Screening Assays, Antitumor; Humans; Male; Molecular Docking Simulation; Molecular Structure; Piperazines; Prostatic Neoplasms; Receptors, Androgen; Structure-Activity Relationship	2019
Synthesis, biological evaluation and molecular docking of 4-Amino-2H-benzo[h]chromen-2-one (ABO) analogs containing the piperazine moiety. Bioorganic & medicinal chemistry, 2019, 10-15, Volume: 27, Issue:20 Topics: Androgen Receptor Antagonists; Antineoplastic Agents; Cell Proliferation; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Fluorescence Polarization; Humans; Male; Molecular Docking Simulation; Molecular Structure; Piperazine; Prostatic Neoplasms; Receptors, Androgen; Structure-Activity Relationship; Tumor Cells, Cultured	2019
A prospective evaluation of the effect of finasteride on prostate health index (phi). International urology and nephrology, 2023, Volume: 55, Issue:5 Topics: Finasteride; Humans; Male; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms	2023
5α-Reductase Inhibitor Use in Patients With Prostate Cancer. JAMA internal medicine, 2019, 10-01, Volume: 179, Issue:10 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Oxidoreductases; Prostatic Neoplasms	2019
5α-Reductase Inhibitor Use in Patients With Prostate Cancer. JAMA internal medicine, 2019, 10-01, Volume: 179, Issue:10 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Oxidoreductases; Prostatic Neoplasms	2019
5α-Reductase Inhibitor Use in Patients With Prostate Cancer-Reply. JAMA internal medicine, 2019, 10-01, Volume: 179, Issue:10 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Oxidoreductases; Prostatic Neoplasms	2019
Estrogen receptor β and treatment with a phytoestrogen are associated with inhibition of nuclear translocation of EGFR in the prostate. Proceedings of the National Academy of Sciences of the United States of America, 2021, 03-30, Volume: 118, Issue:13 Topics: Active Transport, Cell Nucleus; Androgen Antagonists; Androstenes; Animals; Antineoplastic Combined Chemotherapy Protocols; Benzamides; Biopsy; Cell Nucleus; Cohort Studies; ErbB Receptors; Estrogen Receptor beta; Finasteride; Humans; Male; Mice; Mice, Knockout; Neoplasm Grading; Nitriles; Phenylthiohydantoin; Phytoestrogens; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; PTEN Phosphohydrolase; Receptors, Androgen; Receptors, Estrogen	2021
Co-clinical Analysis of a Genetically Engineered Mouse Model and Human Prostate Cancer Reveals Significance of NKX3.1 Expression for Response to 5α-reductase Inhibition. European urology, 2017, Volume: 72, Issue:4 Topics: 5-alpha Reductase Inhibitors; Aged; Animals; Biomarkers, Tumor; Chemotherapy, Adjuvant; Clinical Decision-Making; DNA Mutational Analysis; Dutasteride; Finasteride; Homeodomain Proteins; Humans; Male; Mice, Knockout; Middle Aged; Mutation; Neoadjuvant Therapy; Neoplasm Staging; Patient Selection; Precision Medicine; Predictive Value of Tests; Prostatectomy; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Retrospective Studies; Time Factors; Transcription Factors; Treatment Outcome	2017
Re: Long-Term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. The Journal of urology, 2018, Volume: 199, Issue:1 Topics: Finasteride; Humans; Male; Prostatic Neoplasms	2018
Imaging prostate cancer (PCa) with [ Journal of labelled compounds & radiopharmaceuticals, 2018, 06-15, Volume: 61, Issue:7 Topics: Animals; Finasteride; Male; Molecular Imaging; Organotechnetium Compounds; Prostatic Neoplasms; Rats; Tissue Distribution	2018
Using Medicare Claims to Examine Long-term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute, 2018, 11-01, Volume: 110, Issue:11 Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Biopsy; Case-Control Studies; Finasteride; Follow-Up Studies; Humans; Incidence; Male; Medicare; Middle Aged; Proportional Hazards Models; Prostatic Neoplasms; Public Health Surveillance; United States	2018
Finasteride-Nemesis of More Than 1 Urological Cancer? The Journal of urology, 2018, Volume: 200, Issue:4 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Oxidoreductases; Prostatic Hyperplasia; Prostatic Neoplasms; Urinary Bladder Neoplasms	2018
Re: Using Medicare Claims to Examine Long-Term Prostate Cancer Risk of Finasteride in the Prostate Cancer Prevention Trial. The Journal of urology, 2018, Volume: 200, Issue:4 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Medicare; Prostatic Neoplasms; United States	2018
Long-Term Effects of Finasteride on Prostate Cancer Mortality. The New England journal of medicine, 2019, 01-24, Volume: 380, Issue:4 Topics: 5-alpha Reductase Inhibitors; Early Detection of Cancer; Finasteride; Humans; Male; Middle Aged; Neoplasm Grading; Prostate-Specific Antigen; Prostatic Neoplasms	2019
More on Long-Term Effects of Finasteride on Prostate Cancer Mortality. The New England journal of medicine, 2019, 05-16, Volume: 380, Issue:20 Topics: Finasteride; Humans; Male; Prostatic Neoplasms	2019
More on Long-Term Effects of Finasteride on Prostate Cancer Mortality. The New England journal of medicine, 2019, 05-16, Volume: 380, Issue:20 Topics: Finasteride; Humans; Male; Prostatic Neoplasms	2019
More on Long-Term Effects of Finasteride on Prostate Cancer Mortality. Reply. The New England journal of medicine, 2019, 05-16, Volume: 380, Issue:20 Topics: Finasteride; Humans; Male; Prostatic Neoplasms	2019
5-alpha reductase inhibitors in patients on active surveillance: do the benefits outweigh the risk? Current urology reports, 2013, Volume: 14, Issue:3 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Disease Progression; Dutasteride; Finasteride; Humans; Kallikreins; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Watchful Waiting	2013
Actos, slings, finasteride, and the vaccine compensation solution. The Canadian journal of urology, 2013, Volume: 20, Issue:2 Topics: Finasteride; Humans; Liability, Legal; Male; Patient Rights; Pioglitazone; Prostatic Neoplasms; Risk Assessment; Risk Factors; Suburethral Slings; Thiazolidinediones; United States; United States Food and Drug Administration; Urinary Bladder Neoplasms; Vaccines	2013
5α-reductase inhibition suppresses testosterone-induced initial regrowth of regressed xenograft prostate tumors in animal models. Endocrinology, 2013, Volume: 154, Issue:7 Topics: 5-alpha Reductase Inhibitors; Animals; Azasteroids; Cell Line, Tumor; Cell Proliferation; Dutasteride; Finasteride; Humans; Immunohistochemistry; Letrozole; Male; Mice; Mice, Nude; Mice, SCID; Nitriles; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Testosterone; Triazoles	2013
Rank-based principal stratum sensitivity analyses. Statistics in medicine, 2013, Nov-20, Volume: 32, Issue:26 Topics: AIDS Vaccines; Computer Simulation; Data Interpretation, Statistical; Finasteride; HIV Infections; Humans; Male; Prostatic Neoplasms; Treatment Outcome	2013
Prostate cancer cells differ in testosterone accumulation, dihydrotestosterone conversion, and androgen receptor signaling response to steroid 5α-reductase inhibitors. The Prostate, 2013, Volume: 73, Issue:13 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Cell Line, Tumor; Dihydrotestosterone; Dutasteride; Finasteride; Humans; Male; Prostate; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Tandem Mass Spectrometry; Testosterone	2013
The direct inhibitory effect of dutasteride or finasteride on androgen receptor activity is cell line specific. The Prostate, 2013, Volume: 73, Issue:14 Topics: 5-alpha Reductase Inhibitors; Animals; Azasteroids; Cattle; Cell Culture Techniques; Cell Line, Tumor; Cell Proliferation; Dihydrotestosterone; Dutasteride; Finasteride; Gene Expression Regulation; Humans; Male; Prostate; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction; Transfection	2013
Re: effect of finasteride on serum levels of androstenedione, testosterone and their 5α-reduced metabolites in men at risk for prostate cancer. The Journal of steroid biochemistry and molecular biology, 2013, Volume: 138 Topics: 5-alpha Reductase Inhibitors; Androstenedione; Finasteride; Humans; Male; Prostatic Neoplasms; Testosterone	2013
Response to commentary. The Journal of steroid biochemistry and molecular biology, 2013, Volume: 138 Topics: 5-alpha Reductase Inhibitors; Androstenedione; Finasteride; Humans; Male; Prostatic Neoplasms; Testosterone	2013
Long-term survival of participants in the prostate cancer prevention trial. The New England journal of medicine, 2013, Aug-15, Volume: 369, Issue:7 Topics: 5-alpha Reductase Inhibitors; Finasteride; Follow-Up Studies; Humans; Incidence; Kaplan-Meier Estimate; Male; Neoplasm Grading; Prostatic Neoplasms; Risk; Survival Rate	2013
A role for finasteride in the prevention of prostate cancer? The New England journal of medicine, 2013, Aug-15, Volume: 369, Issue:7 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2013
Finasteride for prostate cancer prevention has no effect on survival, study finds. BMJ (Clinical research ed.), 2013, Aug-20, Volume: 347 Topics: 5-alpha Reductase Inhibitors; Clinical Trials as Topic; Disease-Free Survival; Finasteride; Humans; Male; Prostatic Neoplasms; United States	2013
Urological cancer: reduction in the risk of prostate cancer with finasteride. Nature reviews. Clinical oncology, 2013, Volume: 10, Issue:11 Topics: Finasteride; Humans; Male; Prognosis; Prostatic Neoplasms; Risk Factors; Urologic Neoplasms; Urological Agents	2013
Prostate cancer: mortality unaffected by finasteride treatment. Nature reviews. Urology, 2013, Volume: 10, Issue:10 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2013
Editorial comment. Urology, 2013, Volume: 82, Issue:5 Topics: Biopsy; Finasteride; Humans; Male; Prostate; Prostatic Neoplasms	2013
Preventive and therapeutic efficacy of finasteride and dutasteride in TRAMP mice. PloS one, 2013, Volume: 8, Issue:10 Topics: 5-alpha Reductase Inhibitors; Animals; Azasteroids; Body Weight; Cholestenone 5 alpha-Reductase; Disease Progression; Dutasteride; Finasteride; Lymph Nodes; Lymphatic Metastasis; Male; Mice; Mice, Inbred C57BL; Prostatic Neoplasms; Receptors, Tumor Necrosis Factor, Member 25	2013
Survival in the prostate cancer prevention trial. The New England journal of medicine, 2013, 11-14, Volume: 369, Issue:20 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2013
Survival in the prostate cancer prevention trial. The New England journal of medicine, 2013, 11-14, Volume: 369, Issue:20 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2013
Survival in the prostate cancer prevention trial. The New England journal of medicine, 2013, 11-14, Volume: 369, Issue:20 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2013
Are 5-ARIs suitable for prevention of prostate cancer? The Practitioner, 2013, Volume: 257, Issue:1765 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms; United Kingdom	2013
Finasteride inhibits human prostate cancer cell invasion through MMP2 and MMP9 downregulation. PloS one, 2013, Volume: 8, Issue:12 Topics: 5-alpha Reductase Inhibitors; Cell Line, Tumor; Cell Survival; Down-Regulation; Finasteride; Gene Expression Regulation, Enzymologic; Gene Expression Regulation, Neoplastic; Hepatitis A Virus Cellular Receptor 1; Humans; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Membrane Glycoproteins; Neoplasm Invasiveness; Neoplasm Proteins; Prostatic Neoplasms; Receptors, Virus; Tissue Inhibitor of Metalloproteinase-2	2013
Re: long-term survival of participants in the Prostate Cancer Prevention Trial. The Journal of urology, 2014, Volume: 191, Issue:2 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2014
Re: long-term survival of participants in the Prostate Cancer Prevention Trial. The Journal of urology, 2014, Volume: 191, Issue:2 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2014
Re: long-term survival of participants in the Prostate Cancer Prevention Trial. The Journal of urology, 2014, Volume: 191, Issue:2 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2014
Increased DHT levels in androgenic alopecia have been selected for to protect men from prostate cancer. Medical hypotheses, 2014, Volume: 82, Issue:4 Topics: Adult; Alopecia; Androgens; Cell Proliferation; Dihydrotestosterone; Finasteride; Gene Expression Regulation; Genetic Predisposition to Disease; Humans; Male; Middle Aged; Models, Theoretical; Prostaglandin D2; Prostatic Neoplasms	2014
Finasteride reduces cancer risk, does not increase death risk. Cancer, 2013, Nov-15, Volume: 119, Issue:22 Topics: 5-alpha Reductase Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Mortality; Prostatic Neoplasms	2013
Re: predicting risk of prostate cancer in men receiving finasteride: effect of prostate volume, number of biopsy cores, and american urological association symptom score. The Journal of urology, 2014, Volume: 191, Issue:5 Topics: Biopsy; Finasteride; Humans; Male; Prostate; Prostatic Neoplasms	2014
[Prevention of prostate cancer. Long-term results of the Prostate Cancer Prevention Trial (PCPT)]. Der Internist, 2014, Volume: 55, Issue:8 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2014
Simultaneous pharmacokinetic and pharmacodynamic analysis of 5α-reductase inhibitors and androgens by liquid chromatography tandem mass spectrometry. Talanta, 2015, Volume: 131 Topics: 5-alpha Reductase Inhibitors; Androgens; Androstenedione; Azasteroids; Chromatography, Liquid; Dihydrotestosterone; Dutasteride; Finasteride; Humans; Male; Prostatic Neoplasms; Solid Phase Extraction; Tandem Mass Spectrometry; Testosterone; Tissue Distribution	2015
Prostatic angiogenic responses in late life: antiangiogenic therapy influences and relation with the glandular microenvironment in the transgenic adenocarcinoma of mouse prostate (TRAMP) model. The Prostate, 2015, Apr-01, Volume: 75, Issue:5 Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Angiogenesis Inhibitors; Animals; Blotting, Western; Cyclohexanes; Disease Models, Animal; Endostatins; Fibroblast Growth Factor 2; Finasteride; Hypoxia-Inducible Factor 1, alpha Subunit; Immunohistochemistry; Indoles; Male; Mice; Mice, Transgenic; Neovascularization, Pathologic; O-(Chloroacetylcarbamoyl)fumagillol; Prostatic Neoplasms; Pyrroles; Sesquiterpenes; Tumor Microenvironment; Vascular Endothelial Growth Factor A	2015
5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men With Prostate Cancer. JAMA oncology, 2015, Volume: 1, Issue:3 Topics: 5-alpha Reductase Inhibitors; Databases, Factual; Dutasteride; Finasteride; Humans; Incidence; Kaplan-Meier Estimate; Linear Models; Logistic Models; Male; Multivariate Analysis; Propensity Score; Proportional Hazards Models; Prostatic Hyperplasia; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Risk Factors; Time Factors; Treatment Outcome; United Kingdom	2015
Effect of 5α-Reductase Inhibitor Use on Mortality From Prostate Cancer. JAMA oncology, 2015, Volume: 1, Issue:3 Topics: 5-alpha Reductase Inhibitors; Dutasteride; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms	2015
Reactive stroma in the prostate during late life: The role of microvasculature and antiangiogenic therapy influences. The Prostate, 2015, Volume: 75, Issue:14 Topics: Age Factors; Aging; Angiogenesis Inhibitors; Animals; Finasteride; Male; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microvessels; Prostate; Prostatic Neoplasms; Stromal Cells	2015
Finasteride and Bladder Cancer. European urology, 2016, Volume: 69, Issue:3 Topics: Enzyme Inhibitors; Finasteride; Humans; Prostatic Hyperplasia; Prostatic Neoplasms; Urinary Bladder Neoplasms	2016
Expression of Heat Shock Protein 27 in Benign Prostatic Hyperplasia with Chronic Inflammation. Medical science monitor : international medical journal of experimental and clinical research, 2015, Oct-03, Volume: 21 Topics: Adrenergic alpha-Antagonists; Biomarkers, Tumor; CD3 Complex; Chronic Disease; Cross-Sectional Studies; Disease Progression; Enzyme-Linked Immunosorbent Assay; Finasteride; Gene Expression Regulation; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Immunohistochemistry; Inflammation; Interleukin-6; Lower Urinary Tract Symptoms; Male; Molecular Chaperones; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Transurethral Resection of Prostate; Tumor Necrosis Factor-alpha	2015
Inflammation in Benign Prostate Tissue and Prostate Cancer in the Finasteride Arm of the Prostate Cancer Prevention Trial. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2016, Volume: 25, Issue:3 Topics: 5-alpha Reductase Inhibitors; Case-Control Studies; Finasteride; Humans; Inflammation; Male; Middle Aged; Prostate; Prostatic Neoplasms	2016
The new insight of prostate-specific antigen reduction during finasteride therapy in aging men. Aging clinical and experimental research, 2016, Volume: 28, Issue:6 Topics: Aged; Asian People; Doxazosin; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms	2016
Grade-dependent Response to Finasteride in Early Prostate Cancer. EBioMedicine, 2016, Volume: 7 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2016
Adverse Effects of 5-Alpha Reductase Inhibitor Therapy in Men With Androgenetic Alopecia: Is There Cause for Concern? Actas dermo-sifiliograficas, 2016, Volume: 107, Issue:9 Topics: 5-alpha Reductase Inhibitors; Alopecia; Dutasteride; Erectile Dysfunction; Finasteride; Humans; Insulin Resistance; Libido; Male; Osteoporosis; Prostatic Hyperplasia; Prostatic Neoplasms	2016
Long-term Consequences of Finasteride vs Placebo in the Prostate Cancer Prevention Trial. Journal of the National Cancer Institute, 2016, Volume: 108, Issue:12 Topics: 5-alpha Reductase Inhibitors; Administrative Claims, Healthcare; Aged; Clinical Trials as Topic; Depression; Finasteride; Follow-Up Studies; Humans; Lower Urinary Tract Symptoms; Male; Medical Record Linkage; Medicare; Middle Aged; Prostatic Neoplasms; Protective Factors; Risk Assessment; Risk Factors; Time Factors; United States	2016
Re: 5α-Reductase Inhibitors and the Risk of Cancer-Related Mortality in Men with Prostate Cancer. The Journal of urology, 2016, Volume: 196, Issue:5 Topics: 5-alpha Reductase Inhibitors; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Oxidoreductases; Prostatic Neoplasms	2016
Anti-proliferative activities of finasteride in benign prostate epithelial cells require stromal fibroblasts and c-Jun gene. PloS one, 2017, Volume: 12, Issue:2 Topics: Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Epithelial Cells; Fibroblasts; Finasteride; Gene Expression Regulation, Neoplastic; Genes, jun; Humans; Insulin-Like Growth Factor I; Male; Mice; Mice, Nude; Neoplasm Proteins; Neoplasm Transplantation; Neoplasms, Experimental; Prostatic Neoplasms	2017
Jim's Prostate Cancer. Texas Heart Institute journal, 2017, Volume: 44, Issue:1 Topics: 5-alpha Reductase Inhibitors; Biopsy; Clinical Decision-Making; Disease Progression; Finasteride; Humans; Kallikreins; Male; Neoplasm Grading; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Neoplasms; Time Factors; Treatment Outcome; Watchful Waiting	2017
Cancer Targeting Potential of Cancer biotherapy & radiopharmaceuticals, 2017, Volume: 32, Issue:2 Topics: Acid Phosphatase; Animals; Carcinogenesis; Carcinogens; Disease Models, Animal; Electrophoresis; Finasteride; Hydrogen-Ion Concentration; Kinetics; Male; Methylnitrosourea; Prostate; Prostatic Neoplasms; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Technetium; Time Factors; Tissue Distribution	2017
Finasteride for prevention of prostate cancer. The Medical letter on drugs and therapeutics, 2008, Jun-30, Volume: 50, Issue:1289 Topics: 5-alpha Reductase Inhibitors; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Neoplasms	2008
Evaluation of MENT on primary cell cultures from benign prostatic hyperplasia and prostate carcinoma. International journal of andrology, 2009, Volume: 32, Issue:6 Topics: Androgens; Dihydrotestosterone; Finasteride; Humans; Male; Nandrolone; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Testosterone; Testosterone Congeners	2009
Preventing prostate cancer: new analyses put finasteride back on the map. Journal of the National Cancer Institute, 2008, Aug-20, Volume: 100, Issue:16 Topics: 5-alpha Reductase Inhibitors; Anticarcinogenic Agents; Azasteroids; Bias; Biopsy, Needle; Carcinogens; Confounding Factors, Epidemiologic; Drug Approval; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Incidence; Male; Patents as Topic; Prostatic Hyperplasia; Prostatic Neoplasms; Severity of Illness Index; United States; United States Food and Drug Administration	2008
A 49-year-old Hispanic male with intraepithelial neoplasia and focal atypia. Current urology reports, 2008, Volume: 9, Issue:5 Topics: Biopsy; Enzyme Inhibitors; Expert Testimony; Finasteride; Hispanic or Latino; Humans; Male; Middle Aged; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Surgery, Computer-Assisted; Ultrasonography	2008
New study makes case for prostate cancer drug. ONS connect, 2008, Volume: 23, Issue:10 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2008
Does Proscar prevent prostate cancer? The Johns Hopkins medical letter health after 50, 2008, Volume: 20, Issue:8 Topics: Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms	2008
High-grade prostate cancer and the prostate cancer prevention trial. Cancer prevention research (Philadelphia, Pa.), 2008, Volume: 1, Issue:3 Topics: 5-alpha Reductase Inhibitors; Antineoplastic Agents; Enzyme Inhibitors; Finasteride; Humans; Male; Neoplasm Invasiveness; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; Tumor Burden	2008
Finasteride and high-grade prostate cancer. Cancer prevention research (Philadelphia, Pa.), 2009, Volume: 2, Issue:2 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Neoplasm Staging; Prostatic Neoplasms	2009
Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer. European urology, 2009, Volume: 55, Issue:5 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Chemoprevention; Finasteride; Humans; Male; Primary Prevention; Prognosis; Prostatic Neoplasms; Risk Assessment; Treatment Outcome	2009
Editorial comment on: Pharmacological approaches to reducing the risk of prostate cancer. European urology, 2009, Volume: 55, Issue:5 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Azasteroids; Biopsy, Needle; Chemoprevention; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Primary Prevention; Prognosis; Prostatic Neoplasms; Risk Assessment; Survival Analysis; Treatment Outcome	2009
Editorial comment. Urology, 2009, Volume: 73, Issue:5 Topics: Aged; Biopsy; Enzyme Inhibitors; Finasteride; Health Education; Humans; Male; Marketing of Health Services; Middle Aged; Prostatic Hyperplasia; Prostatic Neoplasms	2009
Guideline supports long-term use of medication to lower prostate cancer risk. JAMA, 2009, May-06, Volume: 301, Issue:17 Topics: 5-alpha Reductase Inhibitors; Aged; Enzyme Inhibitors; Finasteride; Guidelines as Topic; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms	2009
Steroidogenesis inhibitors alter but do not eliminate androgen synthesis mechanisms during progression to castration-resistance in LNCaP prostate xenografts. The Journal of steroid biochemistry and molecular biology, 2009, Volume: 115, Issue:3-5 Topics: Androgen Antagonists; Androgens; Anilides; Animals; Castration; Cell Line, Tumor; Cinnamates; Disease Progression; Drug Combinations; Enzyme Inhibitors; Finasteride; Gene Expression Regulation, Neoplastic; Humans; Ketoconazole; Male; Mice; Mice, Nude; Mifepristone; Molecular Structure; Neoplasm Transplantation; Nitriles; Progesterone; Prostatic Neoplasms; Steroids; Tosyl Compounds; Transplantation, Heterologous	2009
Continuous finasteride therapy for benign prostate hypertrophy upgrades both neuroendorcine differentiation and aggressive prostate cancer. Anticancer research, 2009, Volume: 29, Issue:5 Topics: Cell Differentiation; Enzyme Inhibitors; Finasteride; Humans; Male; Neurosecretory Systems; Prostatic Hyperplasia; Prostatic Neoplasms	2009
Combined effect of the finasteride and doxazosin on rat ventral prostate morphology and physiology. International journal of andrology, 2010, Jun-01, Volume: 33, Issue:3 Topics: Androgens; Animals; Cell Proliferation; Dihydrotestosterone; Doxazosin; Epithelial Cells; Extracellular Matrix; Finasteride; Male; Matrix Metalloproteinase 9; Matrix Metalloproteinases; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms; Rats; Rats, Wistar; RNA, Messenger; Testosterone; Tissue Inhibitor of Metalloproteinase-1; Tissue Inhibitor of Metalloproteinase-2; Transforming Growth Factor beta1	2010
Finasteride treatment alters MMP-2 and -9 gene expression and activity in the rat ventral prostate. International journal of andrology, 2010, Volume: 33, Issue:1 Topics: Androgens; Animals; Extracellular Matrix; Finasteride; Gene Expression; Genes; Male; Matrix Metalloproteinase 2; Matrix Metalloproteinase 9; Matrix Metalloproteinases; Prostate; Prostatic Neoplasms; Rats; Rats, Wistar; Reverse Transcriptase Polymerase Chain Reaction	2010
Finasteride to prevent prostate cancer: a new chapter. Harvard men's health watch, 2009, Volume: 13, Issue:11 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Dutasteride; Finasteride; Humans; Male; Middle Aged; Practice Guidelines as Topic; Prostatic Neoplasms; Testosterone	2009
The influence of prostate volume on prostate-specific antigen performance: implications for the prostate cancer prevention trial outcomes. Clinical cancer research : an official journal of the American Association for Cancer Research, 2009, Jul-15, Volume: 15, Issue:14 Topics: Aged; Biopsy; Diagnosis, Differential; Enzyme Inhibitors; Finasteride; Humans; Logistic Models; Male; Middle Aged; Outcome Assessment, Health Care; Predictive Value of Tests; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies	2009
Alcohol consumption, finasteride, and prostate cancer risk: results from the Prostate Cancer Prevention Trial. Cancer, 2009, Aug-15, Volume: 115, Issue:16 Topics: Aged; Alcohol Drinking; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Neoplasms; Risk	2009
Is it worth the wait? BJU international, 2009, Volume: 104, Issue:1 Topics: Antineoplastic Agents; Azasteroids; Dutasteride; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms	2009
Prostate cancer incidence among finasteride and alpha-blocker users in the Finnish Prostate Cancer Screening Trial. British journal of cancer, 2009, Sep-01, Volume: 101, Issue:5 Topics: Adrenergic alpha-Antagonists; Aged; Cohort Studies; Data Interpretation, Statistical; Finasteride; Finland; Follow-Up Studies; Humans; Incidence; Male; Mass Screening; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Factors; Time Factors	2009
Guideline for 5-alpha-reductase inhibitors in the prevention of prostate cancer is premature. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2009, Oct-20, Volume: 27, Issue:30 Topics: Antineoplastic Agents; Cholestenone 5 alpha-Reductase; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2009
Prolongation of off-cycle interval by finasteride is not associated with survival improvement in intermittent androgen deprivation therapy in LNCaP tumor model. The Prostate, 2010, Feb-01, Volume: 70, Issue:2 Topics: Androgen Antagonists; Androgens; Animals; Cell Cycle; Cell Line, Tumor; Dihydrotestosterone; Enzyme Inhibitors; Estradiol; Finasteride; Male; Mice; Mice, Inbred BALB C; Mice, Nude; Orchiectomy; Prostatic Neoplasms; Survival Analysis; Testosterone; Time Factors; Xenograft Model Antitumor Assays	2010
Prostate cancer prevention (AUGUST 2009). Cleveland Clinic journal of medicine, 2009, Volume: 76, Issue:11 Topics: Azasteroids; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2009
Testosterone replacement in prostate cancer survivors with hypogonadal symptoms. BJU international, 2010, Volume: 105, Issue:10 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Azasteroids; Dutasteride; Enzyme Inhibitors; Finasteride; Hormone Replacement Therapy; Humans; Hypogonadism; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Survivors; Testosterone	2010
Finasteride to prevent prostate cancer: should all men or only a high-risk subgroup be treated? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010, Mar-01, Volume: 28, Issue:7 Topics: Aged; Decision Support Techniques; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Risk	2010
Transparency and reproducibility in data analysis: the Prostate Cancer Prevention Trial. Biostatistics (Oxford, England), 2010, Volume: 11, Issue:3 Topics: Biopsy; Clinical Trials as Topic; Data Interpretation, Statistical; Digital Rectal Examination; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Reproducibility of Results	2010
Comparison of gene expression in LNCaP prostate cancer cells after treatment with bicalutamide or 5-alpha-reductase inhibitors. Urologia internationalis, 2010, Volume: 84, Issue:2 Topics: Anilides; Antineoplastic Agents; Azasteroids; Cell Differentiation; Cell Line, Tumor; Cholestenone 5 alpha-Reductase; Enzyme Inhibitors; Finasteride; Gene Expression Profiling; Gene Expression Regulation, Neoplastic; Humans; Male; Nitriles; Oligonucleotide Array Sequence Analysis; Prostate; Prostatic Neoplasms; Tosyl Compounds	2010
Chemoprevention of prostate cancer. The New England journal of medicine, 2010, Apr-01, Volume: 362, Issue:13 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Biopsy; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Risk	2010
Prostate cancer chemoprevention: what is the role of oncology nurses? Canadian oncology nursing journal = Revue canadienne de nursing oncologique, 2010,Winter, Volume: 20, Issue:1 Topics: 5-alpha Reductase Inhibitors; Antineoplastic Agents; Finasteride; Humans; Male; Middle Aged; Nurse's Role; Oncology Nursing; Patient Selection; Practice Guidelines as Topic; Prostatic Neoplasms	2010
Saturable binding of finasteride to steroid 5alpha-reductase as determinant of nonlinear pharmacokinetics. Drug metabolism and pharmacokinetics, 2010, Volume: 25, Issue:2 Topics: 5-alpha Reductase Inhibitors; Animals; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Male; Nonlinear Dynamics; Prostatic Hyperplasia; Prostatic Neoplasms; Rats	2010
Consequences of switching 5alpha-reductase inhibitors on prostate specific antigen velocity. The Journal of urology, 2010, Volume: 184, Issue:1 Topics: Aged; Azasteroids; Chi-Square Distribution; Cholestenone 5 alpha-Reductase; Cholinergic Antagonists; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Linear Models; Male; Phosphodiesterase Inhibitors; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Quality of Life	2010
Differential expression of steroid 5alpha-reductase isozymes and association with disease severity and angiogenic genes predict their biological role in prostate cancer. Endocrine-related cancer, 2010, Volume: 17, Issue:3 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Angiogenic Proteins; Azasteroids; Biomarkers, Tumor; Blotting, Western; Bone Neoplasms; Cell Nucleus; Cell Proliferation; Dutasteride; Enzyme-Linked Immunosorbent Assay; Finasteride; Gene Expression Profiling; Humans; Immunoenzyme Techniques; Isoenzymes; Lymphatic Metastasis; Male; Membrane Proteins; Middle Aged; Oligonucleotide Array Sequence Analysis; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Tissue Array Analysis; Tumor Cells, Cultured; Vascular Endothelial Growth Factor A	2010
Inhibition of 5alpha-reductase enhances testosterone-induced expression of U19/Eaf2 tumor suppressor during the regrowth of LNCaP xenograft tumor in nude mice. The Prostate, 2010, Oct-01, Volume: 70, Issue:14 Topics: Androgens; Animals; Azasteroids; Cell Division; Cholestenone 5 alpha-Reductase; Dihydrotestosterone; Dutasteride; Enzyme Inhibitors; Finasteride; Gene Expression Regulation, Neoplastic; Humans; Male; Mice; Mice, Nude; Neoplasm Transplantation; Nuclear Proteins; Orchiectomy; Prostate-Specific Antigen; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction; Testosterone; Trans-Activators; Transplantation, Heterologous; Tumor Suppressor Proteins	2010
Prostate cancer: finasteride extends PSA doubling time during intermittent hormone therapy. The Canadian journal of urology, 2010, Volume: 17, Issue:3 Topics: Adenocarcinoma; Aged; Antineoplastic Agents, Hormonal; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Time Factors	2010
Editorial comment. The Canadian journal of urology, 2010, Volume: 17, Issue:3 Topics: Adenocarcinoma; Antineoplastic Agents, Hormonal; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms	2010
Can chemoprevention reduce the risk of prostate cancer? Clinical chemistry, 2010, Volume: 56, Issue:8 Topics: Anticarcinogenic Agents; Azasteroids; Dutasteride; Finasteride; Humans; Male; Prostatic Neoplasms; Risk	2010
Potency of a novel saw palmetto ethanol extract, SPET-085, for inhibition of 5alpha-reductase II. Advances in therapy, 2010, Volume: 27, Issue:8 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androgen Antagonists; Cell-Free System; Drug Evaluation, Preclinical; Finasteride; HEK293 Cells; Humans; In Vitro Techniques; Male; Plant Extracts; Prostatic Hyperplasia; Prostatic Neoplasms; Serenoa	2010
[The influence of benign prostatic hyperplasia drugs on incidence and pathology grading of prostate cancer]. Zhonghua wai ke za zhi [Chinese journal of surgery], 2010, May-15, Volume: 48, Issue:10 Topics: Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Finasteride; Humans; Incidence; Male; Middle Aged; Prostatic Hyperplasia; Prostatic Neoplasms; Retrospective Studies	2010
An in vitro model for preclinical testing of endocrine therapy combinations for prostate cancer. The Prostate, 2010, Oct-01, Volume: 70, Issue:14 Topics: Androgen Antagonists; Androgens; Animals; Apoptosis; Cell Cycle; Cell Line, Tumor; Cell Survival; Cholesterol Side-Chain Cleavage Enzyme; Disease Progression; DNA Primers; Finasteride; Humans; In Situ Hybridization, Fluorescence; Male; Mice; Mice, SCID; Polymerase Chain Reaction; Prostatic Neoplasms; RNA, Messenger; Serine Endopeptidases; Steroids	2010
Knowledge and use of finasteride for the prevention of prostate cancer. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2010, Volume: 19, Issue:9 Topics: Anticarcinogenic Agents; Data Collection; Finasteride; Humans; Incidence; Male; Practice Patterns, Physicians'; Prescriptions; Prostatic Neoplasms; United States; United States Department of Veterans Affairs	2010
Evolving role of 5-alpha reductase inhibitors in chemoprevention. Nature reviews. Clinical oncology, 2010, Volume: 7, Issue:9 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Dutasteride; Finasteride; Humans; Male; Primary Prevention; Prostatic Hyperplasia; Prostatic Neoplasms	2010
Dutasteride and prostate cancer. The New England journal of medicine, 2010, 08-19, Volume: 363, Issue:8 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate; Prostatic Hyperplasia; Prostatic Neoplasms	2010
Battling prostate cancer with 5-alpha-reductase inhibitors: a pyrrhic victory? Journal of general internal medicine, 2011, Volume: 26, Issue:7 Topics: 5-alpha Reductase Inhibitors; Aged; Azasteroids; Chemoprevention; Dutasteride; Finasteride; Humans; Male; Middle Aged; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome	2011
Effects of family history and genetic polymorphism on the cost-effectiveness of chemoprevention with finasteride for prostate cancer. The Journal of urology, 2011, Volume: 185, Issue:3 Topics: 5-alpha Reductase Inhibitors; Aged; Cost-Benefit Analysis; Finasteride; Humans; Male; Middle Aged; Polymorphism, Genetic; Prostatic Neoplasms	2011
Effect of finasteride on the sensitivity of PSA to detect prostate cancer in rebiopsy series. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 2010, Volume: 82, Issue:4 Topics: 5-alpha Reductase Inhibitors; Aged; Biopsy; Finasteride; Humans; Male; Prospective Studies; Prostate-Specific Antigen; Prostatic Neoplasms; Sensitivity and Specificity	2010
Serum estrogen levels and prostate cancer risk in the prostate cancer prevention trial: a nested case-control study. Cancer causes & control : CCC, 2011, Volume: 22, Issue:8 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Case-Control Studies; Estradiol; Estrone; Female; Finasteride; Humans; Male; Middle Aged; Neoplasm Grading; Prostatic Neoplasms; Risk Factors	2011
The risks and benefits of 5α-reductase inhibitors for prostate-cancer prevention. The New England journal of medicine, 2011, Jul-14, Volume: 365, Issue:2 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Drug Approval; Dutasteride; Finasteride; Humans; Incidence; Male; Prostatic Neoplasms; United States; United States Food and Drug Administration	2011
Synthesis, antiproliferative activity, acute toxicity and assessment of the antiandrogenic activities of new androstane derivatives. Archives of pharmacal research, 2011, Volume: 34, Issue:7 Topics: Androgen Antagonists; Androgens; Androstanes; Androstenes; Androstenols; Animals; Antineoplastic Agents; Cell Line; Cell Line, Tumor; Cell Proliferation; Diosgenin; Dose-Response Relationship, Drug; Finasteride; Humans; Inhibitory Concentration 50; Lethal Dose 50; Macrophages; Male; Mice; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Structure-Activity Relationship	2011
5-α reductase inhibitors and prostate cancer prevention: where do we turn now? BMC medicine, 2011, Sep-15, Volume: 9 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Chemoprevention; Drug Approval; Dutasteride; Finasteride; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome; United States; United States Food and Drug Administration	2011
What's wrong with chemoprevention of prostate cancer? The American journal of bioethics : AJOB, 2011, Volume: 11, Issue:12 Topics: 5-alpha Reductase Inhibitors; Advisory Committees; Aged; Antineoplastic Agents; Azasteroids; Biomarkers, Tumor; Chemoprevention; Cost of Illness; Dutasteride; Early Detection of Cancer; Evidence-Based Medicine; Finasteride; Humans; Informed Consent; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment	2011
The effect of finasteride and dutasteride on the growth of WPE1-NA22 prostate cancer xenografts in nude mice. PloS one, 2012, Volume: 7, Issue:1 Topics: Animals; Azasteroids; Body Weight; Cell Line, Tumor; Cell Survival; Dihydrotestosterone; Dutasteride; Finasteride; Humans; Male; Mice; Mice, Nude; Prostatic Neoplasms; Rats; Testosterone; Tumor Burden; Xenograft Model Antitumor Assays	2012
Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5α-reductase inhibitor finasteride. The Journal of steroid biochemistry and molecular biology, 2012, Volume: 130, Issue:1-2 Topics: 3-Hydroxysteroid Dehydrogenases; 5-alpha Reductase Inhibitors; Aldo-Keto Reductase Family 1 Member C3; Androgens; Cell Line, Tumor; Cell Proliferation; Drug Resistance, Neoplasm; Finasteride; Humans; Hydroxyprostaglandin Dehydrogenases; Male; Prostatic Neoplasms; Testosterone	2012
Effect of treatment with 5-α reductase inhibitors on progression in monitored men with favourable-risk prostate cancer. BJU international, 2012, Volume: 110, Issue:5 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Androgen Antagonists; Azasteroids; Biopsy; Disease Progression; Dutasteride; Finasteride; Humans; Lower Urinary Tract Symptoms; Male; Middle Aged; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Retrospective Studies	2012
Prostate cancer in elderly Croatian men: 5-HT genetic polymorphisms and the influence of androgen deprivation therapy on osteopenia--a pilot study. Genetic testing and molecular biomarkers, 2012, Volume: 16, Issue:6 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Bone Density; Bone Diseases, Metabolic; Finasteride; Flutamide; Gene Frequency; Genotype; Humans; Male; Pilot Projects; Polymorphism, Genetic; Prostatic Hyperplasia; Prostatic Neoplasms; Receptor, Serotonin, 5-HT1B; Serotonin	2012
The use of the finasteride-adjusted Prostate Cancer Prevention Trial Prostate Cancer Risk Calculator in a Mexican referral population: a validation study. Urologia internationalis, 2012, Volume: 89, Issue:1 Topics: 5-alpha Reductase Inhibitors; Age Factors; Aged; Antineoplastic Agents, Hormonal; Biopsy; Chi-Square Distribution; Digital Rectal Examination; Finasteride; Genetic Predisposition to Disease; Humans; Incidence; Logistic Models; Male; Mass Screening; Mexico; Middle Aged; Multivariate Analysis; Neoplasm Grading; Odds Ratio; Pedigree; Predictive Value of Tests; Prognosis; Proportional Hazards Models; Prostate-Specific Antigen; Prostatic Neoplasms; Referral and Consultation; Reproducibility of Results; Retrospective Studies; Risk Assessment; Risk Factors	2012
The large sample bounds on the principal strata effect with application to a prostate cancer prevention trial. The international journal of biostatistics, 2012, May-21, Volume: 8, Issue:1 Topics: 5-alpha Reductase Inhibitors; Aged; Bias; Biostatistics; Finasteride; Humans; Male; Middle Aged; Models, Statistical; Multicenter Studies as Topic; Prevalence; Prostatic Neoplasms; Randomized Controlled Trials as Topic	2012
A population-based nested case-control study in taiwan: use of 5α-reductase inhibitors did not decrease prostate cancer risk in patients with benign prostate hyperplasia. The oncologist, 2012, Volume: 17, Issue:7 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Case-Control Studies; Cohort Studies; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Prostatic Neoplasms; Taiwan	2012
Finasteride and prostate cancer: a commentary. The oncologist, 2012, Volume: 17, Issue:7 Topics: 5-alpha Reductase Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms	2012
Does variation in either age at start of therapy or duration of therapy make chemoprevention with finasteride cost-effective? Prostate cancer and prostatic diseases, 2012, Volume: 15, Issue:4 Topics: Age Factors; Aged; Chemoprevention; Cost-Benefit Analysis; Finasteride; Health Care Costs; Humans; Male; Markov Chains; Middle Aged; Prostatic Neoplasms; Quality-Adjusted Life Years	2012
Prostate biopsy in response to a change in nadir prostate specific antigen of 0.4 ng/ml after treatment with 5α-reductase inhibitors markedly enhances the detection rate of prostate cancer. The Journal of urology, 2012, Volume: 188, Issue:3 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Biopsy; Dutasteride; Finasteride; Humans; Male; Middle Aged; Predictive Value of Tests; Prospective Studies; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms	2012
Expectant management of localized prostate cancer--who, what, when, where and how? The Journal of urology, 2012, Volume: 188, Issue:3 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Dutasteride; Finasteride; Humans; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Quality Assurance, Health Care; Watchful Waiting	2012
[Histopathology reports of findings of prostate needle biopsies. Individual treatment]. Der Urologe. Ausg. A, 2013, Volume: 52, Issue:2 Topics: Adenocarcinoma; Attitude of Health Personnel; Biomarkers, Tumor; Biopsy, Needle; Cell Proliferation; Cooperative Behavior; Decision Support Techniques; Disease Progression; Finasteride; Germany; Guideline Adherence; Humans; Interdisciplinary Communication; Male; Middle Aged; Neoplasm Grading; Neoplasm Invasiveness; Palliative Care; Patient Care Planning; Phosphodiesterase 5 Inhibitors; Precision Medicine; Prognosis; Prostate; Prostate-Specific Antigen; Prostatectomy; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Surveys and Questionnaires	2013
Treatment with finasteride and prostate cancer survival. Scandinavian journal of urology, 2013, Volume: 47, Issue:4 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-Antagonists; Aged; Aged, 80 and over; Denmark; Dose-Response Relationship, Drug; Drug Therapy, Combination; Finasteride; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Proportional Hazards Models; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Survival Rate; Treatment Outcome	2013
Prostate cancer chemoprevention with 5α-reductase inhibitors. Urologic oncology, 2012, Volume: 30, Issue:5 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Chemoprevention; Dutasteride; Finasteride; Humans; Male; Neoplasm Grading; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Treatment Outcome	2012
The effects of dutasteride and finasteride on BPH-related hospitalization, surgery and prostate cancer diagnosis: a record-linkage analysis. World journal of urology, 2013, Volume: 31, Issue:3 Topics: 5-alpha Reductase Inhibitors; Adult; Aged; Aged, 80 and over; Azasteroids; Cohort Studies; Dutasteride; Finasteride; Follow-Up Studies; Hospitalization; Humans; Incidence; Lower Urinary Tract Symptoms; Male; Medical Record Linkage; Middle Aged; Proportional Hazards Models; Prostatic Hyperplasia; Prostatic Neoplasms; Retrospective Studies; Risk Factors; Treatment Outcome	2013
High-grade prostate cancer and biochemical recurrence after radical prostatectomy among men using 5α-reductase inhibitors and alpha-blockers. The Prostate, 2013, Volume: 73, Issue:9 Topics: 5-alpha Reductase Inhibitors; Adrenergic alpha-1 Receptor Antagonists; Azasteroids; Cohort Studies; Disease-Free Survival; Dutasteride; Finasteride; Finland; Humans; Kallikreins; Male; Neoplasm Grading; Neoplasm Recurrence, Local; Proportional Hazards Models; Prostate-Specific Antigen; Prostatectomy; Prostatic Neoplasms; Quinazolines; Sulfonamides; Survival Rate; Tamsulosin	2013
Unusual anti-angiogenic effect of combined hormonal blockade. The Journal of urology, 2002, Volume: 168, Issue:4 Pt 1 Topics: Aged; Angiogenesis Inhibitors; Anilides; Antineoplastic Agents, Hormonal; Capillaries; Chemotherapy, Adjuvant; Drug Therapy, Combination; Finasteride; Humans; Leuprolide; Male; Neoplasm Recurrence, Local; Nitriles; Prostatic Neoplasms; Skin; Telangiectasis; Tosyl Compounds; Treatment Outcome	2002
Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. The Journal of urology, 2002, Volume: 168, Issue:5 Topics: Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Biopsy; Case-Control Studies; Finasteride; Humans; Male; Middle Aged; Prostatic Neoplasms; Risk	2002
Impact of a novel neoadjuvant and adjuvant hormone-deprivation approach on quality of life, voiding function, and sexual function after prostate brachytherapy. Cancer, 2003, Mar-01, Volume: 97, Issue:5 Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Aged; Androgen Antagonists; Anilides; Brachytherapy; Chemotherapy, Adjuvant; Diarrhea; Enzyme Inhibitors; Finasteride; Flutamide; Humans; Logistic Models; Male; Nitriles; Penile Erection; Prostatic Neoplasms; Quality of Life; Tosyl Compounds; Treatment Outcome; Urinary Incontinence	2003
[Dual 5-alpha reductase inhibitors in BPH (benign prostatic hyperplasia). Already after 1 month prostate shrinks]. MMW Fortschritte der Medizin, 2003, Feb-27, Volume: 145, Issue:9 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Clinical Trials, Phase III as Topic; Dutasteride; Enzyme Inhibitors; Finasteride; Humans; Infant, Newborn; Male; Placebos; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Risk Factors; Testosterone; Time Factors; Ultrasonography	2003
Supplements and the prostate: widespread use, little evidence. Cleveland Clinic journal of medicine, 2003, Volume: 70, Issue:3 Topics: Adult; Aged; Antioxidants; Clinical Trials as Topic; Dietary Supplements; Finasteride; Humans; Male; Middle Aged; Prostatic Neoplasms; Selenium; Sensitivity and Specificity; Vitamin E; Vitamins	2003
Re: Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. The Journal of urology, 2003, Volume: 169, Issue:5 Topics: Anti-Inflammatory Agents, Non-Steroidal; Finasteride; Humans; Male; Prostatic Neoplasms; Risk	2003
Chemoprevention for prostate cancer - the way forward? BJU international, 2003, Volume: 91, Issue:7 Topics: Antineoplastic Agents; Chemoprevention; Finasteride; Humans; Male; Prostatic Neoplasms	2003
The impact of prostate volume following neoadjuvant androgen deprivation on quality of life and voiding symptoms in patients undergoing permanent prostate brachytherapy. European urology, 2003, Volume: 43, Issue:5 Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Brachytherapy; Cross-Sectional Studies; Finasteride; Humans; Leuprolide; Male; Middle Aged; Neoadjuvant Therapy; Prostate; Prostatic Neoplasms; Quality of Life; Surveys and Questionnaires; Urination Disorders	2003
Re: Effect of nonsteroidal anti-inflammatory agents and finasteride on prostate cancer risk. The Journal of urology, 2003, Volume: 169, Issue:6 Topics: Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Finasteride; Humans; Male; Prostatic Neoplasms	2003
The prevention of prostate cancer--the dilemma continues. The New England journal of medicine, 2003, Jul-17, Volume: 349, Issue:3 Topics: 5-alpha Reductase Inhibitors; Antineoplastic Agents, Hormonal; Finasteride; Humans; Male; Prostatic Neoplasms; Risk Assessment	2003
Stat bite: Estimated effect of finasteride on prostate cancer development. Journal of the National Cancer Institute, 2003, Jul-16, Volume: 95, Issue:14 Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Finasteride; Humans; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Severity of Illness Index; United States	2003
Prostate cancer prevention trial yields positive results, but with a few cautions. Journal of the National Cancer Institute, 2003, Jul-16, Volume: 95, Issue:14 Topics: Aged; Androgen Antagonists; Antineoplastic Agents, Hormonal; Chemoprevention; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Humans; Incidence; Male; Middle Aged; Multicenter Studies as Topic; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Severity of Illness Index; Testosterone	2003
A big study yields big questions. The New England journal of medicine, 2003, Jul-17, Volume: 349, Issue:3 Topics: 5-alpha Reductase Inhibitors; Antineoplastic Agents, Hormonal; Clinical Trials as Topic; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Risk	2003
Pharmaceutical review. BJU international, 2003, Volume: 92, Issue:3 Topics: Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms; Risk Assessment; Urinary Retention	2003
Study of prostate cancer prevention drug shows potential and problems. Report on medical guidelines & outcomes research, 2003, Jul-11, Volume: 14, Issue:13 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms; United States	2003
Chemoprevention for prostate cancer: the Prostate Cancer Prevention Trial. BJU international, 2003, Volume: 92, Issue:4 Topics: Antineoplastic Agents; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms; Risk Factors	2003
Decreased gene expression of steroid 5 alpha-reductase 2 in human prostate cancer: implications for finasteride therapy of prostate carcinoma. The Prostate, 2003, Oct-01, Volume: 57, Issue:2 Topics: Case-Control Studies; Cholestenone 5 alpha-Reductase; Databases, Genetic; Enzyme Inhibitors; Finasteride; Gene Expression; Gene Expression Profiling; Humans; Male; Nucleic Acid Amplification Techniques; Oligonucleotide Array Sequence Analysis; Oxidoreductases; Prostatic Hyperplasia; Prostatic Neoplasms; Reverse Transcriptase Polymerase Chain Reaction	2003
Finasteride may prevent prostate cancer. American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2003, Aug-01, Volume: 60, Issue:15 Topics: Antineoplastic Agents; Clinical Trials as Topic; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Prostatic Neoplasms	2003
Preventing prostate cancer. Finasteride shrinks enlarged prostates and may prevent some cases of prostate cancer. But it's no panacea. Health news (Waltham, Mass.), 2003, Volume: 9, Issue:8 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms	2003
Prevention of prostate cancer with finasteride. The New England journal of medicine, 2003, Oct-16, Volume: 349, Issue:16 Topics: 5-alpha Reductase Inhibitors; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2003
Prevention of prostate cancer with finasteride. The New England journal of medicine, 2003, Oct-16, Volume: 349, Issue:16 Topics: 5-alpha Reductase Inhibitors; Biopsy; Enzyme Inhibitors; Finasteride; Humans; Incidence; Male; Prostatic Neoplasms; Risk	2003
Prevention of prostate cancer with finasteride. The New England journal of medicine, 2003, Oct-16, Volume: 349, Issue:16 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2003
Prevention of prostate cancer with finasteride. The New England journal of medicine, 2003, Oct-16, Volume: 349, Issue:16 Topics: 5-alpha Reductase Inhibitors; Breast Neoplasms; Enzyme Inhibitors; Finasteride; Gynecomastia; Humans; Male; Prostatic Neoplasms	2003
Prevention of prostate cancer with finasteride. The New England journal of medicine, 2003, Oct-16, Volume: 349, Issue:16 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Biopsy; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms	2003
Prevention of prostate cancer with finasteride. The New England journal of medicine, 2003, Oct-16, Volume: 349, Issue:16 Topics: 5-alpha Reductase Inhibitors; Biopsy; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Risk; Testosterone	2003
Prevention of prostate cancer with finasteride. The New England journal of medicine, 2003, Oct-16, Volume: 349, Issue:16 Topics: 5-alpha Reductase Inhibitors; Biopsy; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate; Prostatic Neoplasms; Ultrasonography	2003
Preventing prostate cancer with finasteride: a mixed blessing. Harvard men's health watch, 2003, Volume: 8, Issue:3 Topics: 5-alpha Reductase Inhibitors; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms; Testosterone	2003
Mixed reviews for drug studied to prevent prostate cancer. Mayo Clinic health letter (English ed.), 2003, Volume: 21, Issue:10 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Prostatic Neoplasms; Risk	2003
Dutasteride, the dual 5alpha-reductase inhibitor, inhibits androgen action and promotes cell death in the LNCaP prostate cancer cell line. The Prostate, 2004, Feb-01, Volume: 58, Issue:2 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Androgen Antagonists; Apoptosis; Azasteroids; Cell Division; Dose-Response Relationship, Drug; Dutasteride; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Finasteride; Humans; Ligands; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Testosterone; Tumor Cells, Cultured	2004
Male breast cancer during finasteride therapy. Journal of the National Cancer Institute, 2004, Feb-18, Volume: 96, Issue:4 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Breast Neoplasms, Male; Carcinoma, Ductal; Doxazosin; Drug Labeling; Enzyme Inhibitors; Finasteride; Gynecomastia; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic; United States	2004
Herbal and vitamin supplement use in a prostate cancer screening population. Urology, 2004, Volume: 63, Issue:2 Topics: Adenocarcinoma; Adrenergic alpha-Antagonists; Adult; Aged; Colorado; Complementary Therapies; Dietary Supplements; Doxazosin; Drug Utilization; Family; Finasteride; Health Surveys; Humans; Male; Mass Screening; Middle Aged; Penile Erection; Phytotherapy; Plant Preparations; Prazosin; Prostatic Hyperplasia; Prostatic Neoplasms; Self Medication; Socioeconomic Factors; Sulfonamides; Surveys and Questionnaires; Tamsulosin; Urination Disorders; Vitamins	2004
Third annual meeting of the Society of Urologic Oncology: Bethesda, Maryland, December 13-14, 2002. Clinical prostate cancer, 2003, Volume: 1, Issue:4 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Medical Oncology; Prostate-Specific Antigen; Prostatic Neoplasms; Societies, Medical; Urology	2003
[Finasteride and prostate cancer]. Duodecim; laaketieteellinen aikakauskirja, 2004, Volume: 120, Issue:5 Topics: Finasteride; Finland; Humans; Male; Monitoring, Physiologic; Prognosis; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms	2004
The biological basis for the use of an anti-androgen and a 5-alpha-reductase inhibitor in the treatment of recurrent prostate cancer: Case report and review. Oncology reports, 2004, Volume: 11, Issue:6 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Aged; Androgen Antagonists; Anilides; Antineoplastic Combined Chemotherapy Protocols; Cell Division; Drug Synergism; Enzyme Inhibitors; Finasteride; Humans; Male; Neoplasm Recurrence, Local; Neoplasms, Hormone-Dependent; Nitriles; Phosphorylation; Prostatic Neoplasms; Receptors, Androgen; Tosyl Compounds; Tumor Cells, Cultured	2004
The clinical implications of the Prostate Cancer Prevention Trial (PCPT). BJU international, 2004, Volume: 93, Issue:7 Topics: Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2004
Finasteride and bicalutamide as primary hormonal therapy in patients with advanced adenocarcinoma of the prostate. Annals of oncology : official journal of the European Society for Medical Oncology, 2004, Volume: 15, Issue:6 Topics: Adenocarcinoma; Aged; Anilides; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Erectile Dysfunction; Finasteride; Humans; Male; Middle Aged; Neoplasm Staging; Nitriles; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Tosyl Compounds	2004
Re: Thompson IM, Klein EA, Lippman SM, Coltman CA, Djavan B. Prevention of prostate cancer with finasteride: US/European perspective. Eur Urol 2003;44:650-5. European urology, 2004, Volume: 46, Issue:1 Topics: Enzyme Inhibitors; Europe; Finasteride; Humans; Male; Prostatic Neoplasms; United States	2004
Finasteride (Propecia) and the promotion of high-grade prostate cancer. Archives of dermatology, 2004, Volume: 140, Issue:7 Topics: 5-alpha Reductase Inhibitors; Alopecia; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2004
[Therapy of benign prostatic hyperplasia with finasteride and doxazosin -- long-term studies support the combination]. Aktuelle Urologie, 2004, Volume: 35, Issue:5 Topics: Adrenergic alpha-Antagonists; Controlled Clinical Trials as Topic; Disease Progression; Double-Blind Method; Doxazosin; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Multicenter Studies as Topic; Placebos; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Risk Assessment; Risk Factors; Time Factors	2004
Despite positive studies, popularity of chemoprevention drugs increasing slowly. Journal of the National Cancer Institute, 2004, Oct-06, Volume: 96, Issue:19 Topics: Adenomatous Polyposis Coli; Androgen Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antineoplastic Agents, Hormonal; Breast Neoplasms; Celecoxib; Cell Transformation, Neoplastic; Clinical Trials as Topic; Cost-Benefit Analysis; Drug Prescriptions; Female; Finasteride; Humans; Male; Neoplasms; Prostatic Neoplasms; Pyrazoles; Sulfonamides; Tamoxifen; United States	2004
Re: inflammation as a target for prostate cancer chemoprevention: pathological and laboratory rationale. The Journal of urology, 2004, Volume: 172, Issue:6 Pt 1 Topics: Enzyme Inhibitors; Finasteride; Humans; Inflammation; Male; Prostatic Neoplasms	2004
Serenoa repens (Permixon) inhibits the 5alpha-reductase activity of human prostate cancer cell lines without interfering with PSA expression. International journal of cancer, 2005, Mar-20, Volume: 114, Issue:2 Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Animals; Cell Line, Tumor; Chlorocebus aethiops; COS Cells; Dihydrotestosterone; Finasteride; Humans; Male; Phytotherapy; Plant Extracts; Prostate-Specific Antigen; Prostatic Neoplasms; Serenoa; Testosterone	2005
Potent CYP17 inhibitors: improved syntheses, pharmacokinetics and anti-tumor activity in the LNCaP human prostate cancer model. The Journal of steroid biochemistry and molecular biology, 2004, Volume: 92, Issue:3 Topics: Androstadienes; Androstanols; Animals; Chromatography, High Pressure Liquid; Dose-Response Relationship, Drug; Finasteride; Humans; Imidazoles; Male; Mice; Mice, SCID; Prostatic Neoplasms; Steroid 17-alpha-Hydroxylase; Time Factors; Transplantation, Heterologous; Triazoles	2004
Proscar and propecia--a therapeutic perspective. The Journal of clinical endocrinology and metabolism, 2004, Volume: 89, Issue:12 Topics: Cholestenone 5 alpha-Reductase; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms; Risk Factors	2004
Estrogen receptor beta in prostate cancer. The New England journal of medicine, 2004, Dec-23, Volume: 351, Issue:26 Topics: 5-alpha Reductase Inhibitors; Androstane-3,17-diol; Animals; Antineoplastic Agents, Hormonal; Estrogen Receptor beta; Finasteride; Humans; Ligands; Male; Mice; Prostatic Neoplasms	2004
Evaluation of cell permeation of a potent 5alpha-reductase inhibitor using MALDI-TOF MS. Journal of enzyme inhibition and medicinal chemistry, 2004, Volume: 19, Issue:5 Topics: Benzoates; Cell Line, Tumor; Cell Membrane Permeability; Cell Survival; Cholestenone 5 alpha-Reductase; Drug Screening Assays, Antitumor; Enzyme Inhibitors; Esterases; Esters; Finasteride; Humans; Hydrolysis; Inhibitory Concentration 50; Male; Membranes, Artificial; Molecular Conformation; Piperidines; Prostatic Neoplasms; Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization; Structure-Activity Relationship; Time Factors	2004
Effects of 5 alpha reductase inhibitors on androgen-dependent human prostatic carcinoma cells. Journal of cancer research and clinical oncology, 2005, Volume: 131, Issue:4 Topics: 5-alpha Reductase Inhibitors; Aged; Androgens; Antineoplastic Agents, Hormonal; Azasteroids; Cell Line, Tumor; Cell Proliferation; Cholestenone 5 alpha-Reductase; Enzyme Inhibitors; Finasteride; Humans; Male; Neoplasm Staging; Prostatic Hyperplasia; Prostatic Neoplasms	2005
[The PCPT study: the viewpoint of an urologist involved]. Annales d'urologie, 2004, Volume: 38 Suppl 2 Topics: Cholestenone 5 alpha-Reductase; Clinical Trials as Topic; Finasteride; Humans; Male; Multicenter Studies as Topic; Prostatic Neoplasms; Time Factors; Urology	2004
[Use of 5-alpha-reductase inhibitors in the prevention of prostate cancer]. Annales d'urologie, 2004, Volume: 38 Suppl 2 Topics: Aged; Azasteroids; Cholestenone 5 alpha-Reductase; Clinical Trials as Topic; Dutasteride; Finasteride; Humans; Male; Middle Aged; Prostatic Neoplasms	2004
Gleason grade remains an important prognostic predictor in men diagnosed with prostate cancer while on finasteride therapy. BJU international, 2005, Volume: 95, Issue:4 Topics: Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Neoplasm Staging; Nomograms; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Urination Disorders	2005
Estimated impact of the Prostate Cancer Prevention Trial on population mortality. Cancer, 2005, Apr-01, Volume: 103, Issue:7 Topics: Finasteride; Humans; Incidence; Male; Middle Aged; Models, Statistical; Prostatic Neoplasms; Randomized Controlled Trials as Topic	2005
RE: Effect of the dual 5alpha-reductase inhibitor dutasteride on markers of tumor regression in prostate cancer. The Journal of urology, 2005, Volume: 173, Issue:4 Topics: 5-alpha Reductase Inhibitors; Apoptosis; Azasteroids; Biomarkers, Tumor; Dihydrotestosterone; Dutasteride; Finasteride; Humans; Male; Prostatic Neoplasms; Testosterone	2005
Undetectable prostate specific antigen at 6-12 months: a new marker for early success in hormonally treated patients after prostate brachytherapy. Cancer, 2005, Jun-15, Volume: 103, Issue:12 Topics: Adenocarcinoma; Androgen Antagonists; Antineoplastic Agents, Hormonal; Brachytherapy; Combined Modality Therapy; Enzyme Inhibitors; Finasteride; Humans; Leuprolide; Male; Neoadjuvant Therapy; Neoplasm Staging; Palladium; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Radioisotopes; Risk Factors; Survival Rate; Testosterone; Treatment Outcome; Ultrasonography, Interventional	2005
Role of 5a-reductase inhibitors and selective estrogen receptor modulators as potential chemopreventive agents for prostate cancer. Clinical prostate cancer, 2005, Volume: 3, Issue:4 Topics: Antineoplastic Agents, Hormonal; Chemoprevention; Cholestenone 5 alpha-Reductase; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators; Toremifene	2005
Clinical trials point to complexities of chemoprevention for cancer. JAMA, 2005, Jul-06, Volume: 294, Issue:1 Topics: Aspirin; Breast Neoplasms; Clinical Trials as Topic; Diet; Dihydrotestosterone; Female; Finasteride; Humans; Male; Neoplasms; Prostatic Neoplasms; Selective Estrogen Receptor Modulators; Tamoxifen; Vitamin E	2005
Estimated impact of the prostate cancer prevention trial on population mortality. Cancer, 2005, Oct-01, Volume: 104, Issue:7 Topics: Age Distribution; Aged; Case-Control Studies; Disease-Free Survival; Finasteride; Humans; Male; Middle Aged; Neoplasm Staging; Predictive Value of Tests; Prognosis; Prostate-Specific Antigen; Prostatic Neoplasms; Risk Assessment; Survival Analysis; Treatment Outcome; United States	2005
[Mechanism of inhibiting the proliferation of prostate cancer by finasteride: a study using cDNA microarray]. Zhonghua yi xue za zhi, 2005, Jun-08, Volume: 85, Issue:21 Topics: Antigens, Neoplasm; Biomarkers, Tumor; Cell Line, Tumor; Finasteride; Gene Expression Profiling; Humans; Male; Neoplasms, Hormone-Dependent; Oligonucleotide Array Sequence Analysis; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Signal Transduction	2005
Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. The American journal of medicine, 2005, Volume: 118, Issue:8 Topics: Aged; Aged, 80 and over; Cost-Benefit Analysis; Enzyme Inhibitors; Finasteride; Humans; Male; Markov Chains; Middle Aged; Models, Econometric; Prostatic Neoplasms; Quality-Adjusted Life Years; Randomized Controlled Trials as Topic; United States	2005
Assessing benefit and risk in the prevention of prostate cancer: the prostate cancer prevention trial revisited. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Oct-20, Volume: 23, Issue:30 Topics: Adenocarcinoma; Biopsy, Needle; Enzyme Inhibitors; Finasteride; Humans; Male; Neoplasm Staging; Odds Ratio; Prognosis; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Treatment Outcome	2005
Rebalancing ratios and improving impressions: later thoughts from the prostate cancer prevention trial investigators. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2005, Oct-20, Volume: 23, Issue:30 Topics: Adenocarcinoma; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms; Treatment Outcome	2005
Effects of long-term finasteride treatment on prostate cancer morphology and clinical outcome. Urology, 2005, Volume: 66, Issue:5 Topics: Adult; Aged; Aged, 80 and over; Finasteride; Humans; Male; Middle Aged; Prostatic Neoplasms; Time Factors; Treatment Outcome	2005
Enhancement of intermittent androgen ablation by "off-cycle" maintenance with finasteride in LNCaP prostate cancer xenograft model. The Prostate, 2006, Apr-01, Volume: 66, Issue:5 Topics: Androgens; Animals; Cell Cycle; Cell Line, Tumor; Enzyme Inhibitors; Finasteride; Humans; Male; Mice; Mice, Nude; Orchiectomy; Prostatic Neoplasms; Transplantation, Heterologous	2006
Do the benefits of finasteride outweigh the risks in the prostate cancer prevention trial? The Journal of urology, 2006, Volume: 175, Issue:3 Pt 1 Topics: Aged; Aged, 80 and over; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Markov Chains; Middle Aged; Models, Theoretical; Prostatic Neoplasms; Risk Assessment; Time Factors	2006
Finasteride: middle-age cure-all for alopecia and benign prostatic hyperplasia? Mayo Clinic proceedings, 2006, Volume: 81, Issue:2 Topics: 5-alpha Reductase Inhibitors; Alopecia; Finasteride; Humans; Male; Middle Aged; Prostatic Hyperplasia; Prostatic Neoplasms	2006
[Prostate carcinoma: can 5-alpha reductase inhibitors prevent it?]. Krankenpflege Journal, 2005, Volume: 43, Issue:7-10 Topics: 5-alpha Reductase Inhibitors; Azasteroids; Controlled Clinical Trials as Topic; Dutasteride; Finasteride; Humans; Male; Middle Aged; Multicenter Studies as Topic; Prostatic Neoplasms; Treatment Outcome	2005
Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE). Cancer, 2006, Apr-15, Volume: 106, Issue:8 Topics: Adenocarcinoma; Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Agents, Hormonal; Diethylstilbestrol; Enzyme Inhibitors; Finasteride; Gonadotropin-Releasing Hormone; Humans; Longitudinal Studies; Male; Middle Aged; Neoplasms, Hormone-Dependent; Orchiectomy; Prostatic Neoplasms; Survival Rate	2006
Intermittent use of testosterone inactivating pharmaceuticals using finasteride prolongs the time off period. The Journal of urology, 2006, Volume: 175, Issue:5 Topics: 5-alpha Reductase Inhibitors; Aged; Aged, 80 and over; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies; Time Factors	2006
Finasteride targets prostate vascularity by inducing apoptosis and inhibiting cell adhesion of benign and malignant prostate cells. The Prostate, 2006, Aug-01, Volume: 66, Issue:11 Topics: Apoptosis; Cell Adhesion; Cells, Cultured; Factor VIII; Finasteride; Humans; In Situ Nick-End Labeling; Male; Microcirculation; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Retrospective Studies; Tumor Cells, Cultured	2006
Re: Long-term effects of finasteride on prostate specific antigen levels: results from the Prostate Cancer Prevention Trial. The Journal of urology, 2006, Volume: 176, Issue:1 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms	2006
Pharmacologic basis for the enhanced efficacy of dutasteride against prostatic cancers. Clinical cancer research : an official journal of the American Association for Cancer Research, 2006, Jul-01, Volume: 12, Issue:13 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Administration, Oral; Animals; Azasteroids; Cell Line, Tumor; Cell Proliferation; Chromatography, Liquid; Dihydrotestosterone; Disease Models, Animal; Dutasteride; Enzyme Activation; Enzyme Inhibitors; Finasteride; Gene Expression Profiling; Humans; Male; Mass Spectrometry; Mice; Mice, Nude; Molecular Conformation; Prostatic Neoplasms; Protein Isoforms; Rats; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship; Xenograft Model Antitumor Assays	2006
The cost of prostate cancer chemoprevention: a decision analysis model. Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2006, Volume: 15, Issue:8 Topics: Aged; Chemoprevention; Cost-Benefit Analysis; Decision Support Techniques; Enzyme Inhibitors; Finasteride; Health Care Costs; Health Services Research; Humans; Male; Markov Chains; Middle Aged; Models, Econometric; Prostatic Neoplasms; Sensitivity and Specificity	2006
New finasteride trial results aim to curb controversy. Journal of the National Cancer Institute, 2006, Aug-16, Volume: 98, Issue:16 Topics: Antineoplastic Agents; Enzyme Inhibitors; Finasteride; Humans; Incidence; Male; Prostate-Specific Antigen; Prostatic Neoplasms	2006
Benign prostatic hyperplasia: caveat for finasteride should be discussed before prescribing. BMJ (Clinical research ed.), 2006, Sep-23, Volume: 333, Issue:7569 Topics: Antineoplastic Agents; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Randomized Controlled Trials as Topic	2006
Chemoprevention in prostate cancer. Pharmacotherapy, 2006, Volume: 26, Issue:10 Topics: Chemoprevention; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2006
The prostate cancer prevention trial and its messages. European urology, 2007, Volume: 51, Issue:1 Topics: 5-alpha Reductase Inhibitors; Early Diagnosis; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms	2007
New progesterone derivatives as inhibitors of 5alpha-reductase enzyme and prostate cancer cell growth. Journal of enzyme inhibition and medicinal chemistry, 2006, Volume: 21, Issue:4 Topics: Animals; Cell Line, Tumor; Cholestenone 5 alpha-Reductase; Cricetinae; Finasteride; Humans; Male; Mesocricetus; Models, Chemical; Progesterone; Prostate; Prostatic Neoplasms; Steroids; Testosterone	2006
The evolution of the PCPT from clinical to molecular analyses. Nature clinical practice. Oncology, 2006, Volume: 3, Issue:11 Topics: Biopsy; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic	2006
Re: The Prostate Cancer Prevention Trial: design, biases and interpretation of study results. P. J. Goodman, I. M. Thompson, Jr., C. M. Tangen, J. J. Crowley, L. G. Ford and C. A. Coltman, Jr., J Urol, 175: 2234-2242, 2006. The Journal of urology, 2006, Volume: 176, Issue:6 Pt 1 Topics: Bias; Biopsy; Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Research Design	2006
Can effect of finasteride on prostate-specific antigen be used to decrease repeat prostate biopsy? Urology, 2006, Volume: 68, Issue:6 Topics: Aged; Biomarkers, Tumor; Biopsy; Diagnosis, Differential; Endosonography; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Retrospective Studies	2006
Prostate cancer risk among users of finasteride and alpha-blockers - a population based case-control study. European journal of cancer (Oxford, England : 1990), 2007, Volume: 43, Issue:4 Topics: Adrenergic alpha-Antagonists; Case-Control Studies; Enzyme Inhibitors; Finasteride; Humans; Male; Odds Ratio; Prostatic Hyperplasia; Prostatic Neoplasms; Risk Factors	2007
New answers from the Prostate Cancer Prevention Trial on the chemoprevention of prostate cancer. Archivio italiano di urologia, andrologia : organo ufficiale [di] Societa italiana di ecografia urologica e nefrologica, 2006, Volume: 78, Issue:4 Topics: Clinical Trials as Topic; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2006
A large retrospective analysis of acute urinary retention and prostate-related surgery in BPH patients treated with 5-alpha reductase inhibitors: dutasteride versus finasteride. The American journal of managed care, 2007, Volume: 13 Suppl 1 Topics: Acute Disease; Age Distribution; Aged; Azasteroids; Dutasteride; Finasteride; Follow-Up Studies; Humans; Incidence; Male; Managed Care Programs; Middle Aged; Multivariate Analysis; Probability; Prostatectomy; Prostatic Neoplasms; Retrospective Studies; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Treatment Outcome; Urinary Retention; Urodynamics	2007
Importance of the intracrine metabolism of adrenal androgens in androgen-dependent prostate cancer. Prostate cancer and prostatic diseases, 2007, Volume: 10, Issue:3 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adrenal Glands; Androgens; Cell Line, Tumor; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Humans; Male; Neoplasms, Hormone-Dependent; Prostate-Specific Antigen; Prostatic Neoplasms; Receptors, Androgen; Reverse Transcriptase Polymerase Chain Reaction	2007
Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model. Prostate cancer and prostatic diseases, 2007, Volume: 10, Issue:4 Topics: Adenocarcinoma; Androgen Antagonists; Animals; Animals, Genetically Modified; Antigens, Viral, Tumor; Disease Models, Animal; Disease Progression; Drug Therapy, Combination; Enzyme Inhibitors; Finasteride; Flutamide; Male; Prostate; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Testosterone	2007
[Chemoprevention of prostate cancer. Current status]. Der Urologe. Ausg. A, 2007, Volume: 46, Issue:6 Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Evidence-Based Medicine; Finasteride; Humans; Male; Prospective Studies; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Selective Estrogen Receptor Modulators	2007
Re: expression of major heat shock proteins in prostate cancer: correlation with clinicopathological outcomes in patients undergoing radical prostatectomy. T. Kurahashi, H. Miyake, I. Hara and M. Fujisawa J Urol 2007; 177: 757-761. The Journal of urology, 2007, Volume: 178, Issue:1 Topics: 5-alpha Reductase Inhibitors; Disease Progression; Enzyme Inhibitors; Finasteride; Heat-Shock Proteins; HSP27 Heat-Shock Proteins; Humans; Male; Molecular Chaperones; Neoplasm Proteins; Prostate; Prostatic Neoplasms; Quercetin; Up-Regulation	2007
Quantifying the impact of prostate volumes, number of biopsy cores and 5alpha-reductase inhibitor therapy on the probability of prostate cancer detection using mathematical modeling. The Journal of urology, 2007, Volume: 177, Issue:6 Topics: 5-alpha Reductase Inhibitors; Biopsy; Finasteride; Humans; Male; Models, Theoretical; Organ Size; Predictive Value of Tests; Prostatic Neoplasms; Tumor Burden	2007
Advances in the medical management of benign prostatic hyperplasia. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2007, Jun-19, Volume: 176, Issue:13 Topics: Adrenergic alpha-Antagonists; Doxazosin; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms	2007
Finasteride for chemoprevention of prostate cancer: why has it not been embraced? Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2007, Jul-20, Volume: 25, Issue:21 Topics: California; Chemoprevention; Early Diagnosis; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Mass Screening; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Assessment; Sensitivity and Specificity; Survival Analysis	2007
High-grade prostate cancer in the Prostate Cancer Prevention Trial: fact or artifact? Journal of the National Cancer Institute, 2007, Sep-19, Volume: 99, Issue:18 Topics: Aged; Anticarcinogenic Agents; Bias; Biopsy, Needle; Enzyme Inhibitors; Finasteride; Humans; Incidence; Male; Middle Aged; Models, Statistical; Prostatectomy; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Severity of Illness Index; Treatment Outcome	2007
[The Prostate Cancer Prevention Trial (PCPT). Relevance for clinical practice]. Der Urologe. Ausg. A, 2007, Volume: 46, Issue:10 Topics: 5-alpha Reductase Inhibitors; Aged; Biomarkers, Tumor; Biopsy; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Long-Term Care; Male; Middle Aged; Neoplasm Staging; Prostate; Prostate-Specific Antigen; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Risk Factors	2007
Cost-effectiveness of prostate cancer chemoprevention: a quality of life-years analysis. Cancer, 2008, Mar-01, Volume: 112, Issue:5 Topics: Cost-Benefit Analysis; Finasteride; Humans; Incidence; Male; Markov Chains; Middle Aged; Prostatic Neoplasms; Quality of Life; Quality-Adjusted Life Years; Survival Rate	2008
Dietary patterns, supplement use, and the risk of symptomatic benign prostatic hyperplasia: results from the prostate cancer prevention trial. American journal of epidemiology, 2008, Apr-15, Volume: 167, Issue:8 Topics: Aged; Aged, 80 and over; Alcohol Drinking; Diet; Dietary Supplements; Feeding Behavior; Finasteride; Humans; Incidence; Male; Middle Aged; Nutrition Surveys; Nutritional Status; Odds Ratio; Prospective Studies; Prostatic Hyperplasia; Prostatic Neoplasms; Proteins; Risk Assessment; Risk Factors; Surveys and Questionnaires; United States	2008
Finasteride therapy for benign prostatic hyperplasia. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne, 2008, Feb-26, Volume: 178, Issue:5 Topics: 5-alpha Reductase Inhibitors; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms	2008
Open to debate. The Motion: all men over the age of 50 should be encouraged to take a 5alpha-reductase inhibitor to prevent prostate cancer. European urology, 2008, Volume: 53, Issue:5 Topics: Cholestenone 5 alpha-Reductase; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Morbidity; Ontario; Prognosis; Prostatic Neoplasms; Risk Factors	2008
The Prostate Cancer Prevention Trial and the future of chemoprevention. BJU international, 2008, Volume: 101, Issue:8 Topics: Antineoplastic Agents; Chemoprevention; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic	2008
Finasteride induces apoptosis via Bcl-2, Bcl-xL, Bax and caspase-3 proteins in LNCaP human prostate cancer cell line. International journal of oncology, 2008, Volume: 32, Issue:4 Topics: Apoptosis; bcl-2-Associated X Protein; bcl-X Protein; Caspase 3; Cell Line, Tumor; Cholestenone 5 alpha-Reductase; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms; Proto-Oncogene Proteins c-bcl-2	2008
Development and validation of an LC-MS assay for finasteride and its application to prostate cancer prevention trial sample analysis. Journal of chromatographic science, 2008, Volume: 46, Issue:4 Topics: 5-alpha Reductase Inhibitors; Chromatography, High Pressure Liquid; Drug Stability; Finasteride; Humans; Male; Mass Spectrometry; Middle Aged; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Reproducibility of Results; Sensitivity and Specificity	2008
[The PCPT trial]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2008, Volume: 18 Suppl 3 Topics: Chemoprevention; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Neoplasms; Randomized Controlled Trials as Topic	2008
[PCPT trial: expected bias and their management]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2008, Volume: 18 Suppl 3 Topics: Bias; Chemoprevention; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic	2008
[The pathologist's perspective on the PCPT trial]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2008, Volume: 18 Suppl 3 Topics: Bias; Biopsy; Chemoprevention; Enzyme Inhibitors; Finasteride; Humans; Male; Pathology; Prostatic Neoplasms; Randomized Controlled Trials as Topic	2008
[Contribution of the PCPT trial to finasteride treatment of micturition disorders due to benign prostatic hyperplasia]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2008, Volume: 18 Suppl 3 Topics: Chemoprevention; Decision Trees; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Hyperplasia; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Urination Disorders	2008
[Practical follow-up of a patient treated with finasteride in screening for prostate cancer]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2008, Volume: 18 Suppl 3 Topics: Chemoprevention; Enzyme Inhibitors; Finasteride; Follow-Up Studies; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic	2008
[Relevance of chemoprevention from PCPT trial]. Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 2008, Volume: 18 Suppl 3 Topics: Chemoprevention; Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms; Randomized Controlled Trials as Topic	2008
Does the level of prostate cancer risk affect cancer prevention with finasteride? Urology, 2008, Volume: 71, Issue:5 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostatic Neoplasms; Risk Assessment; Risk Factors	2008
Case records of the Massachusetts General Hospital. Case 15-2008. A 55-year-old man with an elevated prostate-specific antigen level and early-stage prostate cancer. The New England journal of medicine, 2008, May-15, Volume: 358, Issue:20 Topics: 5-alpha Reductase Inhibitors; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Neoplasm Staging; Prognosis; Prostate; Prostate-Specific Antigen; Prostatic Neoplasms; Urinary Retention	2008
Effects of dutasteride on prostate carcinoma primary cultures: a comparative study with finasteride and MK386. The Journal of urology, 2008, Volume: 180, Issue:1 Topics: 5-alpha Reductase Inhibitors; Aged; Azasteroids; Cell Proliferation; Dutasteride; Finasteride; Humans; Male; Prostatic Neoplasms; Tumor Cells, Cultured	2008
[Chemoprevention of cancer of the prostate]. Bulletin du cancer, 1995, Volume: 82 Suppl 3 Topics: Aged; Aged, 80 and over; Animals; Disease Models, Animal; Finasteride; Food; Humans; Male; Middle Aged; Prostatic Neoplasms; Rats; Rats, Wistar; Risk Factors	1995
Treatment of advanced prostate cancer with the combination of finasteride plus flutamide: early results. European urology, 1993, Volume: 24 Suppl 2 Topics: Aged; Drug Therapy, Combination; Erectile Dysfunction; Finasteride; Flutamide; Humans; Luteinizing Hormone; Male; Middle Aged; Pilot Projects; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone	1993
Men's health issues. Archives of family medicine, 1993, Volume: 2, Issue:9 Topics: Adrenergic alpha-Antagonists; Finasteride; Humans; Male; Prazosin; Prostatic Hyperplasia; Prostatic Neoplasms	1993
Prostate cancer. Current therapy in endocrinology and metabolism, 1994, Volume: 5 Topics: 5-alpha Reductase Inhibitors; Aged; Anticarcinogenic Agents; Disease-Free Survival; Estrogens; Finasteride; Gonadotropin-Releasing Hormone; Humans; Luteinizing Hormone; Lymphatic Metastasis; Male; Neoplasm Metastasis; Neoplasm Staging; Prevalence; Prostate-Specific Antigen; Prostatectomy; Prostatic Hyperplasia; Prostatic Neoplasms; Radiotherapy	1994
Clinical development plan: Proscar. Journal of cellular biochemistry. Supplement, 1994, Volume: 20 Topics: Animals; Clinical Trials as Topic; Drug Approval; Female; Finasteride; Humans; Male; Mice; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley	1994
Prostatic specific antigen (PSA) Minerva urologica e nefrologica = The Italian journal of urology and nephrology, 1993, Volume: 45, Issue:2 Topics: Biomarkers, Tumor; Diagnosis, Differential; False Negative Reactions; Finasteride; Humans; Male; Predictive Value of Tests; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Reference Values	1993
Chemoprevention of rat prostate carcinogenesis by use of finasteride or casodex. Journal of the National Cancer Institute, 1995, Jun-07, Volume: 87, Issue:11 Topics: Androgen Antagonists; Anilides; Animals; Antineoplastic Agents; Finasteride; Male; Nitriles; Prostatic Neoplasms; Rats; Rats, Inbred F344; Tosyl Compounds	1995
Finasteride dose-dependently reduces the proliferation rate of the LnCap human prostatic cancer cell line in vitro. Urology, 1995, Volume: 45, Issue:2 Topics: Androgen Antagonists; Cell Division; Cyproterone Acetate; Dihydrotestosterone; Dose-Response Relationship, Drug; Finasteride; Flutamide; Humans; Linear Models; Male; Prostatic Neoplasms; Testosterone; Tumor Cells, Cultured	1995
Clinical review: 67: Approach to chemoprevention of prostate cancer. The Journal of clinical endocrinology and metabolism, 1995, Volume: 80, Issue:3 Topics: Dihydrotestosterone; Finasteride; Humans; Male; Prostate; Prostatic Neoplasms	1995
PCPT update: enrollment mounts, but minority participation lags. Journal of the National Cancer Institute, 1994, Oct-19, Volume: 86, Issue:20 Topics: Finasteride; Humans; Male; Minority Groups; Multicenter Studies as Topic; Prostatic Neoplasms; Randomized Controlled Trials as Topic	1994
Inhibition of the activity of 'basic' 5 alpha-reductase (type 1) detected in DU 145 cells and expressed in insect cells. The Journal of steroid biochemistry and molecular biology, 1994, Volume: 48, Issue:4 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Animals; Azasteroids; Baculoviridae; Brain Neoplasms; Chromatography, High Pressure Liquid; Dihydrotestosterone; Finasteride; Gene Expression; Humans; Hydrogen-Ion Concentration; Isoenzymes; Kinetics; Male; Moths; Prostatic Neoplasms; Recombinant Proteins; Testosterone; Tumor Cells, Cultured	1994
Hormonal chemoprevention of cancer in women. Science (New York, N.Y.), 1993, Jan-29, Volume: 259, Issue:5095 Topics: 5-alpha Reductase Inhibitors; Adult; Age Factors; Aged; Androstenes; Anticarcinogenic Agents; Azasteroids; Breast Neoplasms; Contraceptives, Oral; Endometrial Neoplasms; Estrogen Replacement Therapy; Female; Finasteride; Humans; Incidence; Male; Middle Aged; Ovarian Neoplasms; Progestins; Prostatic Neoplasms; Tamoxifen; United Kingdom; United States	1993
Testosterone metabolism in primary cultures of human prostate epithelial cells and fibroblasts. The Journal of steroid biochemistry and molecular biology, 1995, Volume: 55, Issue:3-4 Topics: 17-Hydroxysteroid Dehydrogenases; Adenosarcoma; Androstenedione; Azasteroids; Blotting, Northern; Cells, Cultured; Cholestenone 5 alpha-Reductase; Chromatography, High Pressure Liquid; Dihydrotestosterone; Enzyme Inhibitors; Epithelium; Etiocholanolone; Fibroblasts; Finasteride; Humans; Male; Meningioma; Oxidoreductases; Placenta; Prostatic Neoplasms; RNA; RNA, Messenger; Testosterone; Tumor Cells, Cultured	1995
Characterization of type I 5 alpha-reductase activity in DU145 human prostatic adenocarcinoma cells. The Journal of steroid biochemistry and molecular biology, 1996, Volume: 58, Issue:2 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Adenocarcinoma; Androstadienes; Benzoquinones; Cell Division; Enzyme Inhibitors; Finasteride; Gene Expression Regulation, Neoplastic; Humans; Isoenzymes; Male; Prostatic Neoplasms; RNA, Messenger; Selection, Genetic; Skin; Testosterone; Tumor Cells, Cultured	1996
Human prostate tumor growth in athymic mice: inhibition by androgens and stimulation by finasteride. Proceedings of the National Academy of Sciences of the United States of America, 1996, Oct-15, Volume: 93, Issue:21 Topics: Androgen-Binding Protein; Animals; Cell Division; Cell Line; Dihydrotestosterone; DNA Primers; Drug Implants; Enzyme Inhibitors; Estradiol; Finasteride; Humans; Male; Medroxyprogesterone Acetate; Mice; Mice, Nude; Orchiectomy; Polymerase Chain Reaction; Prostate-Specific Antigen; Prostatic Neoplasms; Testosterone; Time Factors; Transplantation, Heterologous	1996
Clinical trials referral resource. Breast cancer and prostate cancer. Oncology (Williston Park, N.Y.), 1996, Volume: 10, Issue:1 Topics: 5-alpha Reductase Inhibitors; Adult; Anticarcinogenic Agents; Breast Neoplasms; Clinical Trials as Topic; Female; Finasteride; Humans; Male; Prostatic Neoplasms; Tamoxifen	1996
Evaluation of prostatic intraepithelial neoplasia after treatment with a 5-alpha-reductase inhibitor (finasteride). A methodologic approach. Analytical and quantitative cytology and histology, 1996, Volume: 18, Issue:6 Topics: 5-alpha Reductase Inhibitors; Aged; Bayes Theorem; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostate; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms	1996
Anti-androgenic effects of combination finasteride plus flutamide in patients with prostatic carcinoma. British journal of urology, 1996, Volume: 78, Issue:6 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Finasteride; Flutamide; Follow-Up Studies; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms; Treatment Outcome	1996
Effect of turosteride, a 5 alpha-reductase inhibitor, on the Dunning R3327 rat prostatic carcinoma. The Prostate, 1997, Feb-01, Volume: 30, Issue:2 Topics: 5-alpha Reductase Inhibitors; Adenocarcinoma; Androstenedione; Animals; Antineoplastic Agents, Hormonal; Antineoplastic Combined Chemotherapy Protocols; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Flutamide; Leuprolide; Luteinizing Hormone; Male; Organ Size; Pituitary Gland, Anterior; Prostate; Prostatic Neoplasms; Random Allocation; Rats; Seminal Vesicles; Testis; Testosterone	1997
Effects of chlormadinone acetate and ethinylestradiol treatment on epididymal 5 alpha-reductase activities in patients with prostate cancer. Endocrine journal, 1997, Volume: 44, Issue:1 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Aged; Antineoplastic Agents, Hormonal; Chlormadinone Acetate; Dose-Response Relationship, Drug; Enzyme Inhibitors; Epididymis; Ethinyl Estradiol; Finasteride; Humans; Male; Orchiectomy; Prostatic Neoplasms	1997
Anaemia associated with androgen deprivation in patients with prostate cancer receiving combined hormone blockade. British journal of urology, 1997, Volume: 79, Issue:6 Topics: Age Factors; Aged; Anemia; Anilides; Antineoplastic Combined Chemotherapy Protocols; Finasteride; Flutamide; Hemoglobins; Humans; Male; Nitriles; Prospective Studies; Prostatic Neoplasms; Testosterone; Time Factors; Tosyl Compounds	1997
Finasteride plus flutamide for prostatic carcinoma. British journal of urology, 1997, Volume: 80, Issue:2 Topics: Androgen Antagonists; Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibitors; Finasteride; Flutamide; Humans; Male; Prostatic Neoplasms	1997
Tamoxifen for flutamide/finasteride-induced gynecomastia. Urology, 1997, Volume: 50, Issue:6 Topics: Aged; Androgen Antagonists; Drug Evaluation; Drug Therapy, Combination; Enzyme Inhibitors; Estradiol; Estrogen Antagonists; Finasteride; Flutamide; Gynecomastia; Humans; Male; Middle Aged; Prostatic Neoplasms; Tamoxifen; Testosterone; Time Factors	1997
A five-alpha reductase inhibitor or an antiandrogen prevents the progression of microscopic prostate carcinoma to macroscopic carcinoma in rats. Cancer, 1998, Feb-01, Volume: 82, Issue:3 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; Adenocarcinoma; Aminobiphenyl Compounds; Androgen Antagonists; Anilides; Animals; Carcinogens; Disease Progression; Enzyme Inhibitors; Finasteride; Male; Nitriles; Prostatic Neoplasms; Rats; Rats, Inbred F344; Testosterone; Tosyl Compounds	1998
Biologic variability of prostate-specific antigen and its usefulness as a marker for prostate cancer: effects of finasteride. Finasteride PSA Study Group. Urology, 1998, Volume: 51, Issue:4A Suppl Topics: Adult; Aged; Biomarkers, Tumor; Enzyme Inhibitors; Finasteride; Humans; Male; Middle Aged; Prostate-Specific Antigen; Prostatic Neoplasms	1998
Effect of early treatment of prostate cancer with the 5alpha-reductase inhibitor turosteride in Dunning R3327 prostatic carcinoma in rats. The Prostate, 1998, Jun-01, Volume: 35, Issue:4 Topics: 5-alpha Reductase Inhibitors; Administration, Oral; Animals; Cell Line; Drug Administration Schedule; Enzyme Inhibitors; Finasteride; Male; Orchiectomy; Organ Size; Prostate; Prostatic Neoplasms; Rats; Time Factors	1998
[Use of transrectal ultrasonography in prostate pathology: determination and clinical usefulness of the prostate transition zone]. Revue medicale de Bruxelles, 1998, Volume: 19, Issue:3 Topics: 5-alpha Reductase Inhibitors; Aged; Catheter Ablation; Diagnosis, Differential; Enzyme Inhibitors; Finasteride; Forecasting; Humans; Laser Coagulation; Male; Middle Aged; Prostate; Prostate-Specific Antigen; Prostatic Hyperplasia; Prostatic Neoplasms; Survival Rate; Ultrasonography	1998
Effects of some novel inhibitors of C17,20-lyase and 5alpha-reductase in vitro and in vivo and their potential role in the treatment of prostate cancer. Cancer research, 1998, Sep-01, Volume: 58, Issue:17 Topics: Androgens; Animals; Cholestenone 5 alpha-Reductase; Dihydrotestosterone; Enzyme Inhibitors; Finasteride; Humans; Ketoconazole; Male; Organ Size; Oxidoreductases; Prostate; Prostatic Neoplasms; Rats; Rats, Sprague-Dawley; Steroid 17-alpha-Hydroxylase; Testosterone	1998
Urology. JAMA, 1999, Feb-10, Volume: 281, Issue:6 Topics: Circumcision, Male; Enzyme Inhibitors; Erectile Dysfunction; Finasteride; Humans; Male; Mass Screening; Pain; Piperazines; Plant Extracts; Prostatic Hyperplasia; Prostatic Neoplasms; Purines; Serenoa; Sildenafil Citrate; Sulfones; Urology	1999
Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. The Journal of urology, 1999, Volume: 161, Issue:1 Topics: Double-Blind Method; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Reproducibility of Results	1999
'Clandestine' prostate cancer haunts. CAP today, 1996, Volume: 10, Issue:2 Topics: Androgen Antagonists; Antineoplastic Agents, Hormonal; Biopsy; Combined Modality Therapy; Diagnostic Errors; Finasteride; Gonadotropin-Releasing Hormone; Humans; Leuprolide; Male; Prostate; Prostatectomy; Prostatic Neoplasms	1996
Anaemia in men receiving combined finasteride and flutamide therapy for advanced prostate cancer. BJU international, 1999, Volume: 83, Issue:1 Topics: Aged; Aged, 80 and over; Anemia; Antineoplastic Combined Chemotherapy Protocols; Enzyme Inhibitors; Finasteride; Flutamide; Hematocrit; Hemoglobins; Humans; Male; Middle Aged; Prostatic Neoplasms; Testosterone	1999
Immunohistochemical expression of pi class glutathione S-transferase in the basal cell layer of benign prostate tissue following chronic treatment with finasteride. Journal of clinical pathology, 1999, Volume: 52, Issue:5 Topics: Aged; Drug Administration Schedule; Enzyme Inhibitors; Finasteride; Glutathione Transferase; Humans; Immunoenzyme Techniques; Male; Middle Aged; Prostate; Prostatectomy; Prostatic Hyperplasia; Prostatic Neoplasms; Up-Regulation	1999
Androgen receptor gene alterations and chromosomal gains and losses in prostate carcinomas appearing during finasteride treatment for benign prostatic hyperplasia. Clinical cancer research : an official journal of the American Association for Cancer Research, 1999, Volume: 5, Issue:11 Topics: Chromosome Aberrations; Chromosome Mapping; Chromosomes, Human, Pair 6; Enzyme Inhibitors; Finasteride; Humans; In Situ Hybridization, Fluorescence; Male; Neoplasm Staging; Prostatic Hyperplasia; Prostatic Neoplasms; Receptors, Androgen; X Chromosome	1999
Re: Chemoprevention of urological cancer. The Journal of urology, 2000, Volume: 163, Issue:4 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Prostatic Neoplasms	2000
Chemoprevention: an important treatment option for prostate cancer. The journal of the Royal Society for the Promotion of Health, 2000, Volume: 120, Issue:3 Topics: Aged; Antioxidants; Enzyme Inhibitors; Finasteride; Humans; Incidence; Male; Middle Aged; Prostatic Neoplasms; Randomized Controlled Trials as Topic; Selenium; United States; Vitamin E	2000
Antiandrogenic effects of novel androgen synthesis inhibitors on hormone-dependent prostate cancer. Cancer research, 2000, Dec-01, Volume: 60, Issue:23 Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Androgen Receptor Antagonists; Androstadienes; Animals; Antineoplastic Agents, Hormonal; Cell Division; Chlorocebus aethiops; Finasteride; Growth Inhibitors; Humans; Ketoconazole; Male; Mice; Mice, Nude; Mice, SCID; Neoplasms, Hormone-Dependent; Oleanolic Acid; Pregnadienes; Prostatic Neoplasms; Receptors, Androgen; Saponins; Steroid 17-alpha-Hydroxylase; Tumor Cells, Cultured; Xenograft Model Antitumor Assays	2000
Prostate cancer prevention agent development: Criteria and pipeline for candidate chemoprevention agents. Urology, 2001, Volume: 57, Issue:4 Suppl 1 Topics: Androgen Antagonists; Anti-Inflammatory Agents, Non-Steroidal; Anticarcinogenic Agents; Antioxidants; Cell Differentiation; Cell Division; Drug Evaluation; Estrogen Receptor Modulators; Finasteride; Genetic Therapy; Growth Substances; Humans; Male; Middle Aged; Prostatic Neoplasms; Signal Transduction	2001
Androgen antagonists: Potential role in prostate cancer prevention. Urology, 2001, Volume: 57, Issue:4 Suppl 1 Topics: 5-alpha Reductase Inhibitors; Androgen Antagonists; Benzoquinones; Enzyme Inhibitors; Finasteride; Humans; Male; Prostate-Specific Antigen; Prostatic Neoplasms	2001
As genes differ, so should interventions for cancer. JAMA, 2001, Apr-11, Volume: 285, Issue:14 Topics: 3-Oxo-5-alpha-Steroid 4-Dehydrogenase; 5-alpha Reductase Inhibitors; Antineoplastic Agents; Enzyme Inhibitors; Finasteride; Genetic Predisposition to Disease; Humans; Male; Prostatic Neoplasms	2001
Novel antineoplastic isochalcones inhibit the expression of cyclooxygenase 1,2 and EGF in human prostate cancer cell line LNCaP. Cellular and molecular biology (Noisy-le-Grand, France), 2001, Volume: 47, Issue:6 Topics: Antineoplastic Agents; Cell Division; Cell Survival; Cyclooxygenase 1; Cyclooxygenase 2; Dose-Response Relationship, Drug; Epidermal Growth Factor; Epithelial Cells; ErbB Receptors; Finasteride; Growth Inhibitors; Humans; Isoenzymes; Male; Membrane Proteins; Prostaglandin-Endoperoxide Synthases; Prostate; Prostatic Neoplasms; Receptors, Androgen; Tumor Cells, Cultured	2001
Prostatic intraepithelial neoplasia and putative precursor lesions of prostate cancer: a clinical perspective. BJU international, 2001, Volume: 88, Issue:9 Topics: Enzyme Inhibitors; Finasteride; Humans; Male; Precancerous Conditions; Prostatic Intraepithelial Neoplasia; Prostatic Neoplasms; Risk Factors	2001
Optimism expressed over prostate drug. Journal of the National Cancer Institute, 1991, Dec-04, Volume: 83, Issue:23 Topics: Androstenes; Antineoplastic Agents; Azasteroids; Dihydrotestosterone; Finasteride; Humans; Male; Pilot Projects; Prostatic Hyperplasia; Prostatic Neoplasms; Recurrence	1991
Effect of castration, DES, flutamide, and the 5 alpha-reductase inhibitor, MK-906, on the growth of the Dunning rat prostatic carcinoma, R-3327. The Prostate, 1991, Volume: 18, Issue:3 Topics: 5-alpha Reductase Inhibitors; Androgens; Androstenes; Animals; Azasteroids; Diethylstilbestrol; Finasteride; Flutamide; Male; Orchiectomy; Prostatic Neoplasms; Rats; Rats, Inbred F344	1991